<?xml version="1.0" encoding="utf-8"?>
<!-- Copyright Â©2016 LexisNexis Univentio, The Netherlands. -->
<lexisnexis-patent-document schema-version="1.13" date-produced="20160213" file="EP1123398B1.xml" produced-by="LexisNexis-Univentio" lang="eng" date-changed="20160212" time-changed="113426">
  <bibliographic-data lang="eng">
    <publication-reference publ-type="Grant" publ-desc="Granted patent">
      <document-id id="717445">
        <country>EP</country>
        <doc-number>1123398</doc-number>
        <kind>B1</kind>
        <date>20050810</date>
      </document-id>
    </publication-reference>
    <application-reference>
      <document-id>
        <country>EP</country>
        <doc-number>99970685</doc-number>
        <kind>A</kind>
        <date>19991015</date>
      </document-id>
    </application-reference>
    <language-of-filing>eng</language-of-filing>
    <language-of-publication>eng</language-of-publication>
    <priority-claims date-changed="20151027">
      <priority-claim sequence="1" kind="regional">
        <country>EP</country>
        <doc-number>98119630</doc-number>
        <kind>A</kind>
        <date>19981016</date>
      </priority-claim>
      <priority-claim sequence="2" kind="national">
        <country>IN</country>
        <doc-number>MUM6661998</doc-number>
        <kind>A</kind>
        <date>19981016</date>
      </priority-claim>
      <priority-claim sequence="1" data-format="docdb">
        <country>EP</country>
        <doc-number>99970685</doc-number>
        <kind>A</kind>
        <date>19991015</date>
        <priority-active-indicator>false</priority-active-indicator>
      </priority-claim>
      <priority-claim sequence="2" data-format="docdb">
        <country>EP</country>
        <doc-number>9907844</doc-number>
        <kind>W</kind>
        <date>19991015</date>
        <priority-active-indicator>false</priority-active-indicator>
      </priority-claim>
      <priority-claim sequence="3" data-format="docdb">
        <country>EP</country>
        <doc-number>98119630</doc-number>
        <kind>A</kind>
        <date>19981016</date>
        <priority-active-indicator>true</priority-active-indicator>
      </priority-claim>
      <priority-claim sequence="4" data-format="docdb">
        <country>IN</country>
        <doc-number>666BO1998</doc-number>
        <kind>A</kind>
        <date>19981016</date>
        <priority-active-indicator>true</priority-active-indicator>
      </priority-claim>
      <priority-claim sequence="1" data-format="original">
        <doc-number>EP1999007844</doc-number>
      </priority-claim>
      <priority-claim sequence="2" data-format="original">
        <doc-number>98119630</doc-number>
      </priority-claim>
      <priority-claim sequence="3" data-format="original">
        <doc-number>BO066698</doc-number>
      </priority-claim>
      <priority-claim sequence="1" data-format="epodoc">
        <doc-number>EP19990970685</doc-number>
      </priority-claim>
      <priority-claim sequence="2" data-format="epodoc">
        <doc-number>WO1999EP07844</doc-number>
      </priority-claim>
      <priority-claim sequence="3" data-format="epodoc">
        <doc-number>EP19980119630</doc-number>
      </priority-claim>
      <priority-claim sequence="4" data-format="epodoc">
        <doc-number>IN1998BO66619</doc-number>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability date-changed="20090313">
      <gazette-reference>
        <date>20050810</date>
      </gazette-reference>
      <unexamined-printed-without-grant>
        <date>20010816</date>
      </unexamined-printed-without-grant>
      <printed-with-grant>
        <date>20050810</date>
      </printed-with-grant>
      <publication-of-grant-date>
        <date>20050810</date>
      </publication-of-grant-date>
      <intention-to-grant-date>
        <date>20050216</date>
      </intention-to-grant-date>
    </dates-of-public-availability>
    <dates-rights-effective date-changed="20090313">
      <request-for-examination>
        <date>20010412</date>
      </request-for-examination>
      <first-examination-report-despatched>
        <date>20000727</date>
      </first-examination-report-despatched>
    </dates-rights-effective>
    <term-of-grant>
      <lapse-of-patent>
        <country>AT</country>
        <date>20050810</date>
      </lapse-of-patent>
      <lapse-of-patent>
        <country>SE</country>
        <date>20051110</date>
      </lapse-of-patent>
      <lapse-of-patent>
        <country>FI</country>
        <date>20050810</date>
      </lapse-of-patent>
      <lapse-of-patent>
        <country>CH</country>
        <date>20050810</date>
      </lapse-of-patent>
      <lapse-of-patent>
        <country>LI</country>
        <date>20050810</date>
      </lapse-of-patent>
      <lapse-of-patent>
        <country>GR</country>
        <date>20051110</date>
      </lapse-of-patent>
    </term-of-grant>
    <classification-ipc date-changed="20151027">
      <main-classification>
        <text> 7C 12N  15/13   A</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>13</subgroup>
        <qualifying-character>A</qualifying-character>
      </main-classification>
      <further-classification sequence="1">
        <text> 7C 12N  15/40   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>40</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="2">
        <text> 7C 12N  15/55   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>55</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="3">
        <text> 7C 12N  15/62   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>62</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="4">
        <text> 7C 12N  15/82   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>82</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="5">
        <text> 7C 12N  15/31   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>31</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="6">
        <text> 7C 12N   5/10   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>5</main-group>
        <subgroup>10</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="7">
        <text> 7C 07K  19/00   B</text>
        <edition>7</edition>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>19</main-group>
        <subgroup>00</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
      <further-classification sequence="8">
        <text> 7A 01H   5/00   B</text>
        <edition>7</edition>
        <section>A</section>
        <class>01</class>
        <subclass>H</subclass>
        <main-group>5</main-group>
        <subgroup>00</subgroup>
        <qualifying-character>B</qualifying-character>
      </further-classification>
    </classification-ipc>
    <classifications-ipcr date-changed="20151027">
      <classification-ipcr sequence="1">
        <text>A01H   5/00        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>A</section>
        <class>01</class>
        <subclass>H</subclass>
        <main-group>5</main-group>
        <subgroup>00</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="2">
        <text>C07K  14/21        20060101A I20051008RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>21</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051008</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="3">
        <text>C07K  14/415       20060101A I20051008RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>415</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051008</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="4">
        <text>C07K  14/725       20060101A I20051008RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>725</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051008</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="5">
        <text>C07K  16/10        20060101A I20051008RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>16</main-group>
        <subgroup>10</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051008</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="6">
        <text>C07K  19/00        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>19</main-group>
        <subgroup>00</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="7">
        <text>C12N   5/10        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>5</main-group>
        <subgroup>10</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="8">
        <text>C12N  15/13        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>13</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="9">
        <text>C12N  15/31        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>31</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="10">
        <text>C12N  15/40        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>40</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="11">
        <text>C12N  15/55        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>55</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="12">
        <text>C12N  15/62        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>62</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
      <classification-ipcr sequence="13">
        <text>C12N  15/82        20060101A I20051110RMEP        </text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>82</subgroup>
        <classification-value>I</classification-value>
        <action-date>
          <date>20051110</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
      </classification-ipcr>
    </classifications-ipcr>
    <classifications-cpc date-changed="20151027">
      <classification-cpc sequence="1">
        <text>C12N  15/8283      20130101 FI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>8283</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="2">
        <text>C07K  14/21        20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>21</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="3">
        <text>C07K  14/415       20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>415</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="4">
        <text>C07K  14/7051      20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>7051</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="5">
        <text>C07K  16/10        20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>16</main-group>
        <subgroup>10</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="6">
        <text>C07K2317/13        20130101 LA20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>2317</main-group>
        <subgroup>13</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="7">
        <text>C07K2317/34        20130101 LA20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>2317</main-group>
        <subgroup>34</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="8">
        <text>C07K2317/622       20130101 LA20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>2317</main-group>
        <subgroup>622</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="9">
        <text>C07K2317/73        20130101 LA20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>2317</main-group>
        <subgroup>73</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="10">
        <text>C07K2319/00        20130101 LA20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>2319</main-group>
        <subgroup>00</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>A</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
      <classification-cpc sequence="11">
        <text>C12N  15/8258      20130101 LI20130101BHEP        </text>
        <cpc-version-indicator>
          <date>20130101</date>
        </cpc-version-indicator>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>8258</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <action-date>
          <date>20130101</date>
        </action-date>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
      </classification-cpc>
    </classifications-cpc>
    <classifications-ecla date-changed="20151027">
      <classification-ecla sequence="1" classification-scheme="EC" country="EP">
        <text>C07K 14/21</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>21</subgroup>
      </classification-ecla>
      <classification-ecla sequence="2" classification-scheme="EC" country="EP">
        <text>C07K 14/415</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>415</subgroup>
      </classification-ecla>
      <classification-ecla sequence="3" classification-scheme="EC" country="EP">
        <text>C07K 14/705B12</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>705</subgroup>
        <additional-subgroups>
          <additional-subgroup sequence="1">B  </additional-subgroup>
          <additional-subgroup sequence="2">12 </additional-subgroup>
        </additional-subgroups>
      </classification-ecla>
      <classification-ecla sequence="4" classification-scheme="EC" country="EP">
        <text>C07K 16/10</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>16</main-group>
        <subgroup>10</subgroup>
      </classification-ecla>
      <classification-ecla sequence="5" classification-scheme="EC" country="EP">
        <text>C12N 15/82C4D2</text>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>82</subgroup>
        <additional-subgroups>
          <additional-subgroup sequence="1">C  </additional-subgroup>
          <additional-subgroup sequence="2">4  </additional-subgroup>
          <additional-subgroup sequence="3">D  </additional-subgroup>
          <additional-subgroup sequence="4">2  </additional-subgroup>
        </additional-subgroups>
      </classification-ecla>
      <classification-ecla sequence="6" classification-scheme="EC" country="EP">
        <text>C12N 15/82C8B6C</text>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>82</subgroup>
        <additional-subgroups>
          <additional-subgroup sequence="1">C  </additional-subgroup>
          <additional-subgroup sequence="2">8  </additional-subgroup>
          <additional-subgroup sequence="3">B  </additional-subgroup>
          <additional-subgroup sequence="4">6  </additional-subgroup>
          <additional-subgroup sequence="5">C  </additional-subgroup>
        </additional-subgroups>
      </classification-ecla>
      <classification-ecla sequence="1" classification-scheme="ICO" country="EP">
        <text>M07K317:130</text>
        <section>M</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>317</main-group>
        <subgroup>130</subgroup>
      </classification-ecla>
      <classification-ecla sequence="2" classification-scheme="ICO" country="EP">
        <text>M07K317:622</text>
        <section>M</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>317</main-group>
        <subgroup>622</subgroup>
      </classification-ecla>
      <classification-ecla sequence="3" classification-scheme="ICO" country="EP">
        <text>M07K319:00</text>
        <section>M</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>319</main-group>
        <subgroup>00</subgroup>
      </classification-ecla>
      <classification-ecla sequence="4" classification-scheme="ICO" country="EP">
        <text>M07K317:340</text>
        <section>M</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>317</main-group>
        <subgroup>340</subgroup>
      </classification-ecla>
      <classification-ecla sequence="5" classification-scheme="ICO" country="EP">
        <text>M07K317:730</text>
        <section>M</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>317</main-group>
        <subgroup>730</subgroup>
      </classification-ecla>
    </classifications-ecla>
    <number-of-claims calculated="yes">35</number-of-claims>
    <invention-title id="title_ger" date-changed="20070504" lang="ger" format="original">DURCH MOLEKULARES PATHOGENICID VERMITTELTE KRANKHEITSRESISTENZ IN PFLANZEN</invention-title>
    <invention-title id="title_eng" date-changed="20070504" lang="eng" format="original">MOLECULAR PATHOGENICIDE MEDIATED PLANT DISEASE RESISTANCE</invention-title>
    <invention-title id="title_fre" date-changed="20070504" lang="fre" format="original">PATHOGENICIDE MOLECULAIRE INDUISANT UNE RESISTANCE A LA MALADIE CHEZ DES VEGETAUX</invention-title>
    <references-cited date-changed="20070504">
      <patent-citations name="patcit" date-changed="20070504" />
      <non-patent-citations name="nplcit" date-changed="20061214" />
      <citation>
        <patcit num="1" dnum="EP-A- 0 479 180">
          <document-id>
            <country>EP</country>
            <doc-number>479180</doc-number>
            <kind>A2</kind>
            <date>19920408</date>
          </document-id>
          <application-date>
            <date>19910930</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="2" dnum="WO-A-00/14260">
          <document-id>
            <country>WO</country>
            <doc-number>0014260</doc-number>
            <kind>A1</kind>
            <date>20000316</date>
          </document-id>
          <application-date>
            <date>19990903</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="3" dnum="WO-A-92/12237">
          <document-id>
            <country>WO</country>
            <doc-number>9212237</doc-number>
            <kind>A1</kind>
            <date>19920723</date>
          </document-id>
          <application-date>
            <date>19920102</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="4" dnum="WO-A-95/11305">
          <document-id>
            <country>WO</country>
            <doc-number>9511305</doc-number>
            <kind>A2</kind>
            <date>19950427</date>
          </document-id>
          <application-date>
            <date>19941018</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="5" dnum="WO-A-96/00783">
          <document-id>
            <country>WO</country>
            <doc-number>9600783</doc-number>
            <kind>A1</kind>
            <date>19960111</date>
          </document-id>
          <application-date>
            <date>19950620</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="6" dnum="WO-A-96/09398">
          <document-id>
            <country>WO</country>
            <doc-number>9609398</doc-number>
            <kind>A1</kind>
            <date>19960328</date>
          </document-id>
          <application-date>
            <date>19950919</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="7" dnum="WO-A-96/39806">
          <document-id>
            <country>WO</country>
            <doc-number>9639806</doc-number>
            <kind>A1</kind>
            <date>19961219</date>
          </document-id>
          <application-date>
            <date>19960607</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="8" dnum="WO-A-97/13856">
          <document-id>
            <country>WO</country>
            <doc-number>9713856</doc-number>
            <kind>A1</kind>
            <date>19970417</date>
          </document-id>
          <application-date>
            <date>19961009</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="9" dnum="WO-A-98/03538">
          <document-id>
            <country>WO</country>
            <doc-number>9803538</doc-number>
            <kind>A2</kind>
            <date>19980129</date>
          </document-id>
          <application-date>
            <date>19971024</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <patcit num="10" dnum="WO-A-99/66026">
          <document-id>
            <country>WO</country>
            <doc-number>9966026</doc-number>
            <kind>A2</kind>
            <date>19991223</date>
          </document-id>
          <application-date>
            <date>19990615</date>
          </application-date>
        </patcit>
      </citation>
      <citation>
        <nplcit num="1">
          <text>ZIMMERMANN SABINE ET AL: "Intracellular expression of TMV-specific single-chain Fv fragments leads to improved virus resistance in Nicotiana tabacum." MOLECULAR BREEDING AUG., 1998, vol. 4, no. 4, August 1998 (1998-08), pages 369-379, XP002135713 ISSN: 1380-3743</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0031678633&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
      <citation>
        <nplcit num="2">
          <text>CONRAD, U., ET AL.: "Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity" PLANT MOLECULAR BIOLOGY, vol. 38, September 1998 (1998-09), pages 101-109, XP002135721</text>
          <scopus-url>http://www.scopus.com/record/display.url?eid=2-s2.0-0032168897&amp;origin=inward</scopus-url>
        </nplcit>
      </citation>
    </references-cited>
    <parties date-changed="20061018">
      <applicants>
        <applicant sequence="1" app-type="applicant">
          <addressbook lang="eng">
            <orgname>Fraunhofer-Gesellschaft zur FÃ¶rderung der  angewandten Forschung e.V. </orgname>
            <address>
              <address-1>Hansastrasse 27 c</address-1>
              <city>80686 MÃ¼nchen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="1">
          <addressbook lang="eng">
            <name>FISCHER, Rainer </name>
            <address>
              <address-1>Menzerath 1</address-1>
              <city>D-52156 Monschau</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="2">
          <addressbook lang="eng">
            <name>SCHILLBERG, Stefan </name>
            <address>
              <address-1>Bremenberg 24</address-1>
              <city>D-52072 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="3">
          <addressbook lang="eng">
            <name>NÃHRING, JÃ¶rg </name>
            <address>
              <address-1>Matthiashofstrasse 19</address-1>
              <city>D-52064 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="4">
          <addressbook lang="eng">
            <name>SACK, Markus </name>
            <address>
              <address-1>HÃ¶henweg 61</address-1>
              <city>D-52072 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="5">
          <addressbook lang="eng">
            <name>MONECKE, Michael </name>
            <address>
              <address-1>Hein-GÃ¶rgen-Strasse 19</address-1>
              <city>D-52066 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="6">
          <addressbook lang="eng">
            <name>LIAO, Yu-Cai </name>
            <address>
              <address-1>Vaalserstrasse 48</address-1>
              <city>D-52064 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="7">
          <addressbook lang="eng">
            <name>SPIEGEL, Holger </name>
            <address>
              <address-1>HÃ¶henweg 78</address-1>
              <city>D-52072 Aachen</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="8">
          <addressbook lang="eng">
            <name>ZIMMERMAN, Sabine </name>
            <address>
              <address-1>KyffhÃ¤userstr. 7</address-1>
              <city>D-50674 KÃ¶ln</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="9">
          <addressbook lang="eng">
            <name>EMANS, Neil </name>
            <address>
              <address-1>Val de la Berwinne 13</address-1>
              <city>B-4890 Thimister-Clermont</city>
              <country>BE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="10">
          <addressbook lang="eng">
            <name>HOLZEM, Achim </name>
            <address>
              <address-1>Heinrich Pesch Strasse  182</address-1>
              <city>D-41239 MÃ¶nchengladbach</city>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
    </parties>
    <designation-of-states date-changed="20061018">
      <designation-epc>
        <contracting-states>
          <country>AT</country>
          <country>BE</country>
          <country>CH</country>
          <country>CY</country>
          <country>DE</country>
          <country>DK</country>
          <country>ES</country>
          <country>FI</country>
          <country>FR</country>
          <country>GB</country>
          <country>GR</country>
          <country>IE</country>
          <country>IT</country>
          <country>LI</country>
          <country>LU</country>
          <country>MC</country>
          <country>NL</country>
          <country>PT</country>
          <country>SE</country>
        </contracting-states>
      </designation-epc>
    </designation-of-states>
    <pct-or-regional-filing-data>
      <document-id>
        <country>WO</country>
        <doc-number>EP99007844</doc-number>
        <date>19991015</date>
      </document-id>
    </pct-or-regional-filing-data>
    <pct-or-regional-publishing-data>
      <document-id>
        <country>WO</country>
        <doc-number>0023593</doc-number>
        <date>20000427</date>
      </document-id>
    </pct-or-regional-publishing-data>
    <patent-family date-changed="20100416">
      <main-family family-id="1069037">
        <family-member>
          <document-id>
            <country>AT</country>
            <doc-number>301715</doc-number>
            <kind>T</kind>
            <date>20050815</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>0023593</doc-number>
            <kind>A3</kind>
            <date>20000727</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>BR</country>
            <doc-number>PI9915543</doc-number>
            <kind>A</kind>
            <date>20010814</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69926647</doc-number>
            <kind>T2</kind>
            <date>20061109</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1123398</doc-number>
            <kind>A2</kind>
            <date>20010816</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1123398</doc-number>
            <kind>B1</kind>
            <date>20050810</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69926647</doc-number>
            <kind>D1</kind>
            <date>20050915</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>ES</country>
            <doc-number>2246093</doc-number>
            <kind>T3</kind>
            <date>20060201</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>0023593</doc-number>
            <kind>A2</kind>
            <date>20000427</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
      </main-family>
      <complete-family family-id="984156">
        <family-member>
          <document-id>
            <country>AT</country>
            <doc-number>301715</doc-number>
            <kind>T</kind>
            <date>20050815</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>0023593</doc-number>
            <kind>A3</kind>
            <date>20000727</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>BR</country>
            <doc-number>PI9915543</doc-number>
            <kind>A</kind>
            <date>20010814</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1123398</doc-number>
            <kind>A2</kind>
            <date>20010816</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1123398</doc-number>
            <kind>B1</kind>
            <date>20050810</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>US</country>
            <doc-number>6825325</doc-number>
            <kind>B1</kind>
            <date>20041130</date>
          </document-id>
          <application-date>
            <date>19991018</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>CA</country>
            <doc-number>2345903</doc-number>
            <kind>A1</kind>
            <date>20000427</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>CA</country>
            <doc-number>2345903</doc-number>
            <kind>C</kind>
            <date>20060926</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69926647</doc-number>
            <kind>D1</kind>
            <date>20050915</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>DE</country>
            <doc-number>69926647</doc-number>
            <kind>T2</kind>
            <date>20061109</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>EP</country>
            <doc-number>1123398</doc-number>
            <kind>A1</kind>
            <date>20010816</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>ES</country>
            <doc-number>2246093</doc-number>
            <kind>T3</kind>
            <date>20060201</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>IN</country>
            <doc-number>192141</doc-number>
            <kind>A1</kind>
            <date>20040228</date>
          </document-id>
          <application-date>
            <date>19981016</date>
          </application-date>
        </family-member>
        <family-member>
          <document-id>
            <country>WO</country>
            <doc-number>0023593</doc-number>
            <kind>A2</kind>
            <date>20000427</date>
          </document-id>
          <application-date>
            <date>19991015</date>
          </application-date>
        </family-member>
      </complete-family>
    </patent-family>
  </bibliographic-data>
  <abstract id="abstr_eng" date-changed="20110524" lang="eng" format="equivalent" country="US" doc-number="6825325" kind="B1">
    <p>The present invention is drawn to a fusion protein containing at least one binding domain that specifically recognizes an eptitope of a plant pathogen and at least one additional domain made from a protein or peptide sequence which is toxic to the pathogen or detrimental the replication, transmission or life cycle of the pathogen. The present invention is further drawn to a pathogenocide made from the binding domain, a cellular targeting sequence and/or membrane localization sequence that leads to membrane anchoring. The present invention is further drawn to nucleotide sequences encoding fusion proteins and pathogenocides and to vectors containing the nucleotide sequences; as well as methods of making the fusion proteins and pathogencides and methods of making pathogen resistant plants, plant cells, or plant tissues with the fusion proteins and pathogenocides.</p>
  </abstract>
  <legal-data date-changed="20160212">
    <legal-event sequence="1">
      <publication-date>
        <date>20010816</date>
      </publication-date>
      <event-code-1>17P</event-code-1>
      <effect>+</effect>
      <legal-description>REQUEST FOR EXAMINATION FILED</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <effective-date>
        <date>20010412</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="2">
      <publication-date>
        <date>20010816</date>
      </publication-date>
      <event-code-1>AK</event-code-1>
      <effect>+</effect>
      <legal-description>DESIGNATED CONTRACTING STATES:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <corresponding-kind>A2</corresponding-kind>
      <legal-designated-states>
        <country>AT</country>
        <country>BE</country>
        <country>CH</country>
        <country>CY</country>
        <country>DE</country>
        <country>DK</country>
        <country>ES</country>
        <country>FI</country>
        <country>FR</country>
        <country>GB</country>
        <country>GR</country>
        <country>IE</country>
        <country>IT</country>
        <country>LI</country>
        <country>LU</country>
        <country>MC</country>
        <country>NL</country>
        <country>PT</country>
        <country>SE</country>
      </legal-designated-states>
    </legal-event>
    <legal-event sequence="3">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SCHILLBERG, STEFAN</inventor-name>
    </legal-event>
    <legal-event sequence="4">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>ZIMMERMAN, SABINE</inventor-name>
    </legal-event>
    <legal-event sequence="5">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>MONECKE, MICHAEL</inventor-name>
    </legal-event>
    <legal-event sequence="6">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>FISCHER, RAINER</inventor-name>
    </legal-event>
    <legal-event sequence="7">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>LIAO, YU-CAI</inventor-name>
    </legal-event>
    <legal-event sequence="8">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SPIEGEL, HOLGER</inventor-name>
    </legal-event>
    <legal-event sequence="9">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SACK, MARKUS</inventor-name>
    </legal-event>
    <legal-event sequence="10">
      <publication-date>
        <date>20010912</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>NAEHRING, JOERG</inventor-name>
    </legal-event>
    <legal-event sequence="11">
      <publication-date>
        <date>20031119</date>
      </publication-date>
      <event-code-1>RAP1</event-code-1>
      <legal-description>TRANSFER OF RIGHTS OF AN EP APPLICATION</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <new-owner>FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DERANGEWAND</new-owner>
    </legal-event>
    <legal-event sequence="12">
      <publication-date>
        <date>20040121</date>
      </publication-date>
      <event-code-1>17Q</event-code-1>
      <effect>+</effect>
      <legal-description>FIRST EXAMINATION REPORT</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <effective-date>
        <date>20031208</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="13">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>MONECKE, MICHAEL</inventor-name>
    </legal-event>
    <legal-event sequence="14">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>EMANS, NEIL</inventor-name>
    </legal-event>
    <legal-event sequence="15">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SCHILLBERG, STEFAN</inventor-name>
    </legal-event>
    <legal-event sequence="16">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>LIAO, YU-CAI</inventor-name>
    </legal-event>
    <legal-event sequence="17">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>HOLZEM, ACHIM</inventor-name>
    </legal-event>
    <legal-event sequence="18">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SACK, MARKUS</inventor-name>
    </legal-event>
    <legal-event sequence="19">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>FISCHER, RAINER</inventor-name>
    </legal-event>
    <legal-event sequence="20">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>SPIEGEL, HOLGER</inventor-name>
    </legal-event>
    <legal-event sequence="21">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>NAEHRING, JOERG</inventor-name>
    </legal-event>
    <legal-event sequence="22">
      <publication-date>
        <date>20050323</date>
      </publication-date>
      <event-code-1>RIN1</event-code-1>
      <legal-description>INVENTOR (CORRECTION)</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <inventor-name>ZIMMERMAN, SABINE</inventor-name>
    </legal-event>
    <legal-event sequence="23">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>AK</event-code-1>
      <effect>+</effect>
      <legal-description>DESIGNATED CONTRACTING STATES:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <corresponding-kind>B1</corresponding-kind>
      <legal-designated-states>
        <country>AT</country>
        <country>BE</country>
        <country>CH</country>
        <country>CY</country>
        <country>DE</country>
        <country>DK</country>
        <country>ES</country>
        <country>FI</country>
        <country>FR</country>
        <country>GB</country>
        <country>GR</country>
        <country>IE</country>
        <country>IT</country>
        <country>LI</country>
        <country>LU</country>
        <country>MC</country>
        <country>NL</country>
        <country>PT</country>
        <country>SE</country>
      </legal-designated-states>
    </legal-event>
    <legal-event sequence="24">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>CH</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="25">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>LI</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="26">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>AT</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="27">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FI</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="28">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>BE</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="29">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>IT</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20050810</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="30">
      <publication-date>
        <date>20050810</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <designated-state-event-code>FG4D</designated-state-event-code>
      <designated-state-description>EUROPEAN PATENT GRANTED</designated-state-description>
    </legal-event>
    <legal-event sequence="31">
      <publication-date>
        <date>20050815</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>CH</country>
      </designated-state-authority>
      <designated-state-event-code>EP</designated-state-event-code>
      <designated-state-description>ENTRY IN THE NATIONAL PHASE</designated-state-description>
    </legal-event>
    <legal-event sequence="32">
      <publication-date>
        <date>20050907</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>IE</country>
      </designated-state-authority>
      <designated-state-event-code>FG4D</designated-state-event-code>
      <designated-state-description>EUROPEAN PATENTS GRANTED DESIGNATING IRELAND</designated-state-description>
    </legal-event>
    <legal-event sequence="33">
      <publication-date>
        <date>20050915</date>
      </publication-date>
      <event-code-1>REF</event-code-1>
      <legal-description>CORRESPONDS TO:</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <corresponding-publication-number>69926647</corresponding-publication-number>
      <corresponding-authority>
        <country>DE</country>
      </corresponding-authority>
      <corresponding-publication-date>
        <date>20050915</date>
      </corresponding-publication-date>
      <corresponding-kind>P</corresponding-kind>
    </legal-event>
    <legal-event sequence="34">
      <publication-date>
        <date>20051015</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>CY</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20051015</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="35">
      <publication-date>
        <date>20051017</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>IE</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES</free-text-description>
      <effective-date>
        <date>20051017</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="36">
      <publication-date>
        <date>20051031</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>MC</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES</free-text-description>
      <effective-date>
        <date>20051031</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="37">
      <publication-date>
        <date>20051031</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>LU</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES</free-text-description>
      <effective-date>
        <date>20051031</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="38">
      <publication-date>
        <date>20051110</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>SE</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20051110</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="39">
      <publication-date>
        <date>20051110</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DK</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20051110</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="40">
      <publication-date>
        <date>20051110</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GR</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20051110</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="41">
      <publication-date>
        <date>20060110</date>
      </publication-date>
      <event-code-1>PG25</event-code-1>
      <effect>-</effect>
      <legal-description>LAPSED IN A CONTRACTING STATE ANNOUNCED VIA POSTGRANT INFORM. FROM NAT. OFFICE TO EPO</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>PT</country>
      </designated-state-authority>
      <free-text-description>LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT</free-text-description>
      <effective-date>
        <date>20060110</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="42">
      <publication-date>
        <date>20060201</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>ES</country>
      </designated-state-authority>
      <designated-state-event-code>FG2A</designated-state-event-code>
      <designated-state-description>DEFINITIVE PROTECTION</designated-state-description>
      <corresponding-publication-number>2246093</corresponding-publication-number>
      <corresponding-kind>T3</corresponding-kind>
    </legal-event>
    <legal-event sequence="43">
      <publication-date>
        <date>20060215</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>CH</country>
      </designated-state-authority>
      <designated-state-event-code>PL</designated-state-event-code>
      <designated-state-description>PATENT CEASED</designated-state-description>
    </legal-event>
    <legal-event sequence="44">
      <publication-date>
        <date>20060519</date>
      </publication-date>
      <event-code-1>ET</event-code-1>
      <effect>+</effect>
      <legal-description>FR: TRANSLATION FILED</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
    </legal-event>
    <legal-event sequence="45">
      <publication-date>
        <date>20060719</date>
      </publication-date>
      <event-code-1>26N</event-code-1>
      <effect>+</effect>
      <legal-description>NO OPPOSITION FILED</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <effective-date>
        <date>20060511</date>
      </effective-date>
    </legal-event>
    <legal-event sequence="46">
      <publication-date>
        <date>20060809</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>IE</country>
      </designated-state-authority>
      <designated-state-event-code>MM4A</designated-state-event-code>
      <designated-state-description>PATENT LAPSED</designated-state-description>
    </legal-event>
    <legal-event sequence="47">
      <publication-date>
        <date>20130131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20121213</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="48">
      <publication-date>
        <date>20130131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20121113</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="49">
      <publication-date>
        <date>20130228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20121023</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="50">
      <publication-date>
        <date>20130228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>ES</country>
      </designated-state-authority>
      <payment-date>
        <date>20121023</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="51">
      <publication-date>
        <date>20130329</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>C</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>NL</country>
      </designated-state-authority>
      <payment-date>
        <date>20121018</date>
      </payment-date>
      <fee-payment-year>14</fee-payment-year>
    </legal-event>
    <legal-event sequence="52">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20131024</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="53">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20131024</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="54">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20131018</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="55">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20131022</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="56">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20131022</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="57">
      <publication-date>
        <date>20140131</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20131018</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="58">
      <publication-date>
        <date>20140228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>ES</country>
      </designated-state-authority>
      <payment-date>
        <date>20131022</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="59">
      <publication-date>
        <date>20140228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>NL</country>
      </designated-state-authority>
      <payment-date>
        <date>20131021</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="60">
      <publication-date>
        <date>20140228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>NL</country>
      </designated-state-authority>
      <payment-date>
        <date>20131021</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="61">
      <publication-date>
        <date>20140228</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>ES</country>
      </designated-state-authority>
      <payment-date>
        <date>20131022</date>
      </payment-date>
      <fee-payment-year>15</fee-payment-year>
    </legal-event>
    <legal-event sequence="62">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20141024</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="63">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>O</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20141024</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="64">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>ES</country>
      </designated-state-authority>
      <payment-date>
        <date>20141024</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="65">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <payment-date>
        <date>20141021</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="66">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20141024</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="67">
      <publication-date>
        <date>20150130</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20141024</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="68">
      <publication-date>
        <date>20150227</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>NL</country>
      </designated-state-authority>
      <payment-date>
        <date>20141023</date>
      </payment-date>
      <fee-payment-year>16</fee-payment-year>
    </legal-event>
    <legal-event sequence="69">
      <publication-date>
        <date>20151026</date>
      </publication-date>
      <event-code-1>REG</event-code-1>
      <legal-description>REFERENCE TO A NATIONAL CODE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>FR</country>
      </designated-state-authority>
      <designated-state-event-code>PLFP</designated-state-event-code>
      <designated-state-description>FEE PAYMENT</designated-state-description>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="70">
      <publication-date>
        <date>20160129</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>DE</country>
      </designated-state-authority>
      <payment-date>
        <date>20151022</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
    <legal-event sequence="71">
      <publication-date>
        <date>20160129</date>
      </publication-date>
      <event-code-1>PGFP</event-code-1>
      <effect>+</effect>
      <legal-description>POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE</legal-description>
      <status-identifier>N</status-identifier>
      <docdb-publication-number> EP     1123398A2</docdb-publication-number>
      <docdb-application-id>17458226</docdb-application-id>
      <designated-state-authority>
        <country>GB</country>
      </designated-state-authority>
      <payment-date>
        <date>20151026</date>
      </payment-date>
      <fee-payment-year>17</fee-payment-year>
    </legal-event>
  </legal-data>
  <description id="descr_eng" lang="eng" format="original" date-changed="20070504">
    <heading>
      <b>FIELD OF THE INVENTION</b>
    </heading>
    <p id="p-00001-en">The present invention relates to gene constructs suitable for expressing agents to protect a plant against pathogens and the suitable proteins for such plant protection. These agents are named "molecular pathogenicides". This invention is related to the genetic engineering of plants and to means and methods for conferring pathogen resistance on a plant using a gene or genes encoding: a pathogen specific antibody and a pathogen specific antibody including a toxic activity which blocks stages of the pathogen life cycle, pathogen replication or pathogen movement within a plant or pathogen transmission from plant to plant. The means and methods are given for the immobilisation of recombinant antibodies, antibody fusion proteins and antibody protein complexes in cellular membranes in different orientations and the display of recombinant proteins on the plant cell membrane. This invention also describes novel methods and protein binding partners for assembling protein complexes from individual polypeptide chains during expression of these proteins in vivo. Also given are the methods for activation of the molecular pathogenicides by in vivo proteolytic cleavage.</p>
    <heading>
      <b>BACKGROUND OF THE INVENTION</b>
    </heading>
    <p id="p-00002-en">Plant disease constitutes a major and ongoing threat to human food stocks and animal feed. Most crop plants are regularly exposed to one or more pathogen(s) that can cause incredible damage resulting in substantial economical losses every year. Attack by pathogens, such as viruses, bacteria, fungi, nematodes and insects and is a severe economic problem, which impacts all economically important crops, for example rice, soybean, sweet potato, wheat, potato, grape, maize and ornamental plants. Current protective measures rely heavily on chemical control measures for pathogen vectors, which have undesirable environmental consequences.</p>
    <p id="p-00003-en">A more effective approach to protecting plants from pathogen attack is to create plants that are endogenously resistant to pathogens. However, plant breeders have limited sources of resistance genes against plant diseases. This can now be achieved using genetic engineering techniques, by providing the plant with genetic information required for affecting the pathogens and for being resistant to the disease caused by the pathogen. For example, in the case of a viral pathogen, the host plant is resistant if it has the ability to inhibit or retard the replication of a virus, the symptoms of viral infection or the life cycle of the virus, including its transmission. "Resistant" is the opposite of "susceptible" and may be divided into three levels:<ol><li>1) Full,</li><li>2) Medium,</li><li>3) Partial resistance,</li></ol></p>
    <p id="p-00004-en">A plant may be considered fully resistant when it shows no symptoms on infection and there is no evidence of pathogen replication or reproduction. The host plant may be resistant to the establishment of infection, pathogen reproduction and/or pathogen movement and transmission.</p>
    <p id="p-00005-en">In recent years, the advances in plant molecular virology have enhanced the understanding of pathogen genome organisation and gene function. Moreover, genetic engineering of plants for virus resistance has recently provided new strategies for control of viral disease (Baulcombe, 1994), (Gadani et al., 1990), (Wilson, 1993). The following genes were expressed in transgenic plants in order to confer resistance: viral coat proteins, non-structural proteins of viral genomes, viral anti-sense transcripts, viral satellite RNAs, ribozymes and interferon genes (Baulcombe, 1994), (Gadani et al., 1990), (Wilson, 1993), (Harrison et al., 1987), (Namba et al., 1991), (Anderson et al., 1992). Although most of these approaches have been effective for attenuating infections, resistance was not complete and confined to a small spectrum of viral pathogens (Falk and Bruening, 1994), (Wilson, 1993) and bears significant risks (Palukaitis and Roossinck, 1996).</p>
    <p id="p-00006-en">The major disadvantages of these methods are:<ol><li>1) Host range is limited.</li><li>2) Pathogen range is limited.</li><li>3) Resistance is partial and though symptoms are delayed infection still results in the disease.</li><li>4) Resistance could be broken in case of coat protein mediated resistance and ribozyme mediated resistance.</li><li>5) Expression of viral proteins can lead to enhanced pathogen activity. For example, in the case of viral coat protein mediated resistance, cross encapsidation of mild non-pathogenic strains of virus by the expressed coat protein can occur which then leads to development of a more severe disease.</li></ol></p>
    <p id="p-00007-en">An alternative way to protect plants against pathogen infection is the generation and expression of recombinant antibodies (rAbs), which are often referred to as<b>"Plantibodies".</b> Pathogen-specific recombinant antibodies targeted to different compartments of plant cells or different plant organs overcome many of the problems mentioned before and confer a broader spectrum of resistance to disease (Baulcombe, 1994). To achieve this, recombinant antibodies (PlÃ¼ckthun, 1991), (Winter and Milstein, 1991) against the target proteins have to be generated by cloning the corresponding antibody heavy and light chain genes from hybridoma cells, synthetic, semi-synthetic and immunocompetent phage display or ribosome display libraries; or by the generation of fully synthetic designer antibodies. This is followed by subsequent modification and rAb expression in different compartments of heterologous hosts such as bacteria, yeast, algae, baculovirus infected insect cells, mammalian cells and plants. For example, antibodies and antibody-fusion proteins binding to conserved functional domains of viral coat proteins, movement proteins, replicases or transmission factors can be used to inactivate such targets inside or outside the plant cell through immunomodulation. The feasibility of expressing recombinant antibodies (PlÃ¼ckthun, 1991), (Winter and Milstein, 1991) for the generation of resistance has been shown recently for both animal (Chen et al., 1994), (Duan et al., 1994), (Marasco et al., 1993) and plant viruses (Tavladoraki et al., 1993), (Voss et al., 1995), (Zimmermann et al., 1998). Single chain antibody fragments derived from monoclonal antibodies (scFvs) (Bird et al., 1988) directed against Rev (Duan et al., 1994) and gp120 (Chen et al., 1994) (Marasco et al., 1993) of HIV, inhibited HIV-replication, virion assembly and syncytia formation when expressed intracellularly, or within the ER of human cells.</p>
    <p id="p-00008-en">Interestingly, intracellular expression of an scFv specific for the artichoke mottled crinkle virus coat protein in transgenic Tobacco caused a reduction of infection and a delay in symptom development (Tavladoraki et al., 1993). Targeting of TMV-specific full-size antibodies to the intercellular space of Tobacco plants inhibited viral infections up to 70% (Voss et al., 1995). In the latter case, plant produced antibodies showed the same specificity and affinity for TMV (Fischer et al., 1998) as the parental murine antibody. Cytosolic expression of an engineered scFv derived from this anti-TMV antibody yielded fully resistant Tobacco plants, even under systemic infection conditions (Zimmermann et al., 1998). These studies demonstrate the potential of heterologously expressed recombinant antibodies to combat pathogens via intra- or extra-cellular modulation of pathogen proteins.</p>
    <p id="p-00009-en">Plant cells can synthesise large amounts of antibodies that are functionally indistinguishable from the source monoclonal. For example, full-size antibodies (DÃ¼ring et al., 1990), (Hiatt et al., 1989), (Voss et al., 1995), Fab-fragments (De Neve et al., 1993), scFvs (Owen et al., 1992; Zimmermann et al., 1998), (Tavladoraki et al., 1993), scFv fusion proteins (Spiegel et al., Plant Science 149 (1999), 63-71), bispecific scFv (Fischer et al., 1999) and dAbs (Benvenuto et al., 1991) have been successfully expressed in Tobacco, Potato (Schouten et al., 1997) or <i>Arabidopsis,</i> reaching expression levels as high as 6.8% of the total protein (Fiedler et al., 1997). Targeting of recombinant antibodies by exploiting known protein trafficking signal sequences now permits rAb expression in the cytoplasm (scFv fragments (Tavladoraki et al., 1993; Zimmermann et al., 1998)), the endoplasmic reticulum (Fiedler et al., 1997), chloroplasts (DÃ¼ring et al., 1990) and the intercellular space (Benvenuto et al., 1991; De Neve et al., 1993; Voss et al., 1995; Zimmermann et al., 1998) (full-size, Fab fragments, scFvs and single domain Abs). These results demonstrate the flexibility of the plant system to express any recombinant antibody or recombinant antibody fragments in almost all plant compartments, using targeting sequences that also may be from plants or derived from other eukaryotes.</p>
    <p id="p-00010-en">The advantage of targeted protein expression is that the rAbs can be expressed where the pathogen is most vulnerable and where they will have the maximal protective effect. WO 96/00783 and WO 95/11305 disclose a fusion protein which consists of a binding domain (e.g. an antibody or the Bt Î´-endotoxin) fused to a toxic domain (e.g. a toxic enzyme or a venom) which is toxic or detrimental to a pathogen. In patent application WO 96/09398 the use of antibody-fusion proteins as agents for controlling crop disease caused by pathogens is proposed.</p>
    <p id="p-00011-en">The antibody delivers a toxin which kills the pathogen in transgenic plants or when expressed or applied as an external immunotoxin. WO 96/09398 is focussed on recombinant Ab-fusion proteins - single polypeptides that are either genetically, chemically or "biochemically" linked to form an immunotoxin. However, WO 96/09398 does not provide proof of principle for antibody mediated pathogen resistance and it was doubtful whether any of the hypothetical examples in WO 96/09898 would work to the extent that a protection of plants against pathogen attack can be obtained sufficient to comply with the needs of the breeders and farmers. Thus, there is still a need of means and methods for conferring antipathogenic/predator characteristics to transgenic plants.</p>
    <heading>
      <b>SUMMARY OF THE INVENTION</b>
    </heading>
    <p id="p-00012-en">The objective of this current patent application is to provide means and methods for protecting plants, in particular monocotyledonous and dicotyledonous agricultural crops and omamental plants, against pathogens in a more effective and environmentally sensitive manner. Accordingly, the solution to the technical problem is achieved by providing the embodiments characterised in the claims.</p>
    <p id="p-00013-en">As will be described hereinbelow, the above-mentioned objective is met according to the invention by any one of the following or any combination of the following inventions: i) the expression of pathogen specific recombinant antibodies and parts thereof, or ii) by fusing antibodies or parts thereof to toxins, proteins, or enzymes having activity against the pathogens or to the effective parts of these toxins or enzymes, and then expressing these fusion proteins, or iii) by assembling protein complexes composed of an antibody or fragment thereof <i>in vivo</i> using the novel binding proteins described here and or iv) including a specific protease sensitive sequence, that is cleaved (e.g. in the presence of the pathogen or in a specific plant cell compartment) to release and or activate the toxic activity of any of the recombinant proteins in i) to iii), and v) targeting or integrating any of the recombinant proteins in i) to iv) to cell membranes in any orientation. These agents are also named "molecular pathogenicides". Thus, in one aspect the present invention relates to a fusion protein comprising<ol><li>(a) at least one binding domain comprising an antibody or binding site thereof specifically recognising an epitope of a plant pathogen; and</li><li>(b) a membrane localisation sequence and/or motif that leads to membrane anchoring and, optionally, a cellular targeting sequence.</li></ol></p>
    <p id="p-00014-en">In a further aspect, said fusion protein comprises at least one further domain comprising a protein or peptide sequence which is toxic to the pathogen or detrimental to its replication, transmission or life cycle.</p>
    <p id="p-00015-en">Said domains can be linked by covalent or non-covalent bonds. In a preferred embodiment of the fusion protein of the invention said binding domain comprises an antibody, a T-cell receptor, a pathogen specific receptor, a peptide specific for an epitope of a pathogen, or at least the binding site of any one of those.</p>
    <p id="p-00016-en">In another aspect, the invention relates to membrane associated binding domains and further domains, respectively, as defined herein.</p>
    <p id="p-00017-en">The fusion proteins composed of a pathogen specific antibody and toxin molecule can be made by fusing the respective parts by genetic or biochemical means. In addition, the chimeric protein can preferably be assembled <i>in vivo</i> from its parts by the plant or via expression in the organisms' endogenous protein machinery. These domains or parts thereof, fusion proteins or protein complexes can be targeted to organelles and plant, cell compartments or immobilised and membrane anchored by the addition of signal sequences and or membrane anchors. The recombinant molecular pathogenicide protein preferably contains specific protease cleavage sequences that are cleaved <i>in vivo</i>, by a plant and/or a pathogen specific protease(s), to release and or activate the toxic agent(s), or parts thereof, upon infection.</p>
    <p id="p-00018-en">The fusion protein of the present invention can further comprise a carrier protein suitable for delivering the fusion protein or its domains into a host cell, preferably plant cell or a cellular compartment thereof. Furthermore, the fusion protein of the present invention can comprise a fluorophore such as green fluorescent protein fused to at least one of the above-described domains the fusion protein consists of. In a further aspect, the present invention relates to a pathogenicide comprising at least one binding and/or further domain as defined herein and a cellular targeting sequence and/or membrane localisation sequence and/or motif that leads to membrane anchoring. Preferably, the membrane localisation sequence is proteolytically sensitive.</p>
    <p id="p-00019-en">Suitable membrane anchor sequences, enabling the integration of secretory recombinant antibody fusion proteins and parts thereof in the plasma membrane, include the human T cell receptor transmembrane domains (Gross and Eshhar, 1992), glyco-phosphatidyl inositol (GPI) anchors (Gerber et al., 1992), immunoglobulin superfamily membrane anchors, tetraspan family members (Tedder and Engel, 1994; Wright and Tomlinson, 1994) and any transmembrane sequence(s) from a known protein or synthesised sequences that have a similar function and can be included in the target protein by recombinant DNA technology. Fusion of a protein to these sequences would permit display of the recombinant protein on the lumenal face of organelles of the secretory or endocytic pathway or the plant cell membrane. This has the advantage that the recombinant protein can be targeted to the intracellular space where many pathogens are most vulnerable.</p>
    <p id="p-00020-en">In addition, the antibodies or parts thereof, or the recombinant antibody fusion proteins, or parts thereof, may be targeted to cell membranes where they could face the cytosolic side of the membrane. Suitable targeting sequences for cytoplasmic display, include the transmembrane domains of: KAR1, for nuclear membrane integration (Rose and Fink, 1987), middle-T antigen (Kim et al., 1997), for plasma membrane integration and cytochrome b5, for ER membrane integration (Kim et al., 1997). C-terminal linkages to fatty acids using consensus amino acid sequences leading to post translational prenylation, farnesylation, palmitoylation, myristoylation or ankyrin sequence motifs can also be used. This cytoplasmic display method has the significant advantage that the recombinant proteins can be localised at the site of intracellular pathogen replication, where they will have the most potent effect. In addition, membrane localisation of proteins stabilises the protein and reduces the effect of C-terminal protein degradation <i>in vivo.</i> Preferably, the pathogenicide of the invention comprises the fusion protein described herein.</p>
    <p id="p-00021-en">In a particularly preferred embodiment, the present invention relates to the described pathogenicides wherein said binding domain(s) and/or said further domain(s) are capable of self assembly in vivo.</p>
    <p id="p-00022-en">In a further embodiment, the present invention relates to a polynucleotide encoding a fusion protein or pathogenicide of the invention. Thus, the invention relates to one or more gene constructs that encode a nucleotide sequence encoding an antibody or part thereof which is specific for a pathogen and in the case of fusion proteins, for a nucleotide sequence encoding a protein, enzyme or peptide which has detrimental effects on a pathogen and ideally is toxic to the pathogen. This invention includes antibodies specific for the pathogen and/or for host proteins utilised by the pathogen during its life cycle. This invention also relates to chimeric proteins that consist of an antibody, antibodies or parts thereof, which are specific for a pathogen, and a protein or peptide which has detrimental or ideally toxic effects on the pathogen and which has been constructed by biochemically linking the antibody or parts thereof to the toxin. Furthermore, the present invention relates to a vector comprising the polynucleotide of the invention. Said vector can comprise separate polynucleotides encoding at least one of said binding domain(s) and/or said further domain(s) of the above-described fusion protein. In addition, the present invention relates to a composition comprising vectors wherein each vector contains at least one polynucleotide encoding at least one binding domain and/or at least one further domain of the fusion protein or the pathogenicide of the invention; and wherein the expression of at least two of said polynucleotides results in the production of said fusion protein or said pathogenicide or assembly of the same in vivo.</p>
    <p id="p-00023-en">In a preferred embodiment of the vector or the composition of the invention the polynucleotide is operatively linked to regulatory sequences allowing the expression of the fusion protein, pathogenicide or the domains thereof in a host cell. Said regulatory sequence can be a constitutive, chimeric, tissue specific or inducible promoter.</p>
    <p id="p-00024-en">Furthermore, the present invention relates to a host cell comprising any one of the above-described polynucleotides, vectors or vectors of the compositions.</p>
    <p id="p-00025-en">In another embodiment the present invention relates to a method for the production of a molecular pathogenicide comprising:<ol><li>(a) culturing the host cell of the invention under conditions suitable for the expression of the polynucleotide; and</li><li>(b) recovering the fusion protein, pathogenicide or the domains thereof from the culture.</li></ol></p>
    <p id="p-00026-en">The present invention also relates to a molecular pathogenicide obtainable by the method of the invention or encodable by the polynucleotide of the invention.</p>
    <p id="p-00027-en">This invention also relates to <i>in vivo</i> assembled protein complexes composed of one or more discrete polypeptide chains, encoded by separate nucleotide sequences on one or more constructs, that are assembled by the plant or expression organisms protein synthesis machinery into a protein complex.</p>
    <p id="p-00028-en">Furthermore, the present invention relates to a method for the production of pathogen resistant transgenic plants, plant cells or plant tissue comprising the introduction of a polynucleotide or vector of the invention or the vectors of the composition of the invention into the genome of a plant, plant cell or plant tissue.</p>
    <p id="p-00029-en">The present invention also relates to a transgenic plant cell which contains stably integrated into the genome a polynucleotide or vector of the invention or the vectors of the composition of the invention or obtainable according to the method of the invention.</p>
    <p id="p-00030-en">In addition, the present invention relates to a transgenic plant or plant tissue comprising the above-described plant cells or obtainable by the method of the invention. Encompassed are also the transgenic plants wherein the fusion protein or pathogenicide are made functional against pathogens by <i>in vivo</i> assembly after cotransformation of at least two independent plant expression constructs or after sexual crossing to form hybrid offspring from two parental plants expressing one or more of the domains of the fusion protein or the pathogenicide, or any other form of genetic recombination. Preferably, the transgenic plant of the invention displays improved resistance against a pathogen that the wild type plant was susceptible to.</p>
    <p id="p-00031-en">Furthermore, the present invention relates to harvestable parts and propagation material of a plant of the invention comprising plant cells of the invention.</p>
    <p id="p-00032-en">In a still further embodiment, the present invention relates to a kit comprising any one of the described fusion proteins, pathogenicides, polynucleotides, compositions or molecular pathogenicides of the invention.</p>
    <p id="p-00033-en">In another embodiment the present invention relates to the use of the described antibodies, fusion proteins, polynucleotides, vectors, compositions and molecular pathogenicides of the invention in agriculture for the protection of a plant against the action of a pathogen.</p>
    <p id="p-00034-en">Some aspects of the present invention will be described herein below in more detail.</p>
    <p id="p-00035-en">The term "binding domain" is used to denote polypeptide chain(s) which exhibit a strong monovalent, bivalent or polyvalent binding to a given epitope or epitopes. Preferably, said binding domain is an antibody or a binding site thereof. The antibodies may be generated by hybridoma technology, or ribosome display, or phage display, of natural naÃ¯ve origin, or immunised origin, semi-synthetic or fully synthetic libraries. The term "antibody" is also used to denote designer antibodies. These antibody polypeptides are encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind the given epitope or epitopes. The recognised immunoglobulin genes include the kappa and lambda light chain genes, the mu, delta, gamma, alpha and epsilon constant regions as well as all immunoglobulin variable regions from vertebrate, camelid, avian and pisces species. The term antibody, as used herein, includes in particular those antibodies synthesised or constructed <i>de novo</i> using recombinant DNA methodology, such as recombinant full-size antibodies, dimeric secretory IgA antibodies, multimeric IgM antibodies, F(ab')<sub>2</sub>-fragments, Fab-fragments, Fv-fragments, single chain Fv-fragments (scFvs), bispecific scFvs, diabodies, single domain antibodies (dAb), minibodies and molecular recognition units (MRUs). Antibody sequences may be derived from any vertebrate, camelid, avian or pisces species using recombinant DNA technology, or also by using synthetic, semi-synthetic and naive or immunocompetent phage and ribosome display libraries, gene shuffling libraries, and fully synthetic designer antibodies. In this invention, the antibodies are generated against specific pathogen or host plant epitopes that are involved in the pathogen replication, reproduction or life cycle.</p>
    <p id="p-00036-en">The term "pathogen" is used to denote viral or virus like organisms, bacteria, mycoplasmas, fungi, insects or nematodes that affect the germination of seed, growth, development, reproduction, harvest, yield or utility of a plant.<br /> The term "toxic" refers to an activity, which may be peptide or polypeptide encoded, that affects the reproduction or replication of a pathogen and/or any stages of its life cycle. In the case of viral pathogens, this includes entry into the plant, viral uncoating and disassembly, viral replication, viral assembly, cell to cell and long distance movement and the development, spread, or life cycle of the virus. Suitable toxic activities include RNAse (Leland et al., 1998) and DNAse, ribosome inactivating proteins (Barbieri et al., 1993), (Girbes et al., 1996), (Hartley et al., 1996) and or toxins with antimicrobial activity (Dempsey et al., 1998). Antibodies or recombinant proteins in themselves are also considered toxic when they affect the pathogen by binding to pathogen and or host proteins that are utilised by a pathogen during its replication, reproduction, life cycle or transmission. For example, a fusion protein composed of a virus specific antibody and a viral coat protein will interfere with virus reproduction by both binding to the virus and by disrupting viral assembly or disassembly in the host cell.</p>
    <p id="p-00037-en">The term "molecular pathogenicide" refers to the antibodies and proteins described in this application, which have toxic effects on pathogen(s) either as single fusion proteins, when expressed in combination with other proteins, or when expressed as part of protein complexes that are assembled <i>in vivo</i>.</p>
    <p id="p-00038-en">Monoclonal antibodies (KÃ¶hler and Milstein, 1975) can be raised against almost any epitope or molecular structure of a pathogen or host protein using several techniques. The most common method is the hybridoma technique starting with immunocompetent B lymphocytes from the spleen or thymus which are obtained after immunisation with native antigen, recombinant antigen, antigen fusion proteins, antigen domains or by <i>in vitro</i> or genetic immunisation. In addition, recent advances in molecular biology techniques now permit the use of cloned recombinant antibody fragments and antibodies derived from mice and other organisms than the mouse. Suitable recombinant antibody fragment(s) include the complete recombinant full-size antibodies, dimeric secretory IgA antibodies, multimeric IgM antibodies, the F(ab')<sub>2</sub> fragment, the Fab-fragment, the Fv-fragment, single chain antibody fragments (scFvs), single binding domains (dAbs), a bivalent scFv (diabody) (Poljak, 1994), minibody (Carter and Merchant, 1997), bispecific scFv antibodies (PlÃ¼ckthun and Pack, 1997) where the antibody molecule recognises two different epitopes, (which may be from the pathogen or the host or both the pathogen and the host), triabodies and any other part of the antibody such as, molecular recognition units (MRUs), which show binding to the target epitopes. Genes encoding these suitable recombinant antibody fragment(s) may be derived from vertebrates, camelids, avian or pisces species.<br /> Also, single chain antibodies that have affinities for pathogen or host structures and proteins can be identified using phage display libraries or ribosome display libraries, gene shuffled libraries, which can be constructed from synthetic, semi-synthetic or naÃ¯ve and immunocompetent sources (PlÃ¼ckthun, 1991; Winter et al., 1994; Winter and Milstein, 1991). Phage display and suitable techniques can be used to specifically identify antibodies, or fragments thereof, with the desired binding properties. Using recombinant antibody technology it is possible to identify antibodies or fragments that are highly specific for a single pathogen, or which recognise a consensus epitope conserved between several pathogens, where the antibodies will have a broad specificity against pathogens. The durability and effect of antibody mediated resistance can be improved by i) recombinant antibody affinity maturation, ii) CDR randomisation and selection, iii) stabilisation by framework optimisation of a selected pathogen specific antibody, iv) bi-specific antibody expression, v) the generation of antibody fusion proteins, or vi) the expression of antibodies in combinations with others that may potentiate their individual effects. For example, surface plasmon resonance as employed in the BlAcore system can be used to increase the efficiency of phage displayed antibodies selections, yielding a high increment of affinity from a single library of phage antibodies which bind to an epitope of a pathogen (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). The recombinant antibodies can be identified and utilised according to methods that are familiar to anyone of ordinary skill in the art.</p>
    <heading>
      <b>Antibodies</b>
    </heading>
    <p id="p-00039-en">This invention describes antibodies or fragments thereof which recognise structures of the pathogen or host plant and directly or indirectly lead to resistance or partial resistance when expressed alone or when expressed as chimeric fusion protein coupled to a toxic activity or when expressed and assembled <i>in vivo</i> with a toxic activity to form an <i>in vivo</i> assembled molecular pathogenicide protein complex.<br /> Antibodies can be generated that recognise pathogen-specific epitopes or host plant-specific epitopes which have a role in the life cycle of a pathogen. Suitable antibodies for engineering viral resistance include, but are not limited to, those binding to conserved functional domains of viral coat proteins, movement proteins, or replicases and are an approach to obtain broad-spectrum resistance and reduce the environmental risks by inactivating the targets inside and/or outside the plant cell through immunomodulation. The feasibility of this approach has been recently shown for both animal (Chen et al., 1994), (Duan et al., 1994), (Marasco et al., 1993) and plant viral resistance (Tavladoraki et al., 1993), (Voss et al., 1995), (Zimmermann et al., 1998). These antibodies or fragments thereof may be inactivating in themselves or in combination with one or more other antibodies, or a toxin, or in combination with a carrier, transmembrane domain or signal peptide. Importantly, plant pathogen resistance can be enhanced by the co-expression of multiple antibodies.</p>
    <p id="p-00040-en">In a particular preferred embodiment, the present invention relates to one of the above-described antibodies wherein the antibody or a derivative thereof is capable of binding to the functional domain of a viral movement and/or replicase protein. As could be surprisingly demonstrated in Examples 5 and 6, antibodies directed against a viral movement and replicase, respectively, can be used to engineer enhanced resistance against the virus the movement and replicase gene are derived from. The advantage of using the movement or replicase protein as a target for the antibody or a functional equivalent binding protein is that the functional domains within the movement protein and the replicase can be expected to be highly conserved among different viruses. Thus, the expression of an antibody directed against such a conserved epitope of, for example, the movement protein of TMV can also be expected to be effective against related viruses. Furthermore, due to the conservation of the functional domains in these two viral proteins, a further advantage is that the heterogeneity within one single virus group should not be as high as for, e.g., the coat protein. Thus, the finding of the present invention that the movement and replicase protein of a virus are accessible to antibody targeting within a plant cell, a novel concept for the generation of virus resistant plants became feasible. It is therefore, that in one separate aspect the present invention relates to such antibodies for engineering virus resistance in plants. Viruses that can be the target of this approach are any that use movement proteins during infection as well as all viruses that encode a replicase gene. This can be expected to be effective because viral movement is a common feature of many viral infections (McLean et al., Trends Microbiol. 1, (1993), 105-9) and replicases are essential for viral pathogenesis. The importance of approaches targeting these proteins is underscored by the fact that expressing wild type or defective versions of movement or replicase proteins often results in resistance (Beachy, (1997), Curr. Opin. Biotechnol. 8:215-220). Transgenic plants expressing defective mutant TMV movement protein are resistant to multiple viruses, presumably because of disruptions in intercellular viral movement (Cooper et al., (1995), Virology 206, 307-313) and replicase expression is an effective resistance strategy (Anderson et al., (1992), Proc. Natl. Acad. Sci. USA 89:8759-8763; Baulcombe, (1994), Trends Microbiol. 2:60-63; Brederode et al., (1995), Virology 207:467-474; Nguyen et al., (1996), Proc. Natl. Acad. Sci. USA 93:12643-12467; Rubino and Russo, (1995), Virology 212:240-243).</p>
    <p id="p-00041-en">A disadvantage of the current antibody mediated resistance approaches may be the choice of viral coat proteins as target. Plant viral coat proteins have a broad structural diversity and this can restrict the effect of the expressed antibodies to a small range of viruses and under selective stress, the viral coat protein sequence can alter without loss of function. Generation of recombinant antibodies directed against conserved functional domains of viral replicases and movement proteins may provide a better route for obtaining pathogen resistant plants with a broad-spectrum resistance against viruses. The antigen for producing any one of the above-described antibodies can be derived from naturally occurring movement or replicase proteins or fragments thereof or can be recombinantly produced, chemically synthesized and/or derivatized by methods well known to the person skilled in the art some of which are also further discussed herein. In view of the above, the invention also relates to polynucleotides encoding the above-described antibodies, vectors comprising the same and host cells transformed therewith. Suitable vectors, host cells and strategies for the expression of recombinant antibodies in plants are described herein and can be easily adapted from any one of the other embodiments described herein.</p>
    <heading>
      <b>Toxins</b>
    </heading>
    <p id="p-00042-en">Toxins include all proteins and peptides that have a detrimental or toxic effect on a pathogen during its life cycle and/or an effect on the pathogen during plant infection or pathogen replication, spread or transmission. This includes toxins that specifically kill an infected host cell and so limit the spread and development of a disease.</p>
    <p id="p-00043-en">Suitable toxins include the following:<ol><li> toxic peptide(s) which are specific for the pathogen and mediates toxicity e.g. by membrane permeabilisation based on alteration of membrane potential (Ham et al., 1994; Sangster, 1997).</li><li> blocking peptides which bind to structural or non structural pathogen proteins, or nucleic acid motifs, and inhibit pathogen function, growth, development or toxicity to the host (Hayakawa, 1991; Silburn et al., 1998).</li><li> peptide mimics that bind to pathogen or host protein motifs and that modulate or block the pathogen's replication, e.g. peptide derivatives of proteinase inhibitors that play a physiological role as inhibitors of viral replication and can be used as antiviral agents (Bjorck et al., 1990), (Bjorck et al., 1989).</li><li> binding domains, such as antibodies defined above specifically recognising an epitope of a plant pathogen.</li><li> peptide mimics that bind to pathogen or host protein motifs and that modulate or block the pathogen's movement within the host plant. As an example, the BC peptide, which mimics the nuclear localisation signal region of H1V-1, reduces HIV-1 production by 75% when expressed in infected dividing cultured human T-cells (Friedler et al., 1998).</li><li> toxins which kill the host cell where the pathogen is replicating and has penetrated the cytosol (Barbieri et al., 1993; Hartley et al., 1996; Madshus and Stenmark, 1992), for example (Ribosome inactivating proteins) RIPs which enter the cytosol and are among the most potent cytotoxins known. Ribosome-inactivation is achieved in all cases through the cleavage of an N-glycosidic bond between ribose and a specific adenine residue in the universally conserved sequence 5'-AGUACGA*GAGGA-3' (where A* indicates the target adenine) located 250-400nt from the 3' end of 23S/25S/28S rRNAs (Endo and Tsurugi, 1987), (Hartley et al., 1996). Ribosomes depurinated in this manner are unable to bind the EF-2/GTP complex and protein synthesis is blocked at the translocation step (Montanaro et al., 1975). A single RIP molecule is able to depurinate 1000-2000 mammalian cell ribosomes per min under physiological conditions (Eiklid et al., 1980; Endo and Tsurugi, 1988).</li><li> proteins and enzymes such as RNase A that are potent cytotoxins (Leland et al., 1998). These cytotoxic ribonucleases degrade cellular RNA and cause cell death and can be used to kill infected cells and so prevent the proliferation and spread of a pathogen.</li></ol></p>
    <p id="p-00044-en">These are examples of proteins which will inhibit the replication of a pathogen at a RNA, DNA or protein level by either binding directly to a pathogen protein, replication intermediate or a host factor that is necessary for pathogen replication or movement or transmission and the pathogen life cycle. This strategy is particularly suitable for inactivating viral pathogens. In addition, toxins, such as RIPs or RNase A are described that are suitable for causing cell death on pathogen entry and so halting the spread of infection or proliferation of a pathogen.<br /> In principle all antibodies, proteins, peptides and enzymes that have an activity, that may or may not be enzymatic, which are able to interfere with pathogen life cycles are suitable as part of the present constructs.<br /> In a preferred embodiment of the present invention said enzyme is chitinase or glucanase, glucose oxidase, superoxide dismutase, DNAse or RNAse or RIP or active fragments thereof either singly or in any combination(s).</p>
    <heading>
      <b>Constructs</b>
    </heading>
    <p id="p-00045-en">Gene constructs may comprise the following or any combination of the follow and may be encoded on one or more plasmids: Gene constructs may comprise a nucleotide sequence or nucleotide sequences encoding complete recombinant full-size antibodies, dimeric secretory IgA antibodies, multimeric IgM antibodies, the F(ab')<sub>2</sub> fragment, the Fab-fragment, the Fv-fragment, single chain antibody fragments (scFvs), single binding domains (dAbs), a bivalent scFv (diabody) (Poljak, 1994), minibody (Carter and Merchant, 1997), bispecific scFv antibodies (PlÃ¼ckthun and Pack, 1997; Fischer et al. <i>Eur. J. Biochem.</i> 262, 810-816 (1999)) where the antibody molecule recognises two different epitopes that may come from the pathogen or the host or both, triabodies and any other part of the antibody (molecular recognition units (MRUs)) which shows binding to the target epitopes. Genes encoding these suitable recombinant antibody fragment(s) may be derived from vertebrates, camelids, avian or pisces species.<br /> In the constructs according to the invention, the antibody is preferably fused to a complete sequence of a toxic agent or a part thereof which still has activity, or which is still functionally active. Also, the chimeric protein may be encoded by nucleotide sequences on one or more constructs and may be assembled <i>in vivo</i> by the plant or expression organisms protein assembly and translation machinery. The chimeric protein can also be obtained by biochemical assembly or <i>in vitro</i> or <i>in vivo</i> assembly of the chimeric immunotoxin subunits using the cells endogenous protein assembly machinery. The antibody, antibodies or fragments thereof are fused directly to the toxic agent or linked by a flexible spacer which does not interfere with the structure or function of the two proteins. Such flexible linkers include copies of the (Glycine-Glycine- Glycine- Glycine-Serine)<sub>n</sub> linker, where n is 1 to 4 or more copies of the linker unit, the Genex 212 and 218 linker and the flexible linker peptide of<i>Trichoderma reesi</i> cellobiohydrolase I (CBHI) (Turner et al., 1997), (Tang et al., 1996).</p>
    <heading>
      <b>Constructs for cellular targeting and membrane localisation</b>
    </heading>
    <p id="p-00046-en">In this invention, this targeting approach has the advantage that the molecular pathogenicide or antibody or fragment thereof can be expressed where the pathogen is most vulnerable to the action of the molecular pathogenicide and/or antibody or fragment thereof.<br /> The desired cellular location of the molecular pathogenicide, or any components thereof, can be achieved by using the appropriate cellular targeting signals, these include but are not limited to signal peptides, targeting sequences, retention signals, membrane anchors, post translational modifications and/or membrane transmembrane domains that target the protein to the desired organelle, desired membrane (plasma membrane, ER, Golgi, nucleus, chloroplast or vacuole) or desired membrane orientation (cytoplasmic or lumenal or plant cell membrane display) (Kim et al., 1997; Rose and Fink, 1987). Localisation sequences can be targeting sequences which are described, for example in chapter 35 (protein targeting) of L. Stryer <i>Biochemistry</i> 4<sup>th</sup> edition, W.H. Freeman, 1995. Proteins synthesised without a functional signal peptide are not co-translationally inserted into the secretory pathway and remain in the cytosol. Proteins that carry a signal peptide that directs them to the secretory pathway, which may include a transmembrane sequence or membrane anchor, will be targeted for secretion by default or reside in their target membrane organelles. Targeting signals can direct proteins to the ER, retain them in the ER (LYSLYS motif and KDEL), TGN 38, or will target proteins to cell organelles such as the chloroplasts, vacuole, nucleus, nuclear membrane, peroxisomes and mitochondria. Examples for signal sequences and targeting peptides are described in (von Heijne, 1985) (Bennett and Osteryoung, 1991) (Florack et al., 1994). In addition, the targeting signals may be cryptic and encoded by a host plant cell or heterologous eukaryotic cell proteins or animal proteins where the localisation is known and where the protein can be cloned. By constructing a fusion protein with this protein, a molecular pathogenicide can be targeted to the localisation of the protein without the need for identification of the cryptic targeting signal. Suitable cryptic signals are those encoded by the resident Golgi enzymes.<br /> The molecular pathogenicides described in this invention can be targeted to cellular membranes by incorporating heterologous sequences into the recombinant protein which permit its synthesis as a membrane protein or as a membrane associated protein or its post translational modification to associate it with cellular membranes. Suitable membrane anchor sequences, enabling the integration of recombinant antibody fusion proteins and parts thereof in the plasma membrane, include the human T cell receptor transmembrane domains (Gross and Eshhar, 1992), glyco-phosphatidyl inositol (GPI) anchors (Gerber et al., 1992), immunoglobulin superfamily membrane anchors, tetraspan family members (Tedder and Engel, 1994; Wright and Tomlinson, 1994) and any transmembrane sequence(s) from a known protein or synthesised sequences that have a similar function and can be included in the target protein by recombinant DNA technology.<br /> In addition, the antibodies or parts thereof, or the recombinant antibody fusion proteins, or parts thereof, may be targeted to cell membranes where they could face the cytosolic side of the membrane. Suitable targeting sequences for cytoplasmic display, include the transmembrane domains of: KAR1, for nuclear membrane integration (Rose and Fink, 1987), middle-T antigen (Kim et al., 1997), for plasma membrane integration and cytochrome b5, for ER membrane integration (Kim et al., 1997). C-terminal linkages to fatty acids using consensus amino acid sequences leading to post translational prenylation, farnesylation, palmitoylation, myristoylation or ankyrin sequence motifs can also be used.</p>
    <heading>
      <b>Constructs for antibody stabilisation by membrane display</b>
    </heading>
    <p id="p-00047-en">Pathogen-specific recombinant antibodies can be fused to different transmembrane anchors to improve the expression levels and stability of these molecules inside the plant cell, by targeting the expressed recombinant protein to cell membranes in various orientations. This can be accomplished by adding:<ol><li>a) C-terminal localisation sequences to target and integrate recombinant cytosolic proteins with N-terminal leader peptides into the bilayer of cellular membranes, thus facing to the plant apoplast. Suitable membrane localisation sequences include the human T cell receptor Î² chain transmembrane domain and the human platelet derived growth factor receptor (PDGFR) transmembrane domain, glyco-phosphatidyl inositol (GPI) anchors, immunoglobulin superfamily membrane anchors and any transmembrane sequence(s) from a known protein or synthesised sequences that have a similar function and can be included in the target protein by recombinant DNA technology.</li><li>b) Amino terminal transmembrane proteins with either dual or tetrameric plasma membrane spanning domains to expose both the N- and C-termini of secretory recombinant proteins to the cytosol. This can be achieved by using suitable members of the tetraspan family including CD9, CD20, CD81 and the In-Hc-Ic dualspan typell-IV hybrid of the MHC invariant chain and H-2<sup>d</sup> hybrid protein. This method enables the orientation of a secreted and membrane anchored antibody construct with its N- and C-terminus into the cytosol. Alternatively fusions to SNAP-25 can be used for the same orientation.</li><li>c) C-terminal anchor sequences to target and integrate recombinant cytosolic proteins without N-terminal leader peptides into the bilayer of endomembranes posttranslationally. Suitable targeting sequences include transmembrane domains of KAR1 for nuclear membrane integration (Rose and Fink, 1987), middle-T antigen for plasma membrane integration (Kim et al., 1997) and cytochrome b5 for ER membrane integration (Kim et al., 1997).</li><li>d) Addition of consensus motifs to the protein that permit C-terminal linkages to fatty acids by prenylation, farnesylation, palmitoylation, myristoylation in the cytosol which then lead to membrane integration.</li><li>e) Addition of ankyrin sequence motifs (Lambert and Bennett, 1993; Peters and Lux, 1993).</li></ol></p>
    <heading>
      <b>Constructs for</b>
      <i>
        <b>in vivo</b>
      </i>
      <b>protein complex assembly</b>
    </heading>
    <p id="p-00048-en">In addition, the antibody or fragment thereof can be encoded by a separate nucleotide sequence to that of the toxin and the antibody and toxin, either of which may encode membrane localisation or cellular targeting sequences, can be encoded by one or more vectors, e.g., plasmids. The constructs contain nucleotide sequences encoding complimentary binding proteins so that when the antibody, or fragment thereof, is genetically fused to one binding partner and the toxin, or fragment thereof, is genetically fused to the second binding partner, these two independent proteins will bear mutually recognising binding activities. When these two independent proteins are expressed in the same plant compartment, the binding domains will bind to form a molecular pathogenicide with two subunits and similar properties to an antibody-toxin fusion protein. Suitable binding domains/partners include:<ol><li> A single chain antibody and its corresponding epitope, where the single chain binds to the epitope and thereby enables binding between two independent proteins,</li><li> leucine zippers (Carter et al., 1995),</li><li> Antibody heavy and light chains, where one protein is fused to the heavy chain and assembly of heavy and light chain takes place in the ER,</li><li> other homo- or hetero-binding domains.</li></ol></p>
    <p id="p-00049-en">Anyone of ordinary skill in the art will recognise that the component antibody, antibodies or fragments thereof or component pathogen binding peptides, as described, and component toxin or fragments thereof can each bear a binding partner. When expressed in the same compartment of a plant, or when encountering each other, these binding domains can then permit the assembly of a molecular pathogenicide with all the properties required from the components. Anyone skilled in the art will recognise that this can be achieved by other means than those described above which are intended as examples to better illustrate the principle of <i>in vivo</i> assembly and are not intended to be taken as a limiting or a comprehensive description.</p>
    <heading>
      <b>Carrier proteins</b>
    </heading>
    <p id="p-00050-en">Anyone skilled in the art will also recognise that the various components of the present invention can be expressed in such a way that they are on the surface of a third carrier protein, suitable carriers include glutathione S-transferase (GST) encoded by <i>Schistosoma japonicum</i> (Smith and Johnson, 1988), TMV coat protein, maltose-binding protein and thioredoxin (LaVallie et al., 1993) or other proteins.<br /> In addition, any of the components of the present invention may be tagged with a genetically encoded fluorophore, suitable fluorophores include, but are not limited to, the green fluorescent protein (GFP) from <i>Aequoria victoria.</i> This approach would be especially useful for monitoring the localisation of a pathogen or molecular pathogenicide during infection.<br /> If the fusion protein or proteins are expressed in a heterologous organism for production of the protein or proteins, it may be necessary to modify the gene construct in order to match the codon preference of the organism and to remove mRNA motifs that reduce the stability of the transcript.<br /> All of the components of the molecular pathogenicides described in this invention can be separately transformed into plant lines which can then be sexually crossed to give offspring that product the molecular pathogenicides in a functional form.<br /> Anyone skilled in the art will recognise that the antibodies, peptides and toxins can be combined in several forms and encoded on different plasmids to produce proteins that have the desired effect on the pathogen. Anyone skilled in the art will also recognise that assembling the molecular pathogenicides from individually genetically encoded subunits can be achieved by several methods.</p>
    <heading>
      <b>Target pathogens</b>
    </heading>
    <p id="p-00051-en">Viruses, bacteria, mycoplasmas, fungi, nematodes, insects and other pathogens.</p>
    <heading>Vectors</heading>
    <p id="p-00052-en">The present invention also relates to vectors, particularly plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering that contain a polynucleotide according to the invention or any one of the above-described gene constructs. Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989), (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.</p>
    <p id="p-00053-en">In a preferred embodiment, the polynucleotide present in the vector is linked to regulatory elements which allow the expression of the polynucleotide in prokaryotic and/or eukaryotic cells. Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA. Regulatory elements ensuring expression in prokaryotic and/or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells they comprise normally promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilisation of the transcript, for example, those of the 35S RNA from Cauliflower Mosaic Virus (CaMV). In this respect, the person skilled in the art will readily appreciate that the polynucleotides encoding at least one of the above-described domains of the fusion proteins or pathogenicide of the invention may encode all of the domains or only one. Likewise, said polynucleotides may be under the control of the same promoter or may be separately controlled for expression. Other promoters commonly used are the Figwort Mosaic virus promoter, the polyubiquitin promoter, and the actin promoter for ubiquitous expression. The termination signals usually employed are from the Nopaline Synthase or CaMV 35S gene. A plant translational enhancer often used is the TMV omega sequences, the inclusion of an intron (Intron-1 from the Shrunken gene of maize, for example) has been shown to increase expression levels by up to 100-fold. (Maiti et al., Transgenic Research 6 (1997), 143-156; Ni et al., Plant Journal 7 (1995), 661-676). Additional regulatory elements may include transcriptional as well as translational enhancers.</p>
    <p id="p-00054-en">Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the P<sub>L</sub>, <i>lac</i>, <i>trp</i> or <i>tac</i> promoter in <i>E. coli</i>, and examples for regulatory elements permitting expression in eukaryotic host cells are the <i>AOX1</i> or <i>GAL1</i> promoter in yeast or the CMV-, SV40- , RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitrogene), pSPORT1 (GIBCO BRL). Advantageously, the above-described vectors of the invention comprises a selectable and/or scorable marker. Selectable marker genes useful for the selection of transformed hosts, for example plant cells, callus, plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149); npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin (Herrera-Estrella, EMBO J. 2 (1983), 987-995) and hygro, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481-485). Additional selectable genes have been described, namely trpB, which allows cells to utilise indole in place of tryptophan; hisD, which allows cells to utilise histinol in place of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); mannose-6-phosphate isomerase which allows cells to utilise mannose (WO 94/20627) and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.) or deaminase from Aspergillus terreus which confers resistance to Blasticidin S (Tamura, Biosci. Biotechnol. Biochem. 59 (1995), 2336-2338).</p>
    <p id="p-00055-en">Useful scorable markers are also known to those skilled in the art and are commercially available. Advantageously, said marker is a gene encoding luciferase (Giacomin, Pl. Sci. 116 (1996), 59-72; Scikantha, J. Bact. 178 (1996), 121), green fluorescent protein (Gerdes, FEBS Lett. 389 (1996), 44-47) or Î²-glucuronidase (Jefferson, EMBO J. 6 (1987), 3901-3907). This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing a vector of the invention.</p>
    <heading>
      <b>Host cells and expression of fusion proteins and pathogenicides</b>
    </heading>
    <p id="p-00056-en">The present invention furthermore relates to host cells comprising a vector as described above or a polynucleotide according to the invention. The vector or polynucleotide according to the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained in some form extrachromosomally.</p>
    <p id="p-00057-en">The host cell can be any prokaryotic or eukaryotic cell, such as bacterial, insect, fungal, plant or animal cells. Preferred fungal cells are, for example, those of the genus Saccharomyces, in particular those of the species S. cerevisiae.</p>
    <p id="p-00058-en">Another subject of the invention is a method for the preparation of the above-described fusion proteins and pathogenicides which comprises the cultivation of host cells according to the invention which, due to the presence of a vector or a polynucleotide according to the invention, are able to express such a protein, under conditions which allow expression and optionally assembly of the fusion protein or pathogenicide and recovering of the so-produced protein from the culture. Depending on the specific constructs and conditions used, the protein may be recovered from the cells, from the culture medium or from both. For the person skilled in the art it is well known that it is not only possible to express a native protein but also to express the protein as fusion polypeptides or to add signal sequences directing the protein to specific compartments of the host cell, e.g., ensuring secretion of the peptide into the culture medium, etc. Furthermore, such a protein and fragments thereof can be chemically synthesised and/or modified according to standard methods described, for example herein.</p>
    <p id="p-00059-en">The present invention furthermore relates to molecular pathogenicides encoded by the polynucleotides according to the invention or produced by the above-described method. In this context, it is also understood that the fusion proteins and pathogenicides according to the invention may be further modified by conventional methods known in the art.</p>
    <heading>
      <b>Plant promoters and expression control elements</b>
    </heading>
    <p id="p-00060-en">The fusion constructs are expressed in plants either stably in transgenic plants or transiently under the control of any type of promoter that is active in plants. For long-term resistance in host plants, high yield production of recombinant proteins, stable expression is preferred.<br /> In general, such regulatory elements comprise a promoter active in plant cells. To obtain expression in all tissues of a transgenic plant, preferably constitutive promoters are used, such as the 35 S promoter of CaMV (Odell, Nature 313 (1985), 810-812) or promoters of the polyubiquitin genes of maize (Christensen, Plant Mol. Biol. 18 (1982), 675-689). In order to achieve expression in specific tissues of a transgenic plant it is possible to use tissue specific promoters (see, e.g., Stockhaus, EMBO J. 8 (1989), 2245-2251). Further examples are:<ol><li>a) Expression control elements (e.g. promoters listed below in b to f, enhancer sequences, transcriptional and translational enhancers, transcription terminators, polyadenylation sites etc.) and a selectable marker if necessary.</li><li>b) Constitutive promoters such as the CaMV-35S (Benfey et al., 1989) and the <i>nos</i> promoter (Mitra and Gynheung, 1989).</li><li>c) Viral subgenomic promoters.</li><li>d) Tissue specific promoters and chimeric promoters (Ni et al., 1995), (Comai et al., 1990).</li><li>e) Inducible promoters (Caddick et al., 1998).</li><li>f) Transient expression systems (Kapila et al., 1997).</li></ol></p>
    <p id="p-00061-en">Known are also promoters which are specifically active in tubers of potatoes or in seeds of different plants species, such as maize, Vicia, wheat, barley etc. Inducible promoters may be used in order to be able to exactly control expression. An example for inducible promoters are the promoters of genes encoding heat shock proteins. Also microspore-specific regulatory elements and their uses have been described (WO96/16182). Furthermore, the chemically inducible Tet-system may be employed (Gatz, Mol. Gen. Genet. 227 (1991); 229-237). Further suitable promoters are known to the person skilled in the art and are described, e.g., in Ward (Plant Mol. Biol. 22 (1993), 361-366). The regulatory elements may further comprise transcriptional and/or translational enhancers functional in plants cells. Furthermore, the regulatory elements may include transcription termination signals, such as a poly-A signal, which lead to the addition of a poly A tail to the transcript which may improve its stability.<br /> Furthermore, it is in principle possible to modify the coding sequence in such a way that the protein is located in any desired compartment of the plant cell. These include the endoplasmatic reticulum, the vacuole, the mitochondria, the plastids, the apoplast, the cytoplasm etc. Methods how to carry out this modifications and signal sequences ensuring localisation in a desired compartment are well known to the person skilled in the art.</p>
    <heading>
      <b>Transformation</b>
    </heading>
    <p id="p-00062-en">Methods for the introduction of foreign DNA into plants are also well known in the art. These include, for example, the transformation of plant cells or tissues with T-DNA using Agrobacterium tumefaciens or Agrobacterium rhizogenes, the fusion of protoplasts, direct gene transfer (see, e.g., EP-A 164 575), injection, electroporation, biolistic methods like particle bombardment and other methods known in the art. The vectors used in the method of the invention may contain further functional elements, for example "left border"- and "right border"-sequences of the T-DNA of Agrobacterium which allow for stably integration into the plant genome. Furthermore, methods and vectors are known to the person skilled in the art which permit the generation of marker free transgenic plants, i.e. the selectable or scorable marker gene is lost at a certain stage of plant development or plant breeding. This can be achieved by, for example cotransformation (Lyznik, Plant Mol. Biol. 13 (1989), 151-161; Peng, Plant Mol. Biol. 27 (1995), 91-104) and/or by using systems which utilise enzymes capable of promoting homologous recombination in plants (see, e.g., WO97/08331; Bayley, Plant Mol. Biol. 18 (1992), 353-361); Lloyd, Mol. Gen. Genet. 242 (1994), 653-657; Maeser, Mol. Gen. Genet. 230 (1991), 170-176; Onouchi, Nucl. Acids Res. 19 (1991), 6373-6378). Methods for the preparation of appropriate vectors are described by, e.g., Sambrook (Molecular Cloning; A Laboratory Manual, 2nd Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Suitable strains of Agrobacterium tumefaciens and vectors as well as transformation of Agrobacteria and appropriate growth and selection media are well known to those skilled in the art and are described in the prior art (GV3101 (pMK90RK), Koncz, Mol. Gen. Genet. 204 (1986), 383-396; C58C1 (pGV 3850kan), Deblaere, Nucl. Acid Res. 13 (1985), 4777; Bevan, Nucleic. Acid Res. 12(1984), 8711; Koncz, Proc. Natl. Acad. Sci. USA 86 (1989), 8467-8471; Koncz, Plant Mol. Biol. 20 (1992), 963-976; Koncz, Specialised vectors for gene tagging and expression studies. In: Plant Molecular Biology Manual Vol 2, Gelvin and Schilperoort (Eds.), Dordrecht, The Netherlands: Kluwer Academic Publ. (1994), 1-22; EP-A-120 516; Hoekema: The Binary Plant Vector System, Offsetdrukkerij Kanters B.V., Alblasserdam (1985), Chapter V, Fraley, Crit. Rev. Plant. Sci., 4, 1-46; An, EMBO J. 4 (1985), 277-287). Although the use of Agrobacterium tumefaciens is preferred in the method of the invention, other Agrobacterium strains, such as Agrobacterium rhizogenes, may be used, for example if a phenotype conferred by said strain is desired.<br /> Methods for the transformation using biolistic methods are well known to the person skilled in the art; see, e.g., Wan, Plant Physiol. 104 (1994), 37-48; Vasil, Bio/Technology 11 (1993), 1553-1558 and Christou (1996) Trends in Plant Science 1, 423-431. Microinjection can be performed as described in Potrykus and Spangenberg (eds.), Gene Transfer To Plants. Springer Verlag, Berlin, NY (1995).<br /> The transformation of most dicotyledonous plants is possible with the methods described above. But also for the transformation of monocotyledonous plants several successful transformation techniques have been developed. These include the transformation using biolistic methods as, e.g., described above as well as protoplast transformation, electroporation of partially permeabilized cells, introduction of DNA using glass fibers, etc.</p>
    <p id="p-00063-en">Transformation can be done using any method that leads to expression of construct or constructs in a plant and these methods can be used for stable transformation where the gene of interest is incorporated in the host plant DNA or where the construct is transiently expressed. Examples of transformation technology include:<ol><li>a) <i>Agrobacterium tumefaciens</i> or <i>Agrobacterium rhizogenes</i> mediated transformation (Turpen et al., 1993; White, 1992): based on the insertion of a foreign DNA sequence into the plant genome carried on a plasmid DNA within the agrobacteria. The foreign gene is inserted into the plant genome together with bacterial plasmid sequences.</li><li>b) Particle bombardment (Sanford et al., 1990), (Klein and Fitzpatrick-McElligott, 1993) or biolistic process (Furth, 1997): Particle bombardment uses particles coated with the DNA that penetrate the plant cell at high velocity and the DNA is incorporated into the host genome by host recombination processes. Besides particle bombardment biolistic processes also include injection methods.</li><li>c) Tissue electroporation (Chowrira et al., 1995; D'Halluin et al., 1992): under the influence of an electric field, DNA enters pores in the plant cell membrane and is incorporated into the plant genome by recombination.</li><li>d) Use of liposomes or methods which increase the uptake of free DNA (SpÃ¶rlein and Koop, 1991; White, 1992).</li><li>e) Any method for integration of foreign DNA in a plant cell resulting in transiently or stably transformed plants.</li></ol></p>
    <heading>
      <b>Target plants</b>
    </heading>
    <p id="p-00064-en">The present invention relates to transgenic plant cells which contain a polynucleotide, vector or composition of vectors of the invention. Preferably, said polynucleotide or vector is stably integrated into the genome.<br /> As is immediately evident to the person skilled in the art, the vectors of the present invention can carry nucleic acid molecules encoding the domains of the antibody, fusion protein or pathogenicide of the invention either alone or in combination. The same applies to the above described plant cells, plant tissue and plants transformed therewith. Likewise, said nucleic acid molecules may be under the control of the same regulatory elements or may be separately controlled for expression. In this respect, the person skilled in the art will readily appreciate that the nucleic acid molecules encoding the domains of the fusion protein or pathogenicide can be expressed in the form of a single mRNA as transcriptional and optionally translational fusions. This means that domains are produced as separate polypeptides or in the latter option as a fusion polypeptide that is further processed into the individual proteins, for example via a cleavage site for proteinases that has been incorporated between the amino acid sequences of both proteins. The resultant protein domains can then self-assemble in vivo. Of course, the domains may also be expressed as a bi- or multifunctional polypeptide, preferably disposed by a peptide linker which advantageously allows for sufficient flexibility of both proteins. Preferably said peptide linker comprises plural, hydrophilic, peptide-bonded amino acids of a length sufficient to span the distance between the C-terminal end of one of said proteins and the N-terminal end of the other of said proteins when said polypeptide assumes a conformation suitable for biological activity of both proteins when disposed in aqueous solution in the plant cell. Examples of the above-described expression strategies can be found in the literature, e.g., for dicistronic mRNA (Reinitiation) in Hefferon, J. Gen. Virol. 78 (1997), 3051-3059, fusion proteins are described in Brinck-Peterson, Plant Mol. Biol. 32 (1996), 611-620 and Hotze, FEBS Lett. 374 (1995), 345-350; bifunctional proteins are discussed in Lamp, Biochem. Biophys. Res. Com. 244 (1998), 110-114 and Dumas, FEBS Lett. 408 (1997), 156-160 and for linker peptide and protease it is referred to Doskeland, Biochem. J. 313 (1996), 409-414.</p>
    <p id="p-00065-en">In a preferred embodiment of the invention, the transgenic plant cell comprises a selectable marker. As described above, various selectable markers can be employed in accordance with the present invention. Advantageously, selectable markers may be used that are suitable for direct selection of transformed plants, for example, the phophinothricin-N-acetyltransferase gene the gene product of which detoxifies the herbicide L-phosphinothricin (glufosinate or BASTA); see, e.g., De Block, EMBO J. 6 (1987), 2513-2518 and DrÃ¶ge, Planta 187 (1992), 142-151.</p>
    <p id="p-00066-en">The presence and expression of the polynucleotides or vectors in the transgenic plant cells leads to the synthesis of a fusion protein, antibody or pathogenicide of the invention or assembly of the same which has an influence on pathogen resistance in plants containing such cells.</p>
    <p id="p-00067-en">Thus, the present invention also relates to transgenic plants and plant tissue comprising transgenic plant cells according to the invention. Due to the expression of a fusion protein, the antibody against the viral movement and/or replicase protein or pathogenicide of the invention or their domains, e.g., in cellular compartments and/or plant tissue these transgenic plants may show various physiological, developmental and/or morphological modifications in comparison to wild-type plants. Advantageously, these transgenic plants display a resistance against a pathogen that the corresponding wild type plant was susceptible to.</p>
    <p id="p-00068-en">In general, the plants which can be modified according to the invention can be derived from any desired plant species. They can be monocotyledonous plants or dicotyledonous plants, preferably they belong to plant species of interest in agriculture, wood culture or horticulture, such as crop plants (e.g. maize, rice, barley, wheat, rye, oats etc.), potatoes, oil producing plants (e.g. oilseed rape, sunflower, pea nut, soy bean, etc.), cotton, sugar beet, sugar cane, leguminous plants (e.g. beans, peas etc.), wood producing plants, preferably trees, etc.</p>
    <p id="p-00069-en">In yet another aspect, the invention also relates to harvestable parts and to propagation material of the transgenic plants according to the invention. Harvestable parts can be in principle any useful parts of a plant, for example, leaves, stems, fruit, flowers, seeds, roots etc. Propagation material includes, for example, seeds, fruits, cuttings, seedlings, tubers, rootstocks etc.</p>
    <heading>
      <b>Kits</b>
    </heading>
    <p id="p-00070-en">In addition, the present invention relates to a kit comprising the above-described antibodies, fusion protein, pathogenicide, polynucleotide or vectors. The kit of the invention may contain further ingredients such as selection markers and components for selective media suitable for the generation of transgenic plant cells, plant tissue or plants. The kit of the invention may advantageously be used for carrying out the method of the invention and could be, inter alia, employed in a variety of applications, e.g., in the diagnostic field or as research tool. The parts of the kit of the invention can be packaged individually in vials or in combination in containers or multicontainer units. Manufacture of the kit follows preferably standard procedures which are known to the person skilled in the art. The kit or its ingredients according to the invention can be used in plant cell and plant tissue culture, for example in agriculture. The kit of the invention and its ingredients are expected to be very useful in breeding new varieties of, for example, plants which display improved properties such as those described herein.<br /> It is also immediately evident to the person skilled in the art that the polynucleotides and vectors of the present invention can be employed to produce transgenic plants with a further desired trait due to genetic engineering (see for review TIPTEC Plant Product &amp; Crop Biotechnology 13 (1995), 312-397). This can be, for example, an acquired resistance to other pathogens or quality improvements of the plants comprising (i) herbicide tolerance (DE-A-3701623; Stalker, Science 242 (1988), 419), (ii) insect resistance (Vaek, Plant Cell 5 (1987), 159-169), (iii) virus resistance (Powell, Science 232 (1986), 738-743; Pappu, World Journal of Microbiology &amp; Biotechnology 11 (1995), 426-437; Lawson, Phytopathology 86 (1996), 56 suppl.), (vi) ozone resistance (Van Camp, BioTech. 12 (1994), 165-168), (v) improving the preserving of fruits (Oeller, Science 254 (1991), 437-439), (vi) improvement of starch composition and/or production (Stark, Science 242 (1992), 419; Visser, Mol. Gen. Genet. 225 (1991), 289-296), (vii) altering lipid composition (Voelker, Science 257 (1992), 72-74), (viii) production of (bio)polymers (Poirer, Science 256 (1992), 520-523), (ix) alteration of the flower colour, e.g. by manipulating the anthocyanin and flavonoid biosynthetic pathway (Meyer, Nature 330 (1987), 667-678, WO90/12084), (x) resistance to bacteria, insects and fungi (Duering, Molecular Breeding 2 (1996), 297-305; Strittmatter, Bio/Technology 13 (1995), 1085-1089; Estruch, Nature Biotechnology 15 (1997), 137-141), (xi) inducing and maintaining male and/or female sterility (EP-A1 0 412 006; EP-A1 0 223 399; WO93/25695) and (xii) remediation of contaminated soils (Cunningham, TIBTECH 13 (1995), 393-397).</p>
    <p id="p-00071-en">These and other embodiments are disclosed and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database "Medline" may be utilised which is available on the Internet, for example under http://www.ncbi.nlm.nih.gov/PubMed/medline.html. Further databases and addresses, such as http://www.ncbi.nlm.nih.gov/, http://www.infobiogen.fr/, http://www.fmi.ch/biology/research_tools.html, http://www.tigr.org/, are known to the person skilled in the art and can also be obtained using, e.g., http://www.lycos.com. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.</p>
    <heading>
      <b>Description of the figures</b>
    </heading>
    <heading>P</heading>
    <p>A: schematic of molecular pathogenicide protein complex assembly in a cell compartment; B: Example constructs showing two possible arrangements (Ab1 and Ab2) of the individual V<sub>L</sub> and V<sub>H</sub> domains of both the pathogen specific and epitope specific antibody fragments; C: two possible arrangements (Tox 1 and Tox2) for epitope toxin fusion proteins.</p>
    <p>A: schematic of the final assembled molecular pathogenicide. B: example constructs.</p>
    <heading>
      <b>Examples</b>
    </heading>
    <p id="p-00072-en">The following examples are given to better describe the practice and applications of the present invention and should not be considered to be a limiting description nor interpreted to limit the scope and applications of the present invention. Those skilled in the art will recognise that various modifications can be made to the methods and genes described here without substantively departing from the spirit and scope of the present invention.</p>
    <heading>
      <b>Example 1: Expression of a membrane integrated anti-viral antibody</b>
    </heading>
    <heading>
      <u>Plasma membrane targeted expression of a recombinant antibody against the coat protein of Tobacco Mosaic virus (TMV)</u>
    </heading>
    <p id="p-00073-en">The following steps are taken:<ol><li>1) Antibodies against the coat protein of TMV, intact virions or specific coat protein peptides and monoclonals are generated by hybridoma technology.</li><li>2) Hybridoma cell lines are cloned and cDNA sequences encoding the antibody heavy and light chains are cloned to generate a recombinant antibody or any recombinant version thereof. This is achieved using antibody heavy and light specific oligonucleotides and the reverse transcriptase polymerase chain reaction using isolated mRNA from a single hybridoma clone. This permits cloning of the full size antibody.</li><li>3) The cloned full size specific antibody heavy and light chain cDNAs from step 2 are used as a template for amplification of the heavy and light chain variable domains using specific oligonucleotide primers including a linker peptide sequence (i.e. GENEX 212 or (Gly<sub>4</sub>Ser)<sub>n</sub>) and splice overlap extension polymerase chain reaction. This step then provides the single chain antibody fragment and the two variable domains are linked by a 14 amino acid sequence.</li><li>4) The recombinant scFv gene from step 3 is inserted in a microbial or eukaryotic expression vector.</li><li>5) The binding specificity and function of the recombinant scFv (i.e. specificity and affinity for the target antigen) is checked after expression of the construct from step 4 in a heterologous host, such as in the periplasm of <i>E. coli</i>, using ELISA, surface plasmon resonance or western blotting.</li><li>6) A signal sequence is added to the 5' end of the recombinant scFv nucleotide sequence from step 3. A 3' linker peptide sequence (human T cell receptor constant domain) is added and this is then followed by the addition of a 3' transmembrane sequence from the human T cell receptor Î² chain. Suitable membrane localisation sequences also include the platelet derived growth factor receptor (PDGFR) transmembrane domain.</li><li>7) The 5' untranslated region from chalcone synthase is added to the 5' end of the construct from step 6.</li><li>8) The chimeric gene from step 7 is then inserted into a plant expression vector, such as pSS (Voss et al., 1995), upstream of the 3' untranslated region from Cauliflower mosaic virus, or any other source and the termination region from Cauliflower mosaic virus downstream of the 35SS promoter (Figure2). This vector also contains a selectable marker. In case of markerless and vectorless gene transfer selection marker sequences can be omitted.</li><li>9) <i>Agrobacterium tumefaciens</i> is transformed by N<sub>2</sub> transformation with the construct from step 8.</li><li>10) Expression and function of the recombinant scFv construct in plants are checked by transient expression in plant cells and ELISA, surface plasmon resonance or western blotting.</li><li>11) Transgenic plants are generated by transferring the construct from step 8, and a screenable selection marker, which is present in the pSS expression vector (e.g. the NPT-II gene for kanamycin resistance), into the plant genome by Agrobacteria mediated transformation.</li><li>12) Regenerated plants are screened using the selection marker for integration of the fusion gene.</li><li>13) Expression of the fusion protein in regenerated plants is followed by western blotting cell extracts, ELISA or surface plasmon resonance analysis.</li><li>14) The activity of the expressed fusion protein (i.e. affinity and specificity) is checked by ELISA using intact TMV virions as the antigen.</li><li>15) Localisation of the fusion protein is checked by indirect immuno-fluorescence, or confocal microscopy or immuno-electron microscopy.</li><li>16) The activity of the antibody in generating resistance against viruses is assayed by viral infection bioassays on transgenic plants, generated in steps 11 to 12 by using virions or infectious transcripts.</li></ol></p>
    <p id="p-00074-en">The orientation of Type II or tetraspan membrane protein can be exploited to permit display of molecular pathogenicdes to the cytoplasm after their synthesis in the secretory pathway. For cytoplasmic display of the recombinant scFv, steps 6) to 16) of example 1 are repeated with the following adaptations. The C-terminal membrane localisation sequence including the linker sequence and leader sequence of step 6 in example 1 are removed and a suitable linker and N-terminal targeting sequence belonging to the tetraspan family is added to the pathogen specific recombinant antibody to target and posttranslationally integrate recombinant proteins into the bilayer of plasma membranes. Suitable members of the tetraspan family include CD9, CD20, CD81 and the In-Hc-Ic dualspan typeII-IV hybrid of the MHC invariant chain and H-2<sup>d</sup> hybrid protein. This method enables the orientation of a secreted and membrane anchored antibody construct with its N- and C-terminus into the cytosol.</p>
    <p id="p-00075-en">Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised and cloned against structural and non structural proteins of any pathogen. Membrane anchor sequence(s) can be substituted against any sequence that facilitates membranes integration and provides a biological function. Moreover, example 1 can be combined with expression of any one of examples 2-8 in any combination(s) to give high level resistance to disease.</p>
    <heading>
      <u>Construction of the scFv24 fusion expression cassette</u>
    </heading>
    <p id="p-00076-en">To integrate the TMV-specific scFv24 into the plant cell membrane, the antibody fragment was fused to an N-terminal mammalian signal peptide and C-terminal receptor transmembrane domain. The mouse N-terminal light chain signal peptide from the parental antibody (mAb24) used to generate scFv24 was used to target fusion proteins to the secretory pathway. The transmembrane domain sequence of the human T-cell receptor Î² chain (TcRÎ²) was selected for fusion with the C-terminus of scFv24, for heterologous targeting of the scFv24 antibody to the plasma membrane. To ensure proper folding of the expressed single chain antibody fragments, the construct contained the constant region of TcRÎ² (pscFv24-TcRÎ²) as a linker sequence between the scFv24 fragment and the membrane anchor (Figure 7). The cloning of the neotope-specific anti-tobacco mosaic virus (anti-TMV) single-chain fragment scFv24CM including the leader peptide has been described (Zimmermann et al. 1998). To generate the fusion construct pscFv24-TcRÎ² (Figures 2 and 7), a cDNA fragment encoding the constant and transmembrane domain of the human TcRÎ² chain (Yoshikai et al. Nature 312: 521-524 (1984)) was PCR amplified from human spleen mRNA (Clontech, Heidelberg, Germany) using the primers 5'- GCC<i>GTC GAC</i> GAG GAC CTG AAC AAG GTG TTC CCA - 3' (SEQ ID NO:1) and 5' - GCC <i>TCT AGA</i> TCA GAA ATC CTT TCT CTT G - 3' (SEQ ID NO:2). The primers contained restriction sites <i>Sal</i>I and <i>Xba</i>l (italics) to enable in frame cloning of the PCR product with scFv24CM (Zimmermann et al. 1998) resulting in the final construct scFv24-TcRÎ².<br /> For expression in plant cells, the <i>EcoR</i>I/<i>Xba</i>I fragment (Figure 7) of scFv24-TcRÎ² was subcloned into the <i>EcoR</i>I and Xbal restriction sites of the plant expression vector pSS (Voss et al. (1995)) containing the enhanced 35S promoter (Kay et al. (1987)) and the CaMV termination sequence (Figure 7, pscFv24-TcRÎ²).</p>
    <heading>
      <u>Expression of the scFv24 fusion proteins in <i>N. tabacum</i> cv. BY-2 cell suspensions</u>
    </heading>
    <p id="p-00077-en">To analyze the expression level of the recombinant scFv-fusion protein, the suspension cell line <i>N. tabacum</i> cv. BY-2 was stably transformed with recombinant A.<i>tumefaciens</i> and functional expression of the scFv24 domain of the fusion protein was analyzed by ELISA using anti-mAb24 antisera.<br /> The vector construct pscFv24-TcRÎ² was transferred into <i>A. tumefaciens</i> GV3101 by liquid N<sub>2</sub> transformation (Hofgen and Willmitzer, Nucleic Acids Res. 16: 9877 (1988)).<i>N. tabacum</i> L. cv. bright yellow 2 (BY-2) cells were maintained in Murashige and Skoog basal salt with minimal organics (MSMO+: MSMO (Sigma, Deisenhofen, Germany) plus 200 mg/ml KH<sub>2</sub>PO<sub>4</sub>, 0.6 Âµg/ml thiamine, 3 % sucrose and 0.2 Âµg/ml 2,4-D, pH 5.8) at 24Â°C in the dark on an orbital shaker. Cells were subcultured every week with a 5 % inoculum. Three days after subculture, plant cells were transformed by co-cultivation with recombinant <i>A. tumefaciens</i>, as described (An, Plant Physiol. 79: 568-570 (1985)). Selection of kanamycin-resistant transformants was performed on MSMO+ agar medium supplemented with 75 Âµg/ml kanamycin and 100 Âµg/ml claforan.<br /> For extraction of total soluble proteins from transgenic BY-2 suspension culture, cells from 1 ml culture were collected by centrifugation at 4000 x g for 5 min at 4Â°C. The cell pellet was resuspended in 1 ml protein extraction buffer (200 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02 % (w/v) sodium-azide and 0.1 % (v/v) Tween 20) and cells were disrupted by sonication at 60 watt for 1 min using a sonicator probe (B. Braun, Melsungen, Germany) at 4Â°C. Cell debris was removed by centrifugation at 14000 x g for 10 min at 4Â°C. The clear supernatant containing soluble protein was used for further analysis.<br /> For ELISA and western blotting, anti-mAb24 antisera (Zimmermann et al. (1998)) was used as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA). Protein concentrations were determined with the Bio-Rad Protein Assay using Bovine Serum Albumin (BSA) as standard. Analysis of stably transformed <i>N. tabacum</i> BY-2 cells revealed that scFv24-TcRÎ² was completely intracellular (Figure 8). scFv24-TcRÎ² was not detectable in the culture supernatant, indicating that the TcRÎ² transmembrane domain is stable and suitable for targeting scFv24 to tobacco cell membranes.</p>
    <heading>
      <u>Characterization of transgenic plants</u>
    </heading>
    <p id="p-00078-en">It was then tested whether the heterologous mammalian transmembrane domain TCRÎ² fused to scFv24 would target the single chain antibody to the plasma membrane in stably transformed tobacco plants. Transgenic <i>N. tabacum</i> cv. Petite Havana SR1 were generated by the leaf disc transformation with recombinant <i>A. tumefaciens</i> and transgenic To plants were generated from transformed callus (Horsch et al., Science 227: 1229-1231 (1985)). Extraction of total soluble proteins from tobacco leaves and subsequent analysis of scFv24 by ELISA were performed as described by Fischer <i>et al</i>. [Fischer R, Drossard J, Liao YC, Schillberg S: Characterisation and applications of plant-derived recombinant antibodies. In: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ (1998)]. For ELISA and western blotting, anti-mAb24 antisera (Zimmermann et al. (1998)) was used as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA). Protein concentrations were determined with the Bio-Rad Protein Assay using Bovine Serum Albumin (BSA) as standard. Expression levels of scFv24-TcRÎ² were much higher in transgenic <i>N. tabacum</i> cv. Petite Havana SR1 plants than in suspension cultures (Table 1). The maximum level of detergent extracted scFv24-TcRÎ² was 296 fold higher (8866 ng/g leaf tissue) than that obtained in transgenic suspension cultures (Figure 8).<br /> To determine if the scFv24 fragment was stably integrated into the plasma membrane or secreted into the extracellular space of intact plants, intercellular washing fluid from leaves of transgenic T<sub>1</sub> tobacco plants was analyzed by ELISA. For detection of scFv24 fusion protein in intercellular washing fluids, leaves of <i>N. tabacum</i> cv. Petite Havana SR1 were prepared as described by Fischer <i>et al</i>. (Fischer: Characterisation and applications of plant-derived recombinant antibodies. In: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ (1998)). Total protein extracts from washing fluids were concentrated by ultrafiltration (Microcon 10, Amicon, Witten, Germany) and analyzed by 12% SDS-PAGE (Laemmli, Nature 227: 680-685 (1970)) followed by western blot. There was no detectable antibody in the intercellular washing fluid from ten T<sub>1</sub> progenies of two plant lines (T4<sub>SR1</sub> and T6<sub>SR1</sub>) producing the scFv24-TcRÎ² fusion protein. In general, T<sub>1</sub> plants used for IWF analysis showed high expression levels of intracellular scFv24-TcRÎ² (1570-8940 ng/g leaf tissue).<br /> Western blot analysis of total soluble protein isolated from a T<sub>1</sub> progeny of plant line T4<sub>SR1</sub> showed only the predicted full length 48.2 kDa scFv24-TcRÎ² fusion protein and neither the intact fusion protein nor any degradation products were detectable in the intercellular washing fluid (Figure 9). This demonstrates that scFv24-TcRÎ² was not secreted and remained membrane anchored in transgenic plants.</p>
    <heading>
      <u>Subcellular localization of scFv24-TcRÎ² in transgenic <i>N. tabacum</i> cv. BY-2 protoplasts</u>
    </heading>
    <p id="p-00079-en">Since the scFv24-TcRÎ² construct contains signal peptide and transmembrane sequences, fusion protein should be localised at the plasma membrane. To determine the subcellular localization of the scFv24-fusion protein, transgenic <i>N. tabacum</i> cv. BY-2 protoplasts were generated and analysed by immunofluorescence microscopy (Figure 10).<br /> Protoplasts were prepared by digesting 3 day old tobacco BY-2 cells with 1.5 % (w/v) cellulase Onozuka RS (Yakult Honsha Co., Tokyo, Japan), 0.7 % (w/v) hemicellulase (Sigma) and 0.1 % (w/v) pectolyase Y23 (Seishin Pharmaceuticals, Nihonbashi, Tokyo, Japan) in MES buffer (0.5 % (w/v) MES, 80 mM CaCl<sub>2</sub>, 0.3 M mannitol, pH 5.8) for 1.5 h at 25Â°C on a rotary shaker. Protoplasts were washed with MES buffer, transferred to fresh MSMO+ medium and incubated over night at 24Â°C on an orbital shaker in the dark. Regenerating protoplasts were washed once with MES buffer and settled on poly-L-lysine-coated multiwell slides. Cells were fixed for 15 min at room temperature with 4 % (w/v) formaldehyde in MTS buffer (50 mM Pipes, 5 mM EGTA, 5 mM Mg<sub>2</sub>SO<sub>4</sub>, pH 6.9) plus 0.3 M mannitol. The resulting protoplast ghosts were washed with MTS buffer and incubated for 1 h at room temperature with a 1:2500 dilution of rabbit anti-mAb24 antisera (Zimmermann et al. (1998)) or a 1:50 dilution of mouse anti-human TcR Î² IgG (T Cell Diagnostics, Woburn, MA) in 3 % (w/v) BSA MTS buffer supplemented with 0.3 M mannitol. Cells were washed with MTS buffer and then incubated for 1 h at room temperature with FITC-conjugated goat anti-rabbit or FITC-conjugated goat anti-mouse secondary antibodies (Jackson Immuno Research Laboratories) diluted 1:100 in 3 % (w/v) BSA MTS buffer supplemented with 0.3 M mannitol. After washing with MTS buffer, slides were mounted in Citifluor antifade (Citifluor Ltd., London, England) and imaged on a Zeiss inverted microscope equipped with a 40x oil-immersion objective using 450-490 nm excitation and 520-560 nm emission interference filters. Images were recorded on T-max 400pro film (Kodak, Rochester, NY).<br /> Protoplasting enzymes contain proteases which degrade cell surface proteins and there was no detectable cell surface staining directly after protoplasting BY-2 cells. However, overnight regeneration of protoplasts allowed delivery of newly synthesized membrane bound scFv24 to the cell surface and gave optimal staining. Control wild type <i>N. tabacum</i> cv. BY-2 cells showed no evidence of surface staining (Figure 10A). In contrast, protoplasts derived from the transgenic <i>N. tabacum</i> cv. BY-2 suspension cell line T2<sub>BY-2</sub> producing scFv24-TcRÎ² were brightly stained with anti-Ab24 sera at the plasma membrane, demonstrating the plasma membrane localization of the scFv24-TcRÎ² fusion protein (Figure 10B). In addition, the localisation of scFv24-TcRÎ² to the plasma membrane was also observed by staining with the anti-human TcRÎ² antibody, which recognizes the constant region of TcRÎ² that links the TcRÎ² transmembrane domain to scFv24 (Figure 10C). In addition to plasma membrane labeling, some protoplasts showed nuclear membrane staining for the scFv24-TcRÎ² fusion protein (Figure 10D).</p>
    <heading>
      <u>Immuno-electron microscopy</u>
    </heading>
    <p id="p-00080-en">Immuno-electron microscopy was performed on ultrathin section of leaves, to verify location of membrane bound scFv24.<br /> Small tissue pieces of transgenic <i>N. tabacum</i> cv. Petite Havana SR1 plants were embedded at low temperature for immunogold labeling (Wells, Micron and Microscopica Acta 16: 49-53 (1985)). Immunogold labeling of thin sections on plastic-filmed gold grids was carried out as previously described (McCann et al. J. Microsc. 166: 123-136 (1992)), except that blocking buffer used for the incubations with antibodies contained 3 % (w/v) BSA. Primary antibodies: rabbit anti-mAb24 antiserum at 1:100 dilution (Zimmermann et al. (1998)) or mouse anti-human TcRÎ² IgG at 1:25 dilution (T Cell Diagnostics), were incubated with sections for 1 h. Secondary antibodies were 12 nm gold conjugated goat anti-rabbit or 12 nm gold conjugated goat anti-mouse (Jackson Immuno Research Laboratories) and were incubated with sections at a dilution of 1:40 for 1 h. Bright-field light micrographs of 1 Âµm thick resin sections were viewed at 80 kV on a Joel 1200EX transmission electron microscope, and photographs were taken using Kodak film.<br /> In young leaves of the transgenic To plant T4<sub>SR1</sub> producing scFv24-TcRÎ², scFv24 was localized to both the nuclear and plasma membranes (Figure 11), confirming the subcellular localization of scFv24-TcRÎ² by immunofluorescence in transgenic <i>N</i>.<i>tabacum</i> cv. BY-2 protoplasts. The number of gold particles found in chloroplasts, mitochondria, glyoxysomes, cytoplasmic matrices and vacuoles was consistent with background labeling.</p>
    <heading>
      <u>Bioassays of viral resistance</u>
    </heading>
    <p id="p-00081-en">To analyze the biological effects of the membrane anchored anti-viral TMV-specific antibody on viral resistance, T<sub>1</sub> progenies of plant line expressing the scFv24-TcRÎ² fusion protein (T6<sub>SR1</sub>) were inoculated with TMV.<br /> Seeds were collected from antibody-producing To plants and germinated on MSMO agar medium supplemented with 2 % (w/v) sucrose, 0.4 Âµg/ml thiamine, 0.4 Âµg/ml glycine, 0.1 Âµg/ml nicotine acid, 0.1 Âµg/ml pyridoxine and 75 Âµg/ml kanamycin. Kanamycin-resistant T<sub>1</sub> plants were used for inoculation with TMV-<i>v</i> (1 Âµg/ml) as previously described (Dietzgen, Arch. Virol. 87: 73-86 (1986)). Wild type <i>N. tabacum</i> cv. Petite Havana SR1 plants were used as a control. Disease symptoms were monitored 6 to 20 days post inoculation (p.i.) and for resistant plants up to 180 days p.i..<br /> Lower leaves were infected with TMV and systemic spread of the virus was followed by analyzing upper leaves 6-20 days later. All control non-transgenic tobacco plants were systemically infected, but 16 % (out of 31 analyzed) of scFv24-TcRÎ² transgenic plants had no visible disease symptoms on the upper leaves (Table 2). Furthermore, ELISA analysis demonstrated that some of these plants accumulated virus particles in the upper leaves indicating that though systemic viral spread occurred, no symptoms were developed. Strikingly, in 6 % of scFv24-TcRÎ² transgenic plants no virus was found in the upper leaves up to 90 days post inoculation. Virus could be detected at inoculation sites in the lower leaves by ELISA demonstrating that these plants had been efficiently inoculated with TMV. Antibody-fusion protein expression levels correlated with expression of TMV resistance (Table 2). Higher levels of scFv24 fusion protein expression led to an increased fraction of virus resistant plants, confirming that membrane anchored scFvs could be used to generate plants resistant to virus.</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00082-en">The recombinant fusion protein scFv24-TcRÎ² was functionally expressed in transgenic tobacco suspension cultures and transgenic plants. Expressed scFv24-TcR recognized TMV in ELISA and showed the expected size in immoblot analysis. Furthermore, immunofluorescence and electron microscopy showed that the TcRâ¢ transmembrane domain targeted scFv24 to the tobacco plasma and nuclear membrane. Bioassays of viral infection showed that transgenic tobacco plants expressing scFv24-TcRâ¢ were resistant to systemic TMV infection. These results demonstrated that membrane anchored anti-viral antibody fragments are functional, can be targeted to the plasma membrane <i>in planta</i> and are a novel method to shield plant cells from invading pathogens.<tables><table><title>Levels of functional scFv24 fusion protein in the To generation of transgenic N. tabacum cv. Petite Havanna SR1. Total soluble plant protein was isolated from leaves of transgenic plants producing scFv24-TcRÎ². scFv24-fusion protein expression was quantified by TMV-specific ELISA using anti-mAb24 antisera and expressed as ng scFv24 per g leaf tissue.</title><tgroup cols="5"><thead><row><entry>Construct</entry><entry>Number of transgenic plants</entry><entry>Number of plants expressing functional scFv24</entry><entry>Range of expression (ng/g leaf tissue)</entry><entry>Average expression (ng/g leaf tissue)</entry></row></thead><tbody><row><entry>pscFv24-TcRÎ²</entry><entry>6</entry><entry>6</entry><entry>30 - 8866</entry><entry>1991</entry></row></tbody></tgroup></table></tables><tables><table><title>Virus infection assay of trangenic plants expressing membrane anchored scFv24. 1 Âµg/ml TMV-v was applied onto a lower leaf of non-transgenic N. tabacum cv. Petite Havana SR1 and transgenic T1 progenies from plant line P9SR1 producing scFv24-PDGFR or T6SR1 producing scFv24-TcRÎ². scFv24-fusion protein levels were determined by ELISA using the anti-mAb24 antisera 14 days p.i. and used for group formation (low, average and high producers). a = upper leaves showed no visible disease symptoms; b = based on TMV-ELISA; c = level of resistance of all low, average and high producers, numbers in brackets include all plants without visible disease symptoms.</title><tgroup cols="6"><thead><row><entry>Plant lines</entry><entry>Tested plants</entry><entry>ng scFv24 per g leaf tissue</entry><entry>Healthy phenotype<sup>a</sup></entry><entry>Resistant plants<sup>b</sup></entry><entry>Level of resistance (%)<sup>c</sup></entry></row></thead><tbody><row><entry><i>N. tabacum</i> cv. Petite Havana SR1</entry><entry>62</entry><entry>-</entry><entry>0</entry><entry>0</entry><entry>0</entry></row><row><entry>T6<sub>SR1</sub>, low producer</entry><entry>22</entry><entry>10-500</entry><entry>1</entry><entry>0</entry></row><row><entry>T6<sub>SR1</sub>, average producer</entry><entry>2</entry><entry>501-2000</entry><entry>2</entry><entry>1</entry><entry>6(16)</entry></row><row><entry>T6<sub>SR1</sub>, high producer</entry><entry>7</entry><entry>2001-21500</entry><entry>2</entry><entry>1</entry></row></tbody></tgroup></table></tables></p>
    <heading>
      <b>Example 2: Expression of a neutralising anti-viral antibody with a C-terminal membrane localisation sequence</b>
    </heading>
    <heading>
      <u>Cytoplasmic presentation of a membrane localised recombinant antibody against the coat protein of Tobacco Mosaic virus (TMV)</u>
    </heading>
    <p id="p-00083-en">The steps 1) to 16) of example 1 are repeated with the following adaptations.<ol><li>1) The N-terminal signal sequence is removed and replaced by a start codon.</li><li>2) The C-terminal membrane localisation sequence including the linker sequence of example 1 are replaced by suitable linker and C-terminal targeting sequences to posttranslationally target and integrate recombinant proteins into the bilayer of endomembranes. Suitable targeting sequences include transmembrane domains of KAR1 for nuclear membrane integration (Rose and Fink, 1987), middle-T antigen for plasma membrane integration (Kim et al., 1997) and cytochrome b5 for ER membrane integration (Kim et al., 1997). Moreover, prenylation, farnesylation, palmitoylation, myristoylation and ankyrin sequence motifs can be incorporated.</li></ol></p>
    <p id="p-00084-en">Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised against structural and non structural proteins of any pathogen. Membrane anchor sequence(s) can be substituted against any sequence that facilitates membranes integration and provides a biological function. Moreover, example 2 can be combined with examples 1 and 3-8 in any combination(s).</p>
    <heading>
      <u>Construction of the scFv24 fusion expression cassette</u>
    </heading>
    <p id="p-00085-en">To integrate the TMV-specific scFv24 into the bilayer of endomembranes the antibody fragment was fused to a C-terminal receptor transmembrane domain. No N-terminal signal sequence was included, therefore the scFv fragment is facing to the cytosol. The transmembrane domain sequence of KAR1 was selected for nuclear membrane integration (Rose and Fink, 1987), middle-T antigen for plasma membrane integration (Kim et al., 1997), cytochrome b5 for ER membrane integration (Kim et al., 1997) and syn1 for integration into vesicles (Kim et al., 1997). To ensure proper folding of the expressed single chain antibody fragments, the constructs scFv24-kar1, scFv24-mT, scFv24-cytb5 and scFv24-syn1 contained a Gly<sub>4</sub>Ser linker sequence between the scFv24 fragment and the membrane anchor (Figure 12).<br /> The C-terminal transmembrane domains KAR1, middle-T (mT), cytochrome b5 (cytb5) and synaptobrevin 1 (syn1) including the Gly<sub>4</sub>Ser linker sequence were fused to the scFv24 by PCR. The template scFv24CW cDNA (Zimmermann et al. (1998)), the forward primer -40 (5'-GTT TTC CCA GTC ACG AC-3' (SEQ ID NO:4)) and the following backward primers were used for PCR amplification: for <u>kar1</u> 5'-GGC TCT AGA CGC TCG AGT TTA AAA CCT ATA ATA CAC ATA GAT GTT GCA ATA AAG CAA AAT CAG TAT ACA AAT AGT CCA CCA GAA ATA CTC CCT ATA CTT CTT AGC GGC CGC AGA ACC TCC ACC TCC GTC G-3'(SEQ ID NO:5); for mT 5'-GGC TCT AGA CGC TCG AGT TTA GAA ATG CCT AGA TCT CTT AAT CAA GAT GAA GAG CAT CAA GCA AAT TCC GAG CAG CGC TGC CAA GAA AGT CAC CAA GAG CAA AGT TCT TCC CAA TCT CCT AGC GGC CGC AGA ACC TCC ACC TCC GTC G-3' (SEQ ID NO:6); for <u>cytb5</u> 5'-GGC TCT AGA CGC TCG AGT TTA ATC CTC TGC CAT GTA GAG TCT ATA CAT GAG AGC AAC CAC GAG TGC TGA TAT CGC TGG GAT CAC CCA ATT GGT CCA CCA TGA AGA GTT AGA CTC AAC AGC GGC CGC AGA ACC TCC ACC TCC GTC G-3' (SEQ ID NO:7) and for <u>syn1</u> 5'-GGC TCT AGA CGC TCG AGT TTA AGT GAA GAA ATA AAT AAC AAT AAC AAC AAC AAT AAT AGC ACA AAT AGC ACC AAG CAT AAT CAT CAT CTT ACA ATT CTT CCA AGC GGC CGC AGA ACC TCC ACC TCC GTC G-3'(SEQ ID NO:8). The codons of the transmembrane domains were codon optimized for expression in tobacco, pea and wheat. The 5'-<i>Eco</i>RI and 3'<i>-Xba</i>l restricted PCR fragments were subcloned into pUC18 and sequenced. Mutations in the mT and syn1 transmembrane domain were eliminated by PCR using the forward primer -40 (5'-GTT TTC CCA GTC ACG AC-3' (SEQ ID NO:9)) and the backward primers MUT7MT 5'-GGC TCT AGA CGC TCG AGT TTA GAA ATG CCT AGA TC-3' (SEQ ID NO:10) for mT and SYN1SHORT 5'-GGC TCT AGA CGC TCG AGT TTA AGT GAA GAA ATA AAT AAC AAT AAC AAC AAC-3' (SEQ ID NO:11) for syn1. The chalcone synthase 5' untranslated region and scFv24 was substituted by the <i>Eco</i>RI and <i>Sal</i>I fragment from scFv24CW (Zimmermann et al. (1998)). The subsequent ligation of the <i>Eco</i>RI-<i>Xba</i>I fragments into the plant expression vector pSS, containing an double enhanced 35S promoter (Voss et al. (1995)), resulted in the final expression constructs pscFv24-kar1, pscFv24-mT, pscFv24-cytb5 and pscFv24-syn1 (Figure 12).</p>
    <heading>
      <u>Transient expression in tobacco leaves</u>
    </heading>
    <p id="p-00086-en">To analyze the expression level of the recombinant scFv-fusion proteins, <i>N. tabacum</i> cv. Petite Havana SR1 leaves were transiently transformed with recombinant <i>A</i>.<i>tumefaciens</i> and functional expression of the scFv24 domain of the fusion protein was analyzed by ELISA using anti-mAb24 antisera.<br /> The vector constructs were transferred into <i>A. tumefaciens</i> GV3101 by liquid N<sub>2</sub> transformation (HÃ¶fgen and Willmitzer (1988)). Transient transformation of <i>N</i>.<i>tabacum</i> cv. Petite Havana SR1 was performed as described (Kapila et al., Plant Science 122 (1996) 101-108). To extract total soluble proteins, Tobacco leaves were frozen and ground in liquid nitrogen and scFv-fusion protein level was analysed by ELISA using anti-mAb24 antisera (Zimmermann et al. (1998)) as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA) (Fischer et al. in: C. Cunningham, A.J.R. Porter, (Eds.), Methods in biotechnology Vol. 3: Recombinant proteins in plants: Production and Isolation of Clinically useful compounds. Humana Press, Totowa, NJ (1998), ELISA III).<br /> The fusion proteins scFv24-mT, scFv24-syn1 and the control scFv24 lacking a C-terminal transmembrane domain were not detectable in plant extracts from transient transformation experiments (detection limit: 0.5 ng per gram leaf tissue). However, scFv24-kar1 and scFv24-cytb5 accumulated in the cytosol of plant cells to a maximum level of 1.8 ng and 1.0 ng per gram leaf tissue, respectively.</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00087-en">Generation of stable transformed <i>N. tabacum</i> cv. Petite Havana SR1 and bioassays to analyse the biological effects of cytosolic scFv24-kar1 and scFv24-cytb5 in transgenic tobacco plants are in progress. Based on our results with the scFv24-TcRÎ² (example 1) integration of the fusion proteins into the plant cell membrane was expected via the C-terminal transmembrane domains KAR1 or syn1. The scFv24 is facing to the plant cytosol, which will result in an increased viral resistance because the biological effect of scFv24 is high in the plant cytosol and membrane integration targets the scFv24 to the localisation where the virus is most vulnerable. The virus replication and movement takes place at plant cell membrane systems, therefore virus dissambly will be effectively prevented.</p>
    <heading>
      <b>Example 3: Viral resistance by expression of a molecular pathogenicide</b>
    </heading>
    <heading>
      <u>Fusion of a nuclease activity to a recombinant antibody specific for TMV</u>
    </heading>
    <p id="p-00088-en">The steps 1) to 16) of example 1 and/or the steps 1) to 2) of example 2 are repeated with the following adaptations.<ol><li>1) The plant expression construct contains a 5' signal sequence to enable delivery of the recombinant antibody to the ER lumen and then secretion to the apoplast.</li><li>2) The transmembrane targeting domain is replaced by linker coupling the protein to a C-terminal fusion with a toxin - in this case an RNAse enzyme which degrades cellular RNA, viral RNA, replicative forms and/or replicative intermediates.</li><li>3) Upon binding to the virions in the apoplast, the fusion protein will enter the cytosol of damaged cells via the entering virions, where the cytotoxic RNase will degrade viral RNA, replicative intermediates and replicative forms or/and cellular RNA and cause cell death of virally infected cells and therefore prevent replication and spread of the pathogen.</li></ol></p>
    <p id="p-00089-en">Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised against structural and non structural proteins of any pathogen. The RNase sequence(s) can be substituted against any enzyme sequence that interferes in the pathogen life cycle. Moreover, example 3 can be combined with examples 1-2 and 4-8 in any combination(s).</p>
    <heading>
      <u>Construction of the scFv24 fusion (immunotoxin) expression cassette</u>
    </heading>
    <p id="p-00090-en">To generate an apoplastic expressed immunotoxin, the TMV-specific scFv24 was fused to an N-terminal mammalian signal peptide and C-terminal toxin. The mouse N-terminal light chain signal peptide from the original antibody (mAb24) used to generate scFv24 was used to target fusion proteins to the secretory pathway. The domain III of the <i>Pseudomonas</i> exotoxin (PE) was selected for fusion with the C-terminus of scFv24. The domain III of the <i>Pseudomonas</i> exotoxin mediates the ADP-ribosylation of elongation factor 2, which arrests protein synthesis and causes cell death. To ensure proper folding of the expressed single chain antibody fragments, the cDNA construct contained the cellobiohydrolase I (CBHI) linker of <i>Trichoderma reesi</i> (Mallender and Voss, 1994, J. Biol. Chem. 269, 199-206) between the scFv24 fragment and the domain III of the PE. A 12 amino acid residue epitope tag (tag54) was fused to the C-terminus via a Gly<sub>4</sub>Ser linker to enable detection of the recombinant protein in plant extracts.<br /> The PE domain III was PCR amplified from the plasmid PE38 (Theuer et al., Cancer Res 15, 340-347 (1993)) using the primers PE400-for 5'- GCG GAA TTC GAC GTC GCC ATG GCC TTC CTC GGC GAC GGC GGC GAC - 3' (SEQ ID NO:16) and PE-back 5'- GCG AAG CTT GTC GAC CGG CGG TTT GCC GGG CTG GCT G - 3' (SEQ ID NO:17). The primers contained restriction sites <i>Eco</i>RI, <i>Aat</i>II and <i>Nco</i>I (PE400-for) and <i>Sal</i>I and <i>Hind</i>III (PE-back) for cloning. The PCR fragment was subcloned via <i>Eco</i>RI and <i>Hind</i>III into pUC18 resulting in the construct PE400-intermediate and the sequence was verified by sequencing. To generate the immunotoxin, the scFv29 sequence from the biscFv2429-apoplast in pUC18 (Fischer et al., <i>Eur. J. Biochem.</i> 262, 810-816 (1999)) was removed by <i>Aat</i>II and <i>Sal</i>I and exchanged by the <i>Aat</i>II (internal restriction site) and <i>Sal</i>I fragment of PE400-intermediate. Finally, the <i>Eco</i>RI and <i>Sal</i>I fragment containing the chalcone synthase 5' untranslated region, the leader signal of mAb24 light chain (Voss et al., 1995), the scFv24, the CBHI linker and PE domain III was subcloned into the <i>EcoR</i>I and <i>Sal</i>I restriction sites of pSS derivate containing the enhanced 35S promoter (Kay et al., 1987), the epitope tag54 and the CaMV termination sequence resulting in the final plant expression construct pscFv24-PE400 (Figure 13).</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00091-en">Generation of stable transformed <i>N. tabacum</i> cv. Petite Havana SR1 and bioassays to analyse the biological effects of scFv24-PE400 in transgenic tobacco plants are in progress. However, PE280-tag29 was transiently expressed in tobacco leaves and a slightly degraded product of was detected in plant extracts of transient transformed tobacco leaves, indicating that PE280-tag29 is most likely expressed and secreted to the apoplast and therefore not toxic to the plant cells (see example 7). Consequently, expression of the immunotoxin scFv24-PE400 will be non-toxic to plants.<br /> The scFv24-PE fusion (scFv24-PE400) will be secreted to the apoplast of transgenic tobacco plants. During TMV infection the fusion protein will bind to the virus particle via the scFv24 (as shown for the full-size rAb24) and TMV virions that enter the cell will carry bound scFv24-toxin fusion. PE400 mediates the ADP-ribosylation of elongation factor 2, which arrests protein synthesis and causes cell death. PE is a very effective toxin, as only a few molecules are required to kill the infected cell, thus preventing virus replication and spread, leading to highly resistant plants.</p>
    <heading>
      <u>Molecular Pathogenicide fusion (RNAse fusion)</u>
    </heading>
    <p id="p-00092-en">A C- or N-terminal fusion of a coat protein specific antibody scFv gene (scFv24) with a cDNA encoding a RNAse gene (for example <i>E. coli</i> RNAse E) results in an scFv-enzyme fusion protein which can be targeted to the plant cytoplasm - or to cellular organelles, membranes, or the apoplast to interfere in viral replication.</p>
    <p id="p-00093-en">Such an scFv-RNAse fusion was engineered based on the TMV-specific scFv24 which binds to the intact TMV virions instead of coat protein alone. This scFv24 was chosen for targeting the viral RNA at the earliest timepoint of the viral infection cycle to immediately act on the released viral RNA upon viral dissassembly. A second contruct is based on a 30K specific scFv-RNAse fusion which follows the same set up as given in Fig 14 based on the scFv24. This scFv is described in Example 5 (scFv 30-1 or scFv 30-2) and will be coexpressed with the scFv 24-RNaseE fusion in double transgenic plants transformed with both constructs. For fusion to the above mentioned scFv antibodies the <i>E. coli</i> RNAse E. was selected (Claverie-Martin et al.,<i>J</i>. <i>Biol. Chem.</i> 266, 2843-2851] and connected to the scFv upon PCR-amplification using standard cloning technologies known by any person skilled in the art.</p>
    <heading>
      <b>Example 4: Enhanced coat protein mediated resistance with an antibody-viral coat protein fusion protein</b>
    </heading>
    <heading>
      <u>Fusion of a viral coat protein to a recombinant antibody specific for TMV</u>
    </heading>
    <p id="p-00094-en">The steps 1) to 16) of example 1 and/or the steps 1) to 2) of example 2 are repeated with the following adaptations.<ol><li>1) The transmembrane targeting domain listed in example 1 are removed but the C-terminal anchor and linker sequences of example 2 can be maintained.</li><li>2) The N-terminal signal sequence of example 1 is replaced by an upstream located (N-terminal) TMV coat protein monomer and then connected via a flexible linker to the recombinant antibody cDNA.</li><li>3) The fusion protein is expressed in the cytosol.</li><li>4) Alternatively, the transmembrane domain is replaced by a linker enabling C-terminal fusion with the TMV coat protein monomer. The fusion protein is expressed in the cytosol (without N-terminal signal sequence) or sent into the secretory pathway via a N-terminal signal peptide.</li></ol></p>
    <p id="p-00095-en">Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised against structural and non structural proteins of any pathogen. The N-terminal coat protein sequence(s) can be substituted against any sequence (for example Glutathione S-Transferase, Thioredoxin, plant virus movement proteins, replicase, minimal proteins or domains thereof) that stabilises a cytosolic expressed recombinant antibody and interferes in the pathogen life cycle. Moreover, example 4 can be combined with examples 1-3 and 5-8 in any combination(s).</p>
    <heading>
      <u>Construction of the scFv24 fusion expression cassettes</u>
    </heading>
    <p id="p-00096-en">A cytoplasmically expressed protein (the coat protein of tobacco mosaic virus) was selected as fusion partner to analyse its effect on the function and stability of the TMV-specific scFv24. The tobacco mosaic virus coat protein (CP) was cloned 5' upstream of the scFv24 (Figure 15).<br /> The gene fusion partner coat protein (CP) from TMV was amplified by PCR. cDNAs was amplified from a cDNA clone from TMV as a template. The forward primers introduced a <i>Nco</i>I restriction site (5' end) and the backward primers a C-terminal (Gly<sub>4</sub>Ser)<sub>2</sub> linker sequence and an <i>Aat</i>II restriction site (3' end). The following forward and backward primers were used for PCR amplification: CP-for 5'-ACT GCG CCA TGG CTT ACA GTA TCA CT-3' (SEQ ID NO:20), CP-back 5'-CCG TCA GAC GTC AGA ACC TCC ACC TCC ACT TCC GCC GCC TCC AGT TGC AGG ACC AGA GGT CCA AAC CAA ACC-3' (SEQ ID NO:21). The 5'-<i>Nco</i>I and 3'-<i>Aat</i>II restricted PCR fragments were subcloned into a pUC18 derivative containing the TMV specific scFv24 (Zimmermann et al., 1998) flanked by the 5' Î© untranslated region (omega-sequence) and 3' untranslated region (Pw sequence) from TMV (Schmitz et al., Nucleic Acids Res 24 (1996) 257-263); (Gallie and Kobayashi, Gene 142 (1994) 159-165). A C-terminal His6- (H) or KDEL-sequence (K) were added to scFv24 of the fusion construct by PCR using the backward primers: His6-back 5'-CTA CCC CTC GAG TTT AGT GAT GGT GAT GGT GAT GAG CGG CCG CGT CGA CTG CAG AGA CAG TGA CCA GAG TC-3'(SEQ ID NO:22) and KDEL-back 5'-CCC TCA CTC GAG TTT AGA GCT CAT CTT TCT CAG ATC CAC GAG CGG CCG CAG AAC CTC CAC CTC CGT CGA CTG CAG AGA CAG TGA CCA G-3' (SEQ ID NO:23). The subsequent ligation of the <i>Eco</i>RI-<i>Asc</i>I fragments into the plant expression vector pSS, containing an double enhanced 35S promoter (Voss et al., 1995), resulted in the final expression constructs CP-scFv24H and CP-scFv24K, which were used for analyzing scFv-fusion protein accumulation in the cytoplasm (Figure 15A).<br /> For ER targeting and retention, the plant codon optimized leader sequence derived from the light chain of the murine monoclonal antibody mAb24 (Voss et al., 1995) was integrated between the 5' Î© untranslated region and scFv24 of the cytoplasmic construct containing the KDEL sequence, giving the plant expression vector L-CP-scFv24K (Figure 15C). For targeting the same construct to the apoplast, the c-terminal KDEL sequence was replaced by a His 6 sequence, giving the plant expression vector L-CP-scFv24H (Figure 15D).<br /> Two expression vectors lacking a leader sequence and an N-terminal fusion partner but containing scFv24 with a C-terminal His6 or KDEL sequence were used as controls for cytoplasmic accumulation (scFv24H, scFv24K, Figure 15B).</p>
    <heading>
      <u>Analysis of fusion protein accumulation in the ER</u>
    </heading>
    <p id="p-00097-en">Accumulation of functional fusion protein in the ER was analysed by transient expression in <i>N. tabacum</i> cv. Petite Havana SR1 leaves and functional scFv24 was detected by a TMV-specific ELISA. Plant expression constructs were transferred into<i>A. tumefaciens</i> GV3101 by N<sub>2</sub> transformation (HÃ¶fgen and Willmitzer, Nucleic Acids Res 16 (1988) 9877). Transient transformation of <i>N. tabacum</i> cv. Petite Havana SR1 was performed as described (Kapila et al., Plant Science 122 (1996) 101-108). To extract total soluble proteins, Tobacco leaves were frozen and ground in liquid nitrogen and scFv-fusion protein level was analysed by ELISA and Western blot (Fischer et al., Methods in biotechnology Vol. 3: Recombinant proteins in plants: Production and Isolation of Clinically useful compounds. Humana Press, Totowa, NJ (1998), ELISA III). A Fab fragment of the mAb24 was used as the ELISA standard. Protein concentrations were determined with the BioRad Protein Assay using bovine serum albumin (BSA) as the standard.<br /> The level of functional scFv24 detected for the ER retained L-CP-scFv24K fusion protein, amounted to 1Âµg per gram leaf material (average 0.6Âµg per gram leaf material, Figure 16).<br /> To verify the integrity of scFv24 fusion proteins, western blot analysis was carried out using affinity purified L-CP-scFv24K. For affinity purification of scFv-fusion proteins from plant extracts (prepared as described above), TMV virions were coupled to an activated CNBr sepharose matrix. 300mg of CNBr activated sepharose 4B matrix (Pharmacia, Freiburg, Germany) was resuspended in 1ml PBS pH 7.4 (1.37M NaCl, 27mM KCI, 81 mM Na<sub>2</sub>HPO<sub>4</sub>, 15mM KH<sub>2</sub>PO<sub>4</sub>) and incubated for 1 h at RT on a rotator. The matrix was pelleted (5000xg, 5min, RT), resuspended in 1ml PBS pH7.4 containing 10mg TMV virions and incubated for 2h at RT on a rotator. The TMV coupled matrix was centrifuged (5000xg, 5min, RT), resuspended in 1ml PBS pH 7.4 containing 1 % (w/v) BSA and 1 % (w/v) powdered milk and rotated over night at 8Â°C to block nonspecific binding sites. The TMV coupled matrix was washed three times with PBS pH 7.4 and resuspended in 1ml PBS pH 7.4. 30Âµl TMV-matrix was added to 1.5ml plant extract (prepared as described above) and incubated for 1 h at RT on a rotator. Then the TMV-matrix was washed three times with PBS and the TMV-matrix bound proteins were solubilised in sample buffer and analysed by SDS-PAGE (Laemmli, Nature 227 (1970) 680-685) and Coomassie brillant blue staining.<br /> Intact fusion proteins were detected with the expected size of 49.5kDa for L-CP-scFv24K (Figure 17).</p>
    <heading>
      <u>Analysis of fusion protein accumulation in the cytoplasm</u>
    </heading>
    <p id="p-00098-en">For transient cytoplasmic accumulation of fusion proteins <i>N. benthamiana</i> leaves were used. The vector constructs were transferred into <i>A. tumefaciens</i> GV3101 by liquid N<sub>2</sub> transformation (HÃ¶fgen and Willmitzer, Nucleic Acids Res. 16: 9877 (1988)). Transient transformation of <i>N. benthamiana</i> was performed as described (Kapila et al., Plant Science 122 (1996) 101-108). To extract total soluble proteins, Tobacco leaves were frozen and ground in liquid nitrogen and scFv-fusion protein level was analysed by ELISA and Western blot (Fischer et al., Methods in biotechnology Vol. 3: Recombinant proteins in plants: Production and Isolation of Clinically useful compounds. Humana Press, Totowa, NJ (1998), ELISA III). A Fab fragment of the mAb24 was used as the ELISA standard.<br /> Analysis using the constructs containing the C-terminal His6 sequence (Figure 15) demonstrated that CP-scFv24H was detectable in a TMV-specific ELISA, with an average protein level of 0.9ng functional active scFv24 per gram leaf material.<br /> Protein levels of the control construct scFv24H lacking an N-terminal fusion partner was below the ELISA detection limit (0.5ng) (Figure 18).<br /> We evaluated the influence of a C-terminal KDEL sequence on the accumulation of scFv24 fusion proteins. Addition of the C-terminal KDEL sequence increased the level of the fusion protein (Figure 18). The average protein level of the KDEL tagged CP-scFv24K was 3fold higher than CP-scFv24H (2.9ng per gram leaf material). Level of the control construct scFv24K was below the ELISA detection threshold. A control ELISA performed without the antigen TMV gave no signal, indicating that values of CP-scFv24H and CP-scFv24K could not be correlated with specific binding of CP-fusions to anti TMV polyclonal sera.</p>
    <heading>
      <u>Characterization of transgenic plants expressing cytoplasmic scFv fusion proteins</u>
    </heading>
    <p id="p-00099-en">We then tested to which level the cytoplasmically expressed CP-scFv24K accumulated in stably transformed tobacco plants. Transgenic <i>N. tabacum</i> cv. Petite Havana SR1 were generated by the leaf disc transformation with recombinant <i>A. tumefaciens</i> and transgenic To plants were generated from transformed callus (Horsch et al., Science 227: 1229-1231 (1985)). Extraction of total soluble proteins from tobacco leaves and subsequent analysis of scFv24 by ELISA were performed as described by Fischer <i>et al</i>. (Fischer et al., In: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ (1998)). For ELISA anti-mAb24 antisera (Zimmermann et al., Molecular Breeding 4: 369-379 (1998)) was used as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA) (Fischer, Methods in biotechnology Vol. 3: Recombinant proteins in plants: Production and Isolation of Clinically useful compounds. Humana Press, Totowa, NJ (1998), ELISA III).<br /> Protein levels of CP-scFv24K showed an average of 1.2 ng per gram leaf material in 12 analysed transgenic <i>N. tabacum</i> cv. Petite Havana SR1 plants. The maximum level of detergent extracted CP-scFv24K was 2.3 ng per g leaf tissue, thus higher than the scFv24 without fusion partner and KDEL sequence (maximum 1.8 ng/g leaf tissue; average 0.8 ng/g leaf tissue; Zimmermann et al., Molecular Breeding 4 (1998).</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00100-en">Bioassays to analyse the biological effects of cytosolic CP-scFv24K in transgenic <i>N. tabacum</i> cv. Petite Havana SR1 plants are in progress. Based on other inoculation experiments, an increase of viral resistance can be expected when compared to cytosolic scFv24 without fusion partner which creates a resistant phenotype, based on the increase of scFv24 protein levels and the presence of TMV-CP and TMV-RNA sequences to induce CP-mediated and RNA mediated virus resistance in addition to the primary antibody resistance.</p>
    <heading>
      <b>Example 5: Enhanced resistance by the expression of an anti-viral movement protein antibody</b>
    </heading>
    <heading>
      <u>Expression of recombinant antibodies against the TMV 30K movement protein in transgenic tobacco</u>
    </heading>
    <p id="p-00101-en">The steps 1) to 16) of example 1 and/or the steps 1) to 2) of example 2 are repeated with the following adaptations.<ol><li>1) Specific antibodies recognising the TMV 30K movement protein are raised by hybridoma technology, phage or ribosome display screening and subsequently cloned to engineer single chain antibodies or any recombinant form thereof.</li><li>2) The antibody is expressed in the cytosol or sent into the secretory pathway or membrane localised. The recombinant antibody may cause the desired biological effect without a fusion partner so the toxin sequence may be omitted.</li><li>3) For ELISA and surface plasmon resonance the test antigen for antibody function is the native or the recombinant TMV 30K movement protein or domains thereof.</li><li>4) Additionally to the bioassays listed in example 1 generated transgenic plants will be tested for broad spectrum resistance against different viral strains or viral genera by inoculation of transgenic plants with virions or infectious transcripts.</li></ol></p>
    <p id="p-00102-en">Anyone of skill in the art will recognise that these steps can be followed for any other viral pathogen by selecting antibodies or fragments thereof specific for the movement protein and any functional domain. Moreover, example 5 can be combined with examples 1-4 and 6-8 in any combination(s).</p>
    <heading>
      <u>Generation of anti-30K movement protein specific antibodies by phage display</u>
    </heading>
    <p id="p-00103-en">Movement protein (MP) - specific recombinant antibodies were generated by phage display using bacterially expressed 30K TMV movement protein fused to GST to faciliate affinity purification (Pharmacia GST-System). Female Balb/c mice were immunized using a standard protocol with soluble GST-30K fusion proteins or domains thereof. The native structure of the GST and the fused 30K was tested by GST activity assay (Smith et al., <i>Gene</i> 67 (1988), 31-40) and RNA binding of the 30K (Vaquero, J. Gen. Virol. 78 (1997) 2095-2099). Antibody V<sub>H</sub>- and V<sub>L</sub>- regions were subsequently rescued from plasma cells of hyperimmunized mice and assembled to scFv antibodies using an SOE-PCR protocol (Mc Cafferty et al., Nature 348 (1990), 552-554). An extended set of PCR-primers for V<sub>H</sub> and V<sub>L</sub> family specific amplification was developed and used (Table 4). Using this protocol a library &gt; 10<sup>6</sup> different scFv was generated for scFv presentation on the phage surface in fusion to the gene III M13-pilot protein. Using phage display a panel of 10 different movement protein specific antibodies could be isolated and characterised which all showed strong binding affinity to the bacterial expressed GST-30K fusion protein and not to the bacterially expressed GST-protein alone (Figure 20a). The binding domain of these 10 antibodies on the 30K were mapped by expression of 5 distinct 30K domains and ELISA analysis (Figure 20b). For evaluation of the biological effects of plant expressed anti 30K antibodies the 6 strongest binders were subsequently cloned into plant expression vectors and expressed and analysed by phenotypic evaluation and molecular analyses to evaluate their effects on viral infection with TMV. From these experiments two plant lines expressing the antibody fragments scFv 30-1 and scFv 30-2 (Figure 21) showed significant inhibition on TMV infection confirmed by a healthy phenotype of the plants, reduced amount and delayed accumulation of TMV coat protein compared to wild type <i>N. tabacum</i> Petite Havana SR1.</p>
    <heading>
      <u>Construction of the anti-30K antibody expression cassette for expression in plants</u>
    </heading>
    <p id="p-00104-en">To express the anti-30K antibodies in the cytosol of <i>N. tabacum</i> cv. Petite Havana SR1, the antibody fragments were cloned into the plant expression vector pSSH1 (Figure 19) (Voss et al., Molecular Breeding 1 (1995), 39-50). The cloning of the bispecific antibody fragment BISCA2429, which was used as parental construct for anti-30K antibody expression, including the TMV-derived Omega sequence, into the plant expression vector pSSH1 has been described (Fischer, et al., (1999) <i>Eur. J. Biochem</i>. 262, 810-816). For cloning of the resulting scFvs into this vector the primers used for establishing the phage display library contained the restriction enzyme sites <i>Nco</i> I and <i>Sal</i> I which faciliated the in-frame cloning into the intermediate construct pUC18-BISCA2429 (5'-UTR of TMV omega sequence, scfv, His6 tag). For expression in plant cells, the <i>EcoR</i>I/<i>Xba</i>I fragment (Figure 19) of this intermediate construct was subcloned into the <i>EcoR</i>I and Xbal restriction sites of the plant expression vector pSS containing the enhanced 35S promoter (Kay et al., Science 236 (1987), 1299-1302) and the CaMV termination sequence (Figure 19). The final constructs contained an expression cassette starting with the 35 SS promoter followed by the 5'- UT of the TMV omega sequence, the 30K specific scFv, a His6 tag for affinity purification and the 3'- UTR of CaMV (Figure 19 and 21).</p>
    <heading>
      <u>Generation and molecular characterization of transgenic plants</u>
    </heading>
    <p id="p-00105-en">Upon completion of scFv analysis <i>in vitro,</i> tobacco plants were stably transformed for<i>in vivo</i> testing of scFv effects on TMV infection. Transgenic <i>N. tabacum</i> cv. Petite Havana SR1 were generated by leaf disc transformation using recombinant <i>A. tumefaciens</i> and transgenic To plants were generated from transformed callus (Horsch et al., Science 227 (1985), 1229-1231). From the To generation several plants were selected and homozygous T<sub>1</sub> and T<sub>2</sub> progenies selected for phenotypic and molecular evaluation of scFv-antibody mediated resistance.<br /> To test if the anti 30K-specific scFv expression in transgenic plants had an biological effect on TMV replication and spread within the plant, a time course based TMV coat protein assay was established where the amount of viral coat protein was monitored in upper leaves after infection of transgenic and nontransgenic plants with TMV<i>vulgare.</i> Extraction of TMV coat protein from systemically infected tobacco leaves and subsequent analysis on SDS-PAGE (Laemmli, Nature 227 (1970), 680-685) was performed as described by Fischer <i>et al</i>. (Fischer et al., (1998) In: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ). Monitoring the coat protein expression in systemically infected wild type and control tobacco leaves by western blotting revealed increasing amounts of the TMV coat protein. In case of plants expressing the 30K specific scFvs, accumulation of coat protein was significantly delayed and levels were significantly lower compared to wild type <i>N. tabacum</i> cv. Petite Havana SR1, and transgenic N. tabacum Petite Havana SR 1 expressing a non-related scfv, used as control (Figure 22). Although coat protein was detectable in all transgenic plants they developed no or only mild symptoms based on phenotypic evaluations (Table 3).</p>
    <heading>
      <u>Bioassays to test viral resistance</u>
    </heading>
    <p id="p-00106-en">To analyse the biological effects of the TMV-specific 30K scFvs on viral resistance, T<sub>1</sub> and T<sub>2</sub> progenies of plant lines expressing the scFv 30-1 and scFv 30-2 S (Figure 21) were inoculated with TMV. Seeds were collected from different To plants and germinated on MSMO agar medium supplemented with 2 % (w/v) sucrose, 0.4 Âµg/ml thiamine, 0.4 Âµg/ml glycine, 0.1 Âµg/ml nicotine acid, 0.1 Âµg/ml pyridoxine and 75 Âµg/ml kanamycin. Germinating plants were transferred to soil and fully grown To plants self fertilized for seed collection. Kanamycin-resistant homozygous T<sub>1</sub> and T<sub>2</sub> plants were used for inoculation with TMV-<i>vulgare</i> (40 ng/ml). Four to six week old plants were mechanically infected on two lower leaves using 200 Âµl of the TMV containing suspension. <i>N. tabacum</i> cv. Petite Havana SR1 wild type or transgenic plants producing the tumorspecific scFv T84.66 as a control were inoculated as described. Disease symptoms were monitored 7 to 14 days post inoculation (p.i.). Upon infection of the two lower leaves with TMV, systemic spread of the virus was monitored by phenotypic evaluation of upper leaves after 7, 9, 11 and 14 days p.i. All control plants were systemically infected, and showed increasing amounts of viral coat protein. Transgenic T<sub>1</sub> and T<sub>2</sub> plants derived from different T<sub>0</sub>-plant lines expressing scFv 30K-1 or scFv 30K-2 showed no visible or weak disease symptoms on the upper leaves (Table 3). In cases where the symptom development was visible this was consistent among plants derived from one plant line. In the case of the scFv 30K-2 one plant line was obtained which showed severe symptoms in the T<sub>1</sub> as well as in the T<sub>2</sub> generation. This may be due to positional effects of the transgene or silencing effect of the transgene in the T<sub>1</sub> and T<sub>2</sub> generation. Furthermore, SDS-PAA based analysis and subsequent western-blotting of TMV coat protein accumulation over 72 hrs p.i. in infected plants demonstrated that all of these plants accumulated virus particles in the upper leaves although to a lower degree (Figure 22). This lead to the conclusion that expression of movement protein specific scFv can prevent symptom onset and delay on CP accumulation upon TMV infection.</p>
    <heading>
      <u>Other viral movement proteins</u>
    </heading>
    <p id="p-00107-en">To broaden the application of antiviral antibodies in transgenic plants for engineering resistance the 3a movement protein of cucumber mosaic virus was expressed in <i>E</i>.<i>coli</i> as a GST-fusion (Vaquero et al., (1997) J. Gen. Virol. 78, 2095-2099). Specific anti-3a antibodies were generated by phage display and hybridoma technology using bacterially expressed 3a CMV movement protein as already described for the 30K movement protein of TMV (Figure 19). The mAb 3a-2 was cloned from hybridoma cells (Krebber et al., (1997). J. Immunol. Methods 201, 35-55) and the resulting scFv 3a-2 characterized <i>in vitro</i> by ELISA technique (Figure 23a). Using epitope mapping by peptide display the epitope of the antibody could be mapped to a distinct region on the 3a movement protein.<tables><table><title>Phenotypic evaluation of TMV-30K-specific scFv expressing transgenic N. tabacum plants in the T1 and T2 generation. Different plants were tested from the T1 and the T2 generation for phenotypically visible disease symptoms upon infection of two lower leaves with 40 ng/ml TMV. Disease symptoms were monitored at 7, 9, 11 and 14 days p.i. in the most upper leaves.</title><tgroup cols="5"><thead><row><entry>Construct</entry><entry>T,-Plants</entry><entry>T<sub>2</sub>- Plants</entry></row><row><entry /><entry>No. of infected plants</entry><entry>symptoms</entry><entry>No. of infected plants</entry><entry>symptoms</entry></row></thead><tbody><row><entry>pSS-scFv-30-1</entry><entry>55</entry><entry>no symptoms after 11 to 14 days</entry><entry>22</entry><entry>weak symptoms after 14 days in all plants</entry></row><row><entry>pSS-scFv-30-2</entry><entry>124</entry><entry>weak or medium, rarely severe symptoms</entry><entry>65</entry><entry>no to weak, rarely severe symptoms</entry></row></tbody></tgroup></table></tables></p>
    <heading>
      <b>Example 6: Enhanced resistance by the expression of antibodies against the Tobacco mosaic virus replicase</b>
    </heading>
    <heading>
      <u>Expression of antibodies against the TMV 54K/TMV 183K replicase subunits in transgenic tobacco</u>
    </heading>
    <p id="p-00108-en">The steps 1) to 16) of example 1 and/or the steps 1) to 2) of example 2 are repeated with the following adaptations:<ol><li>1) Specific antibodies recognising the TMV 54K/183K replicase are raised by hybridoma and phage display or ribosome technology by using recombinant TMV 54K / TMV 183K proteins as the antigen and cloned to engineer single chain antibody fragments or any recombinant form thereof including bispecific scFvs.</li><li>2) These antibodies are expressed in the cytosol or targeted to cytoplasmic face of intracellular membranes, where the virus replication complexes are formed, by using a C-terminal sequence as described in example 2. The recombinant antibody may cause the desired biological effect without a fusion to a toxin.</li><li>3) For ELISA and surface plasmon resonance the test antigen for antibody function is the native or the recombinant TMV 54K and 183K replicase proteins or domains thereof.</li><li>4) Additionally to the bioassays listed in example 1, generated transgenic plants will be tested for broad spectrum resistance against different viral strains or viral genera by inoculation of transgenic plants with virions or infectious transcripts.</li></ol></p>
    <p id="p-00109-en">Anyone of skill in the art will recognise that these steps can be followed for any other viral pathogen by selecting antibodies or fragments thereof specific for the movement protein and any functional domain. Moreover, example 6 can be combined with examples 1-5 and 7-8 in any combination(s).</p>
    <heading>
      <u>Anti-replicase specific scFv (scFv 54K)</u>
    </heading>
    <p id="p-00110-en">An alternative method to prevent viral infection is based on the intracellular expression of antibodies such as replicase specific scFvs which can interact with the viral replicase to interfere or inhibit viral proliferation in infected cells. As described in example 5 for the 30K movement protein the "54K protein" of TMV, was expressed in<i>E. coli</i> and antibodies were generated using standard hybridoma technologies available to anyone skilled in the art. The 54K protein can be considered as an integrative component of the 183K protein, the major replicase protein of TMV, since it is expressed from its own subgenomic RNA and promoter but it shares the same reading frame of the last 1400 bases of the 183K protein. Herein conserved regions such as the GDD-Motif are encoded which can be found in all plant viral replicases. Antibody V<sub>H</sub> and V<sub>L</sub> regions were cloned from hybridomas using the same set of primers described in example 5 and assembled into scFv antibodies using standard cloning procedures (Krebber et al. (1997), J. Immunol. Methods 201, 35-55). The activity of the resulting scFv antibody scFv 54-1 (Figure 23a) was monitored by western blot detection and ELISA using the bacterial expressed GST-54K. The epitope of the scFv 54-1 was determined by peptide display (Figure 25b) and could be mapped to a distinct region on the 54K/ 183K gene of TMV.</p>
    <heading>
      <u>Plant virus minimal proteins</u>
    </heading>
    <p id="p-00111-en">Alternative viral proteins for engineering viral resistance are the "plant viral minimal proteins" 1 min, 2min and 3min as decribed for PLRV. One characteristic of the minimalprotein 3min is its ability to bind to nucleic acids wherby preferentially single stranded RNA is bound (Figure 24) (PrÃ¼fer et al., (1992) EMBO Journal 11, 1111-1117). 3min-specific antibodies were generated by hybridoma technology using bacterial expressed GST-3 min as antigen and the antibody scFv 3min was cloned from hybridoma cells (Figure 23c). Since the 3min protein of PLRV is described as a nucleic acid binding protein the native structure of the bacterial expressed GST-3min could be confirmed by nucleic acid binding assays using GST 3min and <i>in vitro</i> transcripts of viral RNA and DNA. Using the antibody scFv 3 min the RNA/DNA binding activity of the 3min protein could be completely blocked <i>in vitro</i>. Using epitope mapping by peptide display the epitope of the antibody could be mapped to a distinct region on the 3min minimal protein wherby the epitope identified by peptide display overlapped with the GST cloning region of the GST-3min construct (Figure 25c).</p>
    <heading>
      <u>Epitopemapping of antiviral scFvs (scfv 29. 3min and 54 K-1)</u>
    </heading>
    <p id="p-00112-en">For elucidation of viral epitopes recognised by the developed recombinant antibodies two peptide display libraries were used for epitope mapping of monoclonal antibodies (Cortese et al. (1995), Curr. Opin. Biotechnol. 6, 73-80). Both libraries express 9mer random peptides at the N-terminus of filamentous phage pVIII protein. One library displays the peptides in linear form, the other library displays the peptides flanked by two Cysteine-residues which form a disulfide-bridge, constraining the peptide to a loop structure.<br /> To identify the epitopes of scFv 29, scFv 54-1, and scFv 3min immunotubes were coated using 20Âµg affinity purified antigen using a standard procedure available to anyone skilled in the art (Cortese et al., (1995) Curr. Opin. Biotechnol. 6, 73-80). For the first round of panning, 5 x 10<sup>12</sup> phages in 1ml PBS were incubated with the immobilized antigen (16 h, 4Â°C). After extensive washing (15 times PBST and 5 times PBS), bound phages were eluted with 1ml Glycine-HCl pH 2.2, 0. 1 % (w/v) BSA (10min, 20Â°C), neutralized with 60 Âµl 2M Tris and used for infection of <i>E. coli</i>. The titer of eluted phages was determined by plating 100 Âµl of the infected bacteria on 2 x TY-Amp-plates and counting the colony forming units. Enrichment factors were calculated upon comparison to a control panning using BSA as antigen. Monoclonal phages from the third round of panning were tested for reactivity to their antigens by phage-ELISA.<br /> Positively identified phages from phage ELISA, using both phage libraries individually on all scFvs, were subsequentely sequenced. Obtained sequences were aligned and the resulting consensus sequence was determined. In all three cases (scFv 29, scFv 54-1 and scFv 3min) a consensus sequence could be determined (Figure 25). The resulting consensus sequence could also be mapped back to the parental sequence of the antigen the antibodies were generated against. Since the 9mer random peptide library presents preferentially linear peptides it is considered that all three epitopes of the scFvs represent a linear motif on the antigen. The epitope of scFv29, scFv54-1 and scFv3min were determined by peptide display and a consensus sequence was mapped for each scFv (Figure 25). For the scFv29, the consensus sequence was mapped to a distinct region of the coat protein (Figure 25a) and the scFv54-1 consensus sequence was mapped to a distinct region of the TMV 54K protein (Figure 25b). For the scFv3min the consensus sequence contained part of the GST and 3min proteins (Figure 25c) at the point where the 3min was fused to the GST. ScFv3min can be considered useful for engineering virus resistance as it inhibits the nucleic acid binding activity of the 3min protein (Figure 24).</p>
    <heading>
      <b>Example 7:</b>
      <i>
        <b>In vivo</b>
      </i>
      <b>assembly of a molecular pathogenicide</b>
    </heading>
    <heading>
      <u>
        <i>In vivo</i> assembly of a molecular pathogenicide consisting of a TMV specific antibody labelled with an epitope specific single chain antibody and an epitope tag labelled toxin</u>
    </heading>
    <p id="p-00113-en">The following steps are taken:<ol><li>1) Antibodies are generated against intact TMV virions and monoclonals are generated by hybridoma technology.</li><li>2) Hybridoma cell lines are cloned and cDNA sequences encoding the antibody variable regions are cloned to generate a single chain antibody or any recombinant version thereof binding to the TMV virions (scFv24).</li><li>3) The single chain antibody binding to the intact virions (scFv24) is fused to a cloned cDNA from the single chain antibody (scFv-epitag29), which binds to a specific amino acid epitope (epitag29), using a flexible linker such as the linker peptide of <i>Trichoderma reesi</i> cellobiohydrolase I (CBHI) to generate a recombinant protein which recognises the pathogen, TMV, and the epitope tag. The scFv-epitag29 has been previously generated (by conventional hybridoma technology and then cloned as an scFv) and the specific epitope identified by phage peptide display. Any other high affinity antibody recognising an identified peptide epitope would be suitable as one half of the binding pair with its corresponding epitope as the other partner.</li><li>4) The recombinant gene from step 3 is inserted in a microbial or eukaryotic expression vector.</li><li>5) The binding specificity and function (i.e. specificity and affinity) of the recombinant protein from step 3 is checked after expression in a heterologous host, such as in the periplasm of <i>E.coli</i>.</li><li>6) A signal sequence is added to the N-terminus of the recombinant bispecific scFv construct from step 3, to permit delivery of the protein to the ER and secretion to the apoplast upon expression in plants. A 5' untranslated and a 3' untranslated region and a detection tag sequence (i.e. c-myc) will be introduced by recombinant DNA technology, if necessary.</li><li>7) The chimeric gene from step 6 is inserted into a plant expression vector, e.g. pSS (Voss et al., 1995). Suitable plant expression vectors include suitable promoter, enhancer, terminator and selection marker sequences. In case of markerless and vectorless gene transfer selection marker sequences can be omitted.</li><li>8) The cDNA encoding a RIP (ribosome inactivating protein) fused via a suitable linker to the epitag-29 epitope tag (either at the N- or C-terminus), which is specifically recognised by scFv-epitag29, is prepared in parallel to generate a second independent expression construct encoding a tagged RIP gene.</li><li>9) The tagged RIP gene is inserted in a microbial or eukaryotic expression vector and the functionality of the RIP-epitope fusion is checked upon expression in a heterologous host.</li><li>10) A second, independent plant expression vector, such as pSS, containing the recombinant tagged RIP gene with an N-terminal signal peptide will be prepared, as described in step 6 and step 7. The tagged RIP sequence can then be integrated either in tandem array on the same plasmid as the fusion protein from step 3 or integrated in a second independent plasmid. Note that the sequences remain discrete even if they are in tandem array.</li><li>11) Both plant expression constructs listed in steps 6 and 10 are transformed into two independent plant lines or they are co-transformed into the same plant genome, or if the antibody fusion protein from step 3 and the tagged toxin from step 10 are integrated in tandem array that construct is transformed into the same plants.</li><li>12) Regenerated plants are screened using the selection marker for integration of the fusion gene in the independent plant lines or the co-transformed lines from step 11.</li><li>13) Transgenic plants that express only one of either the antibody fusion protein from step 3 or epitope tagged RIP from step 10 are then sexually crossed to give offspring which will produce both proteins. Plants producing both proteins, whether from this or earlier steps, will produce assembled protein complexes were the two binding partners, the epitope specific antibody (scFv-epitag29) and the epitope bind and permit assembly of a molecular pathogenicide protein complex.</li><li>14) Expression of the bispecific scFv fusion protein and/or the tagged RIP as well as the <i>in vivo</i> assembled molecular pathogenicide is monitored by western blotting cell extracts, ELISA or surface plasmon resonance analysis. Activity of the bispecific scFv is checked by ELISA using intact TMV virions as the antigen.</li><li>15) Activity of the assembled molecular pathogenicide is checked by ELISA and cytotoxicity assays.</li><li>16) Localisation of the fusion protein is checked by indirect immuno-fluorescence, confocal microscopy or immuno-electron microscopy and western blotting or ELISA or surface plasmon resonanace analysis of the intercellular washing fluid.</li><li>17) The biological activity of the <i>in vivo</i> assembled molecular pathogenicide against TMV is assayed by bioassays on the generated transgenic plants using virions or infectious transcripts.</li></ol></p>
    <p id="p-00114-en">Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised and cloned against structural and non structural proteins of any pathogen. Instead of RIPs, similar toxins with cell killing activity or interference in pathogenicity (RNAase, DNase etc.) can be used. Assembly of molecular pathogenicides can be achieved by using any epitope tag and a given epitope specific antibody with a suitable and stable molecular interaction <i>in vivo,</i> or any other pair of proteins that bind to each other. Moreover, example 7 can be combined with examples 1-6 and 8 in any combination(s).</p>
    <heading>
      <u>Constructs for analysing assembly of fusion partners</u>
    </heading>
    <p id="p-00115-en">To analyse assembly of a molecular pathogenicide consisting of a TMV specific antibody labelled with an epitope specific single chain antibody and an epitope tag labelled toxin different constructs were generated and assembly was studied by immunoblot and ELISA.<i>TMV specific antibody labelled with an epitope specific single chain antibody (biscFv2429):</i> The single chain antibody binding to the intact virions (scFv24) was fused to a cloned cDNA from the single chain antibody scFv-epitag29, which binds to a specific amino acid epitope (epitag29), using the flexible linker peptide of<i>Trichoderma reesi</i> cellobiohydrolase I (CBHI) to generate a recombinant protein which recognises the pathogen, TMV, and the epitope tag. The scFv-epitag29 has been previously generated (by convential hybridoma technology and then cloned as an scFv) as described for the scFv24 (Schillberg et al., <i>Transgenic Research</i> 8, 255-263 (1999)) and the specific epitope identified by phage peptide display. The mouse N-terminal light chain signal peptide from the original antibody (mAb24) used to generate scFv24 was used to target biscFv2429 to the secretory pathway. For expression in plant cells, the 5' UT from the chalcone synthase was introduced and the cassette was inserted between the enhanced 35S promoter and the CaMV termination sequence in the pSS expression vector (Figure 26) (Fischer et al., <i>Eur. J</i>.<i>Biochem</i>. 262, 810-816 (1999)).</p>
    <p id="p-00116-en">
      <i>Epitope tag labelled toxin (PE280-tag29 and PE400-tag29):</i> Two constructs were generated containing parts of the <i>Pseudomonas</i> exotoxin (PE) and the C-terminal epitag-29 fused via a Gly<sub>4</sub>Ser linker. The construct PE280-tag29 (Figure 26B) contains the sequence from amino acid (aa) 280 to aa 609, which comprises domain II and domain III from PE. The construct PE400-tag29 (Figure 26C) contains PE domain III from aa 400 to aa 609. PE domain III mediates the ADP-ribosylation of elongation factor 2, which arrests the protein synthesis and causes cell death. The epitag-29, which is specifically recognised by scFv-epitag29, was fused C-terminal to both constructs via Gly<sub>4</sub>Ser linker. The mouse N-terminal light chain signal peptide from the murine monoclonal antibody mAb24 was used to target PE280-tag29 and PE400-tag29 to the secretory pathway.<br /> The PE280 and PE400 were PCR amplified from the plasmid PE38 using the following primers: for PE280: PE280-for 5'- GCG GAA TTC GAC GTC GCC ATG GGC TGG GAA CAA CTG GAG CAG -3' (SEQ ID NO:157) and PE-back 5'- GCG AAG CTT GTC GAC CGG CGG TTT GCC GGG CTG GCT G - 3' (SEQ ID NO:158); for PE400: PE400-for 5'- GCG GAA TTC GAC GTC GCC ATG GCC TTC CTC GGC GAC GGC GGC GAC - 3' (SEQ ID NO:159) and PE-back 5'- GCG AAG CTT GTC GAC CGG CGG TTT GCC GGG CTG GCT G - 3' (SEQ ID NO:160). The primers contained restriction sites <i>Eco</i>RI, <i>Aat</i>II and <i>Nco</i>I (PE280-for and PE400-for) and and<i>Hind</i>III (PE-back) for cloning. The PCR fragments were subcloned via <i>Eco</i>RI and<i>Hind</i>III into pUC18 resulting in the constructs PE280- and PE400-intermediate and the sequence was verified by sequencing. The <i>Nco</i>I/<i>Sa</i>lI fragment from both constructs (PE280- and PE400-intermediate) was subcloned into a pUC18 derivate containing the chalcone synthase 5' untranslated region, the codon optimized leader signal from mAb24 light chain and the C-terminal epitope tag29 resulting in the constructs PE280-tag29 and PE400-tag29. For expression in plant cells, the<i>EcoR</i>I/<i>Xba</i>I fragments (Figure 26) of PE280-tag29 and PE400-tag29 were subcloned into the <i>EcoR</i>I and <i>Xbal</i> restriction sites of the plant expression vector pSS (Voss et al., Molecular Breeding 1: 39-50 (1995)) containing the enhanced 35S promoter (Kay et al., Science 236: 1299-1302 (1987)) and the CaMV termination sequence (Figure 26B and C).</p>
    <p id="p-00117-en">
      <i>Control construct, epitope tag labelled GST (GST-tag29):</i> To analyse the assembly of the epitag29 and the corresponding antibody, the control construct GST-tag29 was generated by introducing the epitag-29 sequence into the pGEX-5X-3 vector (Pharmacia) at the C-terminus of GST.</p>
    <heading>
      <u>Analysis of GST-tag29</u>
    </heading>
    <p id="p-00118-en">The epitag-29 is specifically recognised by scFv-epitag29 and the corresponding recombinant full-size antibody mAb29 or its recombinant version rAb29. To analyse the binding specificity of rAb29 to epitag-29, affinity purified, bacterial expressed GST-tag29 was diluted either in PBS or in protein extract of a wild type <i>N. tabacum</i> cv. Petite Havana SR1 plant and serial dilutions were seperated on a SDS-PAA gel and blotted onto a nitrocellulose membrane.<br /> The recombinant plasmid GST-tag29 was transformed into <i>E. coli</i> BL21 (DE3) (Stratagene, La Jolla. CA, USA) and the fusion protein was expressed by inducing a log phase culture with 0.2-1.0 mM IPTG for 1-3 h at 30Â°C. GST-tag29 fusion protein was affinity purified on glutathione agarose by batch purification according to the manufacturer's instructions (Pharmacia). Serial dilutions of GST-tag29 were resolved by SDS-PAGE and blotted onto Hybondâ¢-C nitrocellulose membranes (Amersham, Braunschweig, Germany). The membranes were blocked overnight with 2% non-fat skim milk in PBS (MPBS) at 4Â°C followed by incubation with rAb29 (Schillberg, et al.,<i>Transgenic Research</i> 8, 255-263 (1999)) at room temperature for 2 h. Bound antibodies were detected using goat anti-mouse IgG conjugated to alkaline phosphatase (Jackson ImmunoResearch, West Grove, PA, USA) and the substrates Ï-nitrobluetetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP).<br /> As shown in Figure 27A, 80 ng GST-tag29 in PBS was detectable using rAb29. Although in tobacco extract the detection limit decreased to 200 ng GST-tag29 (Figure 27B), this result indicates that plant derived proteins did not prevent binding of rAb29 to the epitag-29.</p>
    <p id="p-00119-en">The <i>in vivo</i> assembly in a plant cell was simulated by ELISA, in which the scFv-epitag29 bound to epitop-29. As shown in Figure 28, a significant OD reactivity was detectable, indicating that binding of the two partners took place in plant extracts.</p>
    <heading>
      <u>Transient expression in tobacco leaves</u>
    </heading>
    <p id="p-00120-en">To analyze the protein level of the recombinant PE280-tag29, <i>N. tabacum</i> cv. Petite Havana SR1 leaves were transiently transformed with recombinant <i>A. tumefaciens</i> and accumulation of PE280-tag29 was analyzed by immunoblot.<br /> Plant expression construct PE280-tag29 was transferred into <i>A. tumefaciens</i> GV3101 by N<sub>2</sub> transformation (HÃ¶fgen and Willmitzer, Nucleic Acids Res 16 (1988) 9877). Transient transformation of <i>N. tabacum</i> cv. Petite Havana SR1 was performed as described (Kapila et al., Plant Science 122 (1996) 101-108). To extract total soluble proteins, Tobacco leaves were frozen and ground in liquid nitrogen and scFv-fusion protein level was analysed by Western blot (Fischer et al., in: C. Cunningham, A.J.R. Porter, (Eds.), Methods in biotechnology Vol. 3: Recombinant proteins in plants: Production and Isolation of Clinically useful compounds. Humana Press, Totowa, NJ (1998)).<br /> A protein of the expected size (37.1 kDa) was not detectable in plant extracts (Figure 29). However a degradation product was detectable, indicating that the recombinant PE280-tag29 protein accumulated in tobacco leaves. The plant leaves showed a healthy phenotype, indicating that PE280-tag29 was most likely secreted to the apoplast and therefore not toxic to the plant cell.</p>
    <heading>
      <u>Characterization of transgenic plants</u>
    </heading>
    <p id="p-00121-en">
      <i>N. tabucum</i> cv. Petite Havana SR1 was transformed with the construct PE280-tag29 using recombinant agrobacteria. Transgenic <i>N. tabacum</i> cv. Petite Havana SR1 were generated by the leaf disc transformation with recombinant <i>A. tumefaciens</i> and transgenic To plants were generated from transformed callus (Horsch et al., Science 227: 1229-1231 (1985)). Regeneration of transgenic plants is in progress.<br /> In addition, transgenic <i>N. tabucum</i> cv. Petite Havana SR1 plants accumulating biscFv2429 in the apoplast will be retransformed with the plant expression construct PE280-tag29 to analyse <i>in vivo</i> assembly and biological effects of the molecular pathogenicide.</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00122-en">The Molecular Pathogenicide will be assembled in the ER via the scFv-epitag29 and epitag29. The presented experiments show that proteins can be assembled using scFv-epitag29 and epitag29 in plant extracts. Upon assembly the Molecular Pathogenicide will be secreted to the apoplast. During TMV infection the fusion protein will bind to the virus particle via the scFv24 part and TMV virions that enter the cell will carry bound scFv24-toxin fusion. PE400 mediates the ADP-ribosylation of elongation factor 2, which arrests protein synthesis and causes cell death. PE is a very effective toxin as only a few molecules are required to kill the infected cell, thus preventing virus replication and spread, leading to highly resistant plants.</p>
    <heading>
      <b>Example 8:</b>
      <i>
        <b>In vivo</b>
      </i>
      <b>proteolysis</b>
    </heading>
    <p id="p-00123-en">The steps 1) to 16) of example 1 and steps 1) to 2) example 2 are repeated with the following adaptations.<ol><li>1) A protease cleavage sequence which is processed by a plant and/or a pathogen protease <i>in vivo</i> is added either between the recombinant scFv construct and the C-terminal membrane localisation sequence, using a suitable linker, or between an N-terminal toxin and a C-terminal membrane anchored recombinant antibody or <i>vice versa</i>.</li><li>2) The chimeric gene is inserted into a plant expression vector e.g. pSS (Voss et al., 1995).</li><li>3) Suitable protease cleavage sequences include a selected sequence from a random linker library (Doskeland, Biochem. J. 313 (1996), 409-414) that had been selected by <i>in vitro</i> proteolysis and any known protease site that is unique to the fusion protein and does not destroy the molecular viricide and its activity <i>in vivo.</i></li></ol></p>
    <p id="p-00124-en">As an example, the c-myc tag or the CBHI linker is sensitive to plant proteases. Anyone of skill in the art will recognise that these steps can be followed for any other pathogen by selecting antibodies or fragments thereof specific for the target pathogen. For example, antibodies can be raised and cloned against structural and non structural proteins of any pathogen. In addition, toxins can be cloned C- or N-terminal of the protease cleavage sequence. Toxins include all proteins and peptides that have a detrimental or toxic effect on a pathogen during its life cycle and/or an effect on the pathogen during plant infection or pathogen replication, spread or transmission. This includes toxins that specifically kill an infected host cell and so limit the spread and development of a disease. Moreover, example 8 can be combined with examples 1-7 in any combination(s).</p>
    <heading>
      <u>Construction of the scFv24 fusion expression cassettes</u>
    </heading>
    <p id="p-00125-en">To integrate the TMV-specific scFv24 into the plant cell membrane, the antibody fragment was fused to an N-terminal mammalian signal peptide and C-terminal receptor transmembrane domain. The mouse N-terminal light chain signal peptide from the parental antibody (mAb24) used to generate scFv24 was used to target fusion proteins to the secretory pathway. We selected the transmembrane domain sequences of the human platelet derived growth factor receptor (PDGFR) for fusion with the C-terminus of scFv24, for heterologous targeting of the scFv24 antibody to the plasma membrane. To ensure proper folding of the expressed and subsequent cleaved single chain antibody fragment, the construct contained the c-<i>myc</i> sequence (pscFv24-PDGFR) as a linker and cleavage sequence between the scFv24 fragment and the membrane anchor (Figure 30).<br /> To construct pscFv24-PDGFR, the cDNA encoding the c-<i>myc</i> epitope followed by the human platelet-derived growth factor receptor (PDGFR) transmembrane domain (18) was excised from the pHOOK-1 vector (Invitrogen, Leek, Netherlands) and ligated into the <i>Sal</i>I and <i>Xba</i>I restriction sites of the pscFv24-TcRÎ² plasmid (Example 1) to generate the pscFv24-PDGFR fusion construct (Figure 30).</p>
    <heading>
      <u>Expression of the scFv24 fusion protein in <i>N. tabacum</i> cv BY-2 cell suspensions</u>
    </heading>
    <p id="p-00126-en">To analyze the expression level of the recombinant scFv-fusion proteins, the suspension cell line <i>N. tabacum</i> cv. BY-2 was stably transformed with recombinant <i>A. tumefaciens</i> and functional expression of the scFv24 domain of the fusion protein was analyzed by ELISA using anti-mAb24 antisera.<br /> The vector construct pscFv24-PDGFR was transferred into <i>A. tumefaciens</i> GV3101 by liquid N<sub>2</sub> transformation (HÃ¶fgen and Willmitzer, Nucleic Acids Res. 16: 9877 (1988)). <i>N. tabacum</i> L. cv. bright yellow 2 (BY-2) cells were maintained in Murashige and Skoog basal salt with minimal organics (MSMO+: MSMO (Sigma, Deisenhofen, Germany) plus 200 mg/ml KH<sub>2</sub>PO<sub>4</sub>, 0.6 Âµg/ml thiamine, 3 % sucrose and 0.2 Âµg/ml 2,4-D, pH 5.8) at 24Â°C in the dark on an orbital shaker. Cells were subcultured every week with a 5 % inoculum. Three days after subculture, plant cells were transformed by co-cultivation with recombinant <i>A. tumefaciens,</i> as described (An, Plant Physiol. 79: 568-570 (1985)). Selection of kanamycin-resistant transformants was performed on MSMO+ agar medium supplemented with 75 Âµg/ml kanamycin and 100 Âµg/ml claforan.<br /> For extraction of total soluble proteins from transgenic BY-2 suspension culture, cells from 1 ml culture were collected by centrifugation at 4000 x <i>g</i> for 5 min at 4Â°C. The cell pellet was resuspended in 1 ml protein extraction buffer (200 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02 % (w/v) sodium-azide and 0.1 % (v/v) Tween 20) and cells were disrupted by sonication at 60 watt for 1 min using a sonicator probe (B. Braun, Melsungen, Germany) at 4Â°C. Cell debris was removed by centrifugation at 14000 x g for 10 min at 4Â°C. The clear supernatant containing soluble protein was used for further analysis.<br /> For ELISA and western blotting, anti-mAb24 antisera (Zimmermann et al., Molecular Breeding 4: 369-379 (1998)) or the anti-c-<i>myc</i> monoclonal antibody 9E10 (Evan et al., Mol. Cell. Biol. 5: 3610-3616 (1985)) were used as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit or goat anti-mouse alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA). Protein concentrations were determined with the Bio-Rad Protein Assay using Bovine Serum Albumin (BSA) as standard.<br /> Analysis of stably transformed <i>N. tabacum</i> BY-2 cells revealed that scFv24-PDGFR was present in both cell extracts and culture supernatant (Figure 31). Transgenic cell suspension lines showed similar expression levels for both recombinant proteins, but 44-88 % (mean value = 69 %, n = 5) of scFv24-PDGFR was secreted into the culture supernatant. This indicated that the scFv24-PDGFR is released by proteolysis from the plasma membrane.</p>
    <heading>
      <u>Characterization of transgenic plants</u>
    </heading>
    <p id="p-00127-en">We then tested whether the heterologous mammalian transmembrane domain PDGFR fused to scFv24 would target the single chain antibody to the plasma membrane in stably transformed tobacco plants. Transgenic <i>N. tabacum</i> cv. Petite Havana SR1 were generated by the leaf disc transformation with recombinant <i>A. tumefaciens</i> and transgenic To plants were generated from transformed callus (Horsch et al., Science 227: 1229-1231 (1985)). Extraction of total soluble proteins from tobacco leaves and subsequent analysis of scFv24 by ELISA were performed as described by Fischer <i>et al</i>. (Fischer et al., in: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ (1998)). For ELISA and western blotting, anti-mAb24 antisera (Zimmermann et al., Molecular Breeding 4: 369-379 (1998)) was used as a primary antibody in combination with a 1:5000 dilution of goat anti-rabbit alkaline phosphatase conjugated secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA). Protein concentrations were determined with the Bio-Rad Protein Assay using Bovine Serum Albumin (BSA) as a standard.<br /> Expression levels of scFv24-PDGFR were much higher in transgenic <i>N. tabacum</i> cv. Petite Havana SR1 plants than in suspension cultures (Table 5). The maximum level of detergent extracted scFv24-PDGFR was 13 fold higher (388 ng/g leaf tissue) than that obtained in transgenic suspension cultures (Figure 31).<br /> In <i>N. tabacum</i> cv. BY-2 suspension cells producing the scFv24-PDGFR fusion protein, scFv24 was detectable in the culture supernatant. To determine if scFv24 fragments were secreted into the extracellular space of intact plants, intercellular washing fluid from leaves of transgenic T<sub>1</sub> tobacco plants was analyzed by ELISA. For detection of scFv24 fusion proteins in intercellular washing fluids, leaves of <i>N. tabacum</i> cv. Petite Havana SR1 were prepared as described by Fischer <i>et al</i>. (Fischer et al., in: Cunningham C, Porter AJR (eds), Recombinant proteins in plants: Production and Isolation of Clinically useful compounds, pp. 45-68. Vol. 3. Humana press, Totowa, NJ (1998)). Total protein extracts from washing fluids were concentrated by ultrafiltration (Microcon 10, Amicon, Witten, Germany) and analyzed by 12% SDS-PAGE (Laemmli, Nature 227: 680-685 (1970)) followed by western blot. scFv24 was present in the intercellular washing fluid of seven progenies of a plant line (P9<sub>SR1</sub>) producing scFv24-PDGFR and the level of secreted scFv24 did not correlate to levels of protein expression in intact leaves. In general, T<sub>1</sub> plants used for IWF analysis showed scFv24 expression levels of 1080-1540 ng/g leaf tissue. Therefore, the protein is cleaved by a host protease.<br /> Western blot analysis, using an anti-mAb24 antisera, revealed that a single 28kDa scFv24 polypeptide was detected in the intercellular washing fluid of T<sub>1</sub> progenies from scFv24-PDGFR transgenics (P9<sub>SR1</sub>). This corresponded to a fusion protein cleavage product since the predicted molecular weight of scFv24-PDGFR was 35KDa. However, both the full length (35KDa) and cleaved (28KDa) fragments of scFv24 were present in total soluble cell protein extracts at a 1:1 ratio of full-length product to the fragment (Figure 32A). Western blot analysis of total soluble protein extracts with an anti c<i>-myc</i> antibody only detected the intact fusion protein scFv24-PDGFR (Figure 32B). This indicates that the scFv24 fragment in the apoplast was cleaved off the membrane near or within the c<i>-myc</i> epitopSe tag.</p>
    <heading>
      <u>Bioassays of viral resistance</u>
    </heading>
    <p id="p-00128-en">To analyze the biological effects of the membrane anchored anti-viral TMV-specific antibody on viral resistance, T<sub>1</sub> progenies of plant line expressing the scFv24-PDGFR fusion protein (P9<sub>SR1</sub>) were inoculated with TMV.<br /> Seeds were collected from antibody-producing To plants and germinated on MSMO agar medium supplemented with 2 % (w/v) sucrose, 0.4 Âµg/ml thiamine, 0.4 Âµg/ml glycine, 0.1 Âµg/ml nicotine acid, 0.1 Âµg/ml pyridoxine and 75 Âµg/ml kanamycin. Kanamycin-resistant T<sub>1</sub> plants were used for inoculation with TMV-<i>v</i> (1 Âµg/ml) as previously described (Dietzgen et al., Arch. Virol. 87: 73-86 (1986)). Wild type<i>N. tabacum</i> cv. Petite Havana SR1 plants were used as a control. Disease symptoms were monitored 6 to 20 days post inoculation (p.i.) and for resistant plants up to 180 days p.i..<br /> Lower leaves were infected with TMV and systemic spread of the virus was followed by analyzing upper leaves 6-20 days later. All non-transgenic tobacco control plants were systemically infected, but 19 % (out of 68 analyzed) of scFv24-PDGFR transgenic plants had no visible disease symptoms on the upper leaves (Table 6). Furthermore, ELISA analysis demonstrated that some of these plants accumulated virus particles in the upper leaves indicating that though systemic viral spread occurred, no symptoms were developed. Strikingly, in 13 % of scFv24-PDGFR transgenic plants no virus was found in the upper leaves up to 90 days post inoculation. Virus could be detected at inoculation sites in the lower leaves by ELISA demonstrating that these plants had been efficiently inoculated with TMV. Antibody-fusion protein expression levels correlated with expression of TMV resistance (Table 6). Higher levels of scFv24 fusion protein expression led to an increased fraction of virus resistant plants.</p>
    <heading>
      <u>Conclusions</u>
    </heading>
    <p id="p-00129-en">It could be shown that the linker region between the scFv24 and the PDGFR transmembrane domain is sensitive to plant proteases, the scFv24 is cleaved off <i>in vivo</i> and secreted to the apoplast in transgenic plants. scFv24 retains its function post cleavage and creates a virus resistant phenotype.<tables><table><title>Levels of functional scFv24 fusion protein in the To generation of transgenic N. tabacum cv. Petite Havanna SR1. Total soluble plant protein was isolated from leaves of transgenic plants producing scFv24-PDGFR. scFv24-fusion protein expression was quantified by TMV-specific ELISA using anti-mAb24 antisera and expressed as ng scFv24 per g leaf tissue.</title><tgroup cols="5"><thead><row><entry>Construct</entry><entry>Number of transgenic plants</entry><entry>Number of plants expressing functional scFv24</entry><entry>Range of expression (ng/g leaf tissue)</entry><entry>Average expression (ng/g leaf tissue)</entry></row></thead><tbody><row><entry>pscFv24-PDGFR</entry><entry>12</entry><entry>9</entry><entry>3 - 388</entry><entry>114</entry></row></tbody></tgroup></table></tables><tables><table><title>Virus infection assay of trangenic plants expressing membrane anchored scFv24. 1 Âµg/ml TMV-v was applied onto a lower leaf of non-transgenic N. tabacum cv. Petite Havana SR1 and transgenic T1 progenies from plant line P9SR1 producing scFv24-PDGFR. scFv24-fusion protein levels were determined by ELISA using an anti-mAb24 antisera 14 days p.i. and used for group formation (low, average and high producers). a = upper leaves showed no visible disease symptoms; b = based on TMV-ELISA; c = level of resistance of all low, average and high producers, numbers in brackets include all plants without visible disease symptoms.</title><tgroup cols="6"><thead><row><entry>Plant lines</entry><entry>Tested plants</entry><entry>ng scFv24 per g leaf tissue</entry><entry>Healthy phenotype<sup>a</sup></entry><entry>Resistant plants<sup>b</sup></entry><entry>Level of resistance (%)<sup>c</sup></entry></row></thead><tbody><row><entry><i>N. tabacum</i> cv.</entry></row><row><entry>Petite Havana SR1</entry><entry>62</entry><entry>-</entry><entry>0</entry><entry>0</entry><entry>0</entry></row><row><entry>P9<sub>SR1</sub>, low producer</entry><entry>34</entry><entry>10-500</entry><entry>1</entry><entry>0</entry></row><row><entry>P9<sub>SR1</sub>, average</entry><entry>23</entry><entry>501-2000</entry><entry>6</entry><entry>4</entry><entry>13(19)</entry></row><row><entry>producer</entry></row><row><entry>P9<sub>SR1</sub>, high producer</entry><entry>11</entry><entry>2001-4200</entry><entry>6</entry><entry>5</entry></row></tbody></tgroup></table></tables></p>
    <heading>
      <b>References</b>
    </heading>
    <p id="p-00130-en">
      <ol>
        <li>Anderson, J.M., P. Palukaitis, and M. Zaitlin. 1992. A defective replicase gene induces resistance to cucumber mosaic virus in transgenic sugarbeet plants. Proc. Natl. Acad. Sci. USA. 89:8759-8763.</li>
        <li>Barbieri, L., M.G. Battelli, and F. Stirpe. 1993. Ribosome-inactivating proteins from plants. Biochim Biophys Acta. 1154:237-282.</li>
        <li>Baulcombe, D. 1994. Novel strategies for engineering virus resistance in plants. Current Opinion in BioTechnology. 5:117-124.</li>
        <li>Benfey, P., L. Ren, and N.-H. Chua. 1989. The CaMV 35S enhancer contains at least two domains which can confer different developmental and tissue-specific expression patterns. EMBO J. 8:2195-2202.</li>
        <li>Bennett, A., and K. Osteryoung. 1991. Protein transport and targeting within the endomembrane system of plants. In Plant Genetic Engineering. Vol. 1. D. Grierson, editor. Blackie publishing, London. 199-237.</li>
        <li>Benvenuto, E., R.J. Ordas, R. Tavazza, G. Ancora, S. Biocca, A. Cattaneo, and P. Galeffi. 1991. 'Phytoantibodies': a general vector for the expression of immunoglobulin domains in transgenic plants. Plant Mol Biol. 17:865-74.</li>
        <li>Bird, R.E., K.D. Hardman, J.W. Jacobson, S. Johnson, B.M. Kaufmann, S.-M. Lee, T. Lee, H.S. Pope, G.S. Riordan, and M. Whitlow. 1988. Single-chain antigen-binding proteins. Science. 242:423-426.</li>
        <li>Bjorck, L., P. Akesson, M. Bohus, J. Trojnar, M. Abrahamson, I. Olafsson, and A. Grubb. 1989. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature. 337:385-6.</li>
        <li>Bjorck, L., A. Grubb, and L. Kjellen. 1990. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. Nature. 337:385-386.</li>
        <li>Caddick, M., A. Greenland, I. Jepson, K. Krause, N. Qu, K. Riddell, M. Salter, W. Schuch, U. Sonnewald, and A. Tomsett. 1998. An ethanol inducible gene switch for plants used to manipulate carbon metabolism. Nat. Biotechnol. 16:177-180.</li>
        <li>Carter, P., and A. Merchant. 1997. Engineering antibodies for imaging and therapy. Curr Opin Biotechnol. 8:449-454.</li>
        <li>Carter, P., J. Ridgway, and Z. Zhu. 1995. Toward the production of bispecific antibody fragments for clinical applications. J Hematother. 4:463-470.</li>
        <li>Chen, S.Y., Y. Khouri, J. Bagley, and W.A. Marasco. 1994. Combined intra- and extracellular immunisation against human immunodeficiency virus type 1 infection with a human anti-gp 120 antibody. Proc. Natl. Acad. Sci USA. 91:5932-5936.</li>
        <li>Chowrira, G., V. Akella, and P. Lurquin. 1995. Electroporation-mediated gene transfer into intact nodal meristems in planta. Generating transgenic plants without in vitro tissue culture. Mol Biotechnol. 3:17-23.</li>
        <li>Comai, L., P. Moran, and D. Maslyar. 1990. Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements. Plant Mol. Biol. 15:373-381.</li>
        <li>De Neve, M., M. De Loose, A. Jacobs, H. Van Houdt, B. Kaluza, U. Weidle, M. Van Montagu, and A. Depicker. 1993. Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis. Transgenic Res. 2:227-37.</li>
        <li>Dempsey, D., H. Silva, and D. Klessig. 1998. Engineering disease and pest resistance in plants. Trends Microbiol. 6:54-61.</li>
        <li>D'Halluin, K., E. Bonne, M. Bossut, M. De Beuckeleer, and J. Leemans. 1992. Transgenic maize plants by tissue electroporation. Plant Cell. 4:1495-1505.</li>
        <li>Duan, L., O. Bagasra, M.A. Laughlin, J.W. Oakes, and R.J. Pomerantz. 1994. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single chain antibody. Proc. Natl. Acad. Sci USA. 91:5075-5079.</li>
        <li>DÃ¼ring, K., S. Hippe, F. Kreuzaler, and J. Schell. 1990. Synthesis and selfassembly of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Mol. Biol. 15:281-293.</li>
        <li>Eiklid, K., S. Olsnes, and A. Pihl. 1980. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res. 126:321-6.</li>
        <li>Endo, Y., and K. Tsurugi. 1987. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 262:8128-30.</li>
        <li>Endo, Y., and K. Tsurugi. 1988. The RNA N-glycosidase activity of ricin A-chain. Nucleic Acids Symp Ser. 19:139-42.</li>
        <li>Falk, B.W., and G. Bruening. 1994. Will transgenic crops generate new viruses and new diseases. Science. 263:1395-1396.</li>
        <li>Fiedler, U., J. Phillips, O. Artsaenko, and U. Conrad. 1997. Optimisation of scFv antibody production in transgenic plants. Immunotechnology. 3:205-216.</li>
        <li>Fischer, R.S., A. Schillberg, Y.-D. Stierhof, and F. Kreuzaler. 1999. Production, characterisation and molecular cloning of Tobacco Mosaic Virus (TMV)-specific neutralizing monoclonal antibodies with different epitope specificities. Molecular Immunology.</li>
        <li>Florack, D., W. Dirkse, B..Visser, F. Heidekamp, and W. Stiekema. 1994. Expression of biologically active hordothionins in tobacco. Effects of pre- and pro-sequences at the amino and carboxyl termini of the hordothionin precursor on mature protein expression and sorting. Plant Mol Biol. 24:83-96.</li>
        <li>Friedler, A., N. Zakai, O. Karni, Y. Broder, L. Baraz, M. Kotler, A. Loyter, and C. Gilon. 1998. Backbone cyclic peptide, which mimics the nuclear localisation signal of human immunodeficiency virus type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells. Biochemistry. 37:5616-5622.</li>
        <li>Furth, P. 1997. Gene transfer by biolistic process. Mol Biotechnol. 7:139-143.</li>
        <li>Gadani, F., M. Mansky, R. Medici, W.A. Miller, and J.H. Hill. 1990. Genetic engineering of plants for virus resistance. Archives of Virology. 115:1-21.</li>
        <li>Gerber, L.D., K. Kodukula, and S. Udenfriend. 1992. Phosphatidylinositol glycan (PI-G) anchored membrane proteins. Amino acid requirements adjacent to the site of cleavage and PI-G attachment in the COOH-terminal signal peptide. J Biol Chem. 267:12168-73.</li>
        <li>Girbes, T., J. Ferreras, R. Iglesias, L. Citores, C. De Torre, M. Carbajales, P. Jimenez, F. De Benito, and R. Munoz. 1996. Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Cell Mol Biol (Noisy-le-grand). 42:461-471.</li>
        <li>Gross, G., and Z. Eshhar. 1992. Endowing T cells with antibody specificity using chimeric T cell receptors. Faseb J. 6:3370-8.</li>
        <li>Ham, P.J., C. Albuquerque, B. Smithies, R. Chalk, S. Klager, and H. Hagen. 1994. Antibacterial peptides in insect vectors of tropical parasitic disease. Ciba Found Symp. 186:140-51.</li>
        <li>Harrison, B.D., M.-A. Mayo, and D.C. Baulcombe. 1987. Virus resistance in transgenic plants that express cucumber mosaic virus satellite RNA. Nature. 328:799-802.</li>
        <li>Hartley, M.R., J.A. Chaddock, and M.S. Bonness. 1996. The structure and function of ribosome inactivating proteins. Trends in Plant Science. 1:254-260.</li>
        <li>Hayakawa, Y. 1991. Structure of a growth-blocking peptide present in parasitzed insect hemolymph. J Biol Chem. 266:7982-7984.</li>
        <li>Hiatt, A., R. Cafferkey, and K. Bowdish. 1989. Production of antibodies in plants. Nature. 342:469-470.</li>
        <li>Kapila, J., R. De Rycke, M. Van Montagu, and G. Angenon. 1997. An Agrobacterium mediated transient gene expression system for intact leaves. Plant Sci. 122:101-108.</li>
        <li>Kim, P., F. Janiak-Spens, W. Trimble, B. Leber, and D. Andrews. 1997. Evidence for multiple mechanisms for membrane binding and integration via carboxyl-terminal insertion sequences. Biochemistry. 36:8873-8882.</li>
        <li>Klein, T., and S. Fitzpatrick-McElligott. 1993. Particle bombardment: a universal approach for genetransfer to cells and tissues. Curr Opin Biotechnol. 4:583-590.</li>
        <li>KÃ¶hler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495-497.</li>
        <li>Lambert, S., and V. Bennett. 1993. From anemia to cerebellar dysfunction. A review of the ankyrin gene family. Eur J Biochem. 211:1-6.</li>
        <li>LaVallie, E., E. DiBlasio, S. Kovacic, K. Grant, P. Schendel, and J. McCoy. 1993. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (N Y). 11:187-193.</li>
        <li>Leland, P., L. Schultz, B. Kim, and R. Raines. 1998. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A. 95:10407-10412.</li>
        <li>Madshus, I., and H. Stenmark. 1992. Entry of ADP-ribosylating toxins into cells. Curr Top Microbiol Immunol. 175:1-26.</li>
        <li>Marasco, W.A., W.A. Haseltine, and S.Y. Chen. 1993. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp 120 single-chain antibody. Proc. Natl. Acad. Sci USA. 90:7889-7893.</li>
        <li>Mitra, A., and A. Gynheung. 1989. Three distinct regulatory elements comprise the upstream promoter of the nopaline synthase gene. Mol. Gen. Genet. 215:294-299.</li>
        <li>Montanaro, L., S. Sperti, A. Mattioli, G. Testoni, and F. Stirpe. 1975. Inhibition by ricin of protein synthesis in vitro. Inhibition of the binding of elongation factor 2 and of adenosine diphosphate-ribosylated elongation factor 2 to ribosomes. Biochem J. 146:127-31.</li>
        <li>Namba, S., K. Ling, C. Gonsalves, D. Gonsalves, and J.L. Slightom. 1991. Expression of the gene encoding the coat protein of cucumber mosaic virus (CMV) strain WL appears to provide protection to sugarbeet plants against infection by several different strains. Gene. 107:181-188.</li>
        <li>Ni, M., D. Cui, J. Einstein, S. Narasimhulu, C.E. Vergara, and S.B. Gelvin. 1995. Strength and tissue specificity of chimeric promoters derived from octopine and nopaline synthase genes. Plant J. 7:661-676.</li>
        <li>Owen, M., A. Gandecha, B. Cockburn, and G. Whitelam. 1992. Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco. Bio/Technology. 10:790-794.</li>
        <li>Palukaitis, P., and M.J. Roossinck. 1996. Spontaneous change of a benign satellite RNA of cucumber mosaic virus to a pathogenic variant. Nature Biotechnology. 14:1264-1268.</li>
        <li>Peters, L.L., and S.E. Lux. 1993. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol. 30:85-118.</li>
        <li>PlÃ¼ckthun, A. 1991. Antibody engineering. Current Opinion in Biotechnology. 2:238-246.</li>
        <li>Pluckthun, A., and P. Pack. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:83-105.</li>
        <li>Poljak, R.J. 1994. Production and structure of diabodies. Structure. 2:1121-3.</li>
        <li>Rose, M., and G. Fink. 1987. KAR1, a gene required for function of both intranuclear and extranuclear microtubules in yeast. Cell. 48:1047-1060.</li>
        <li>Sanford, J.C., E.D. Wolf, and N.K. Allen. 1990. Method for transporting substances into living cells and apparatus therefore. Patent #4,945,050. Cornell Research Foundation Inc, Ithaca, NY.</li>
        <li>Sangster, B. 1997. Identification of cytotoxic peptide as possible mechanism for neurotoxicity of HIV viral envelope and AIDS pathogenesis. Med Hypotheses. 48:463-8.</li>
        <li>Schouten, A., J. Roosien, J.M. de Boer, A. Wilmink, M.-N. Rosso, D. Bosch, W.J. Stiekema, F.J. Gommers, J. Bakker, and A. Schots. 1997. Improving scFv antibody expression levels in the plant cytosol. FEBS letters. 415:235-241.</li>
        <li>Silburn, K., D. McPhee, A. Maerz, P. Poumbourios, R. Whittaker, A. Kirkpatrick, W. Reilly, M. Manthey, and C. Curtain. 1998. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. AIDS Res Hum Retroviruses. 14:385-392.</li>
        <li>Smith, D., and K. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 67:31-40.</li>
        <li>SpÃ¶rlein, B., and H.-U. Koop. 1991. Lipofectin: direct gene transfer to higher plants using cationic liposomes. Theor. Appl. Genet. 83:1-5.</li>
        <li>Tang, Y., N. Jiang, C. Parakh, and D. Hilvert. 1996. Selection of linkers for a catalytic single-chain antibody using phage display technology. J Biol Chem. 271:15682-6.</li>
        <li>Tavladoraki, P., E. Benvenuto, S. Trinca, D. DeMartinis, and P. Galeffi. 1993. Transgenic plants expressing a functional scFv antibody are protected from virus attack. Nature. 366:469-472.</li>
        <li>Tedder, T.F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 15:450-4.</li>
        <li>Turner, D.J., M.A. Ritter, and A.J. George. 1997. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods. 205:43-54.</li>
        <li>Turpen, T.H., A.M. Turpen, N. Weinzettl, M.H. Kumagai, and W.O. Dawson. 1993. Transfection of whole plants from wounds inoculated wtih Agrobacterium tumefaciens containing cDNA of Tobacco Mosaic Virus. J. Virol. Meth. 42:227-240.</li>
        <li>von Heijne, G. 1985. Signal sequences. The limits of variation. J Mol Biol 1985. 184:99-105.</li>
        <li>Voss, A., M. Niersbach, R. Hain, H.J. Hirsch, Y.C. Liao, F. Kreuzaler, and R. Fischer. 1995. Reduced virus infectivity in N. tabacum secreting a TMV-specific full size antibody. Mol. Breeding. 1:39-50.</li>
        <li>White, F.F. 1992. Vectors for gene transfer in higher plants. In Transgenic Plants. Vol. 1. Academic Press. 15-47.</li>
        <li>Wilson, T.M.A. 1993. Strategies to protect crop plants against viruses: Pathogen-derived resistance blossoms. Proc. Natl. Acad. Sci. USA. 90:3134-3141.</li>
        <li>Winter, G., A.D. Griffiths, R.E. Hawkins, and H.R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu Rev Immunol. 12:433-55.</li>
        <li>Winter, G., and C. Milstein. 1991. Man made antibodies. Nature. 349:293-299.</li>
        <li>Wright, M.D., and M.G. Tomlinson. 1994. The ins and outs of the transmembrane 4 superfamily. Immunol Today. 15:588-94.</li>
        <li>Zimmermann, S., S. Schillberg, Y.C. Liao, and R. Fischer. 1998. Intracellular expression of a TMV-specific single chain Fv fragment leads to improved virus resistance in Nicotiana tabacum. Molecular Breeding. 4:369-379.</li>
      </ol>
    </p>
    <heading>SEQUENCE LISTING</heading>
    <p id="p-00131-en">
      <ol>
        <li>&lt;110&gt; Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung e.V.</li>
        <li>&lt;120&gt; Molecular Pathogenicide Mediated Plant Disease Resistance</li>
        <li>&lt;130&gt; C2428 EP S3</li>
        <li>&lt;140&gt; EP 99 07 844<br /> &lt;141&gt; 1999-10-18</li>
        <li>&lt;160&gt; 163</li>
        <li>&lt;210&gt; 1<br /> &lt;211&gt; 33<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 1</li>
        <li>&lt;210&gt; 2<br /> &lt;211&gt; 28<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 2</li>
        <li>&lt;210&gt; 3<br /> &lt;211&gt; 1378<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 3</li>
        <li>&lt;210&gt; 4<br /> &lt;211&gt; 17<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 4</li>
        <li>&lt;210&gt; 5<br /> &lt;211&gt; 130<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 5</li>
        <li>&lt;210&gt; 6<br /> &lt;211&gt; 148<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 6</li>
        <li>&lt;210&gt; 7<br /> &lt;211&gt; 145<br /> &lt;212&gt; DNA</li>
        <li>&lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 7</li>
        <li>&lt;210&gt; 8<br /> &lt;211&gt; 130<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 8</li>
        <li>&lt;210&gt; 9<br /> &lt;211&gt; 17<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 9</li>
        <li>&lt;210&gt; 10<br /> &lt;211&gt; 35<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 10</li>
        <li>&lt;210&gt; 11<br /> &lt;211&gt; 51<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 11</li>
        <li>&lt;210&gt; 12<br /> &lt;211&gt; 900<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 12</li>
        <li>&lt;210&gt; 13<br /> &lt;211&gt; 918<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 13</li>
        <li>&lt;210&gt; 14<br /> &lt;211&gt; 915<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 14</li>
        <li>&lt;210&gt; 15<br /> &lt;211&gt; 900<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 15</li>
        <li>&lt;210&gt; 16<br /> &lt;211&gt; 45<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 16</li>
        <li>&lt;210&gt; 17<br /> &lt;211&gt; 37<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 17</li>
        <li>&lt;210&gt; 18<br /> &lt;211&gt; 1604<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 18</li>
        <li>&lt;210&gt; 19<br /> &lt;211&gt; 1050<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 19</li>
        <li>&lt;210&gt; 20<br /> &lt;211&gt; 26<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 20</li>
        <li>&lt;210&gt; 21<br /> &lt;211&gt; 72<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 21</li>
        <li>&lt;210&gt; 22<br /> &lt;211&gt; 71<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 22</li>
        <li>&lt;210&gt; 23<br /> &lt;211&gt; 88<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 23</li>
        <li>&lt;210&gt; 24<br /> &lt;211&gt; 1561<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 24</li>
        <li>&lt;210&gt; 25<br /> &lt;211&gt; 1582<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 25</li>
        <li>&lt;210&gt; 26<br /> &lt;211&gt; 1059<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 26</li>
        <li>&lt;210&gt; 27<br /> &lt;211&gt; 1077<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 27</li>
        <li>&lt;210&gt; 28<br /> &lt;211&gt; 1654<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 28</li>
        <li>&lt;210&gt; 29<br /> &lt;211&gt; 259<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 29</li>
        <li>&lt;210&gt; 30<br /> &lt;211&gt; 267<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 30</li>
        <li>&lt;210&gt; 31<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 31</li>
        <li>&lt;210&gt; 32<br /> &lt;211&gt; 57<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 32</li>
        <li>&lt;210&gt; 33<br /> &lt;211&gt; 60<br /> &lt;212&gt; DNA</li>
        <li>&lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 33</li>
        <li>&lt;210&gt; 34<br /> &lt;211&gt; 56<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 34</li>
        <li>&lt;210&gt; 35<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 35</li>
        <li>&lt;210&gt; 36<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 36</li>
        <li>&lt;210&gt; 37<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 37</li>
        <li>&lt;210&gt; 38<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 38</li>
        <li>&lt;210&gt; 39<br /> &lt;211&gt; 57<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 39</li>
        <li>&lt;210&gt; 40<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 40</li>
        <li>&lt;210&gt; 41<br /> &lt;211&gt; 59<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 41</li>
        <li>&lt;210&gt; 42<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 42</li>
        <li>&lt;210&gt; 43<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 43</li>
        <li>&lt;210&gt; 44<br /> &lt;211&gt; 58<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 44</li>
        <li>&lt;210&gt; 45<br /> &lt;211&gt; 49<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 45</li>
        <li>&lt;210&gt; 46<br /> &lt;211&gt; 57<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 46</li>
        <li>&lt;210&gt; 47<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 47</li>
        <li>&lt;210&gt; 48<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 48</li>
        <li>&lt;210&gt; 49<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA</li>
        <li>&lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 49</li>
        <li>&lt;210&gt; 50<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 50</li>
        <li>&lt;210&gt; 51<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 51</li>
        <li>&lt;210&gt; 52<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 52</li>
        <li>&lt;210&gt; 53<br /> &lt;211&gt; 46<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 53</li>
        <li>&lt;210&gt; 54<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 54</li>
        <li>&lt;210&gt; 55<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 55</li>
        <li>&lt;210&gt; 56<br /> &lt;211&gt; 48<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 56</li>
        <li>&lt;210&gt; 57<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 57</li>
        <li>&lt;210&gt; 58<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 58</li>
        <li>&lt;210&gt; 59<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 59</li>
        <li>&lt;210&gt; 60</li>
        <li>&lt;211&gt; 46<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 60</li>
        <li>&lt;210&gt; 61<br /> &lt;211&gt; 46<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 61</li>
        <li>&lt;210&gt; 62<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 62</li>
        <li>&lt;210&gt; 63<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 63</li>
        <li>&lt;210&gt; 64<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 64</li>
        <li>&lt;210&gt; 65<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 65</li>
        <li>&lt;210&gt; 66<br /> &lt;211&gt; 47<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 66</li>
        <li>&lt;210&gt; 67<br /> &lt;211&gt; 50<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 67</li>
        <li>&lt;210&gt; 68<br /> &lt;211&gt; 50<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 68</li>
        <li>&lt;210&gt; 69<br /> &lt;211&gt; 53<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 69</li>
        <li>&lt;210&gt; 70<br /> &lt;211&gt; 56<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 70</li>
        <li>&lt;210&gt; 71<br /> &lt;211&gt; 53<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 71</li>
        <li>&lt;210&gt; 72<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 72<br /> 000</li>
        <li>&lt;210&gt; 73<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 73<br /> 000</li>
        <li>&lt;210&gt; 74<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 74<br /> 000</li>
        <li>&lt;210&gt; 75<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 75<br /> 000</li>
        <li>&lt;210&gt; 76<br /> &lt;211&gt; 22<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;</li>
        <li>&lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 76<br /> 000</li>
        <li>&lt;210&gt; 77<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 77<br /> 000</li>
        <li>&lt;210&gt; 78<br /> &lt;211&gt; 23<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 78<br /> 000</li>
        <li>&lt;210&gt; 79<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 79<br /> 000</li>
        <li>&lt;210&gt; 80<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 80<br /> 000</li>
        <li>&lt;210&gt; 81<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 81<br /> 000</li>
        <li>&lt;210&gt; 82<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 82<br /> 000</li>
        <li>&lt;210&gt; 83<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 83<br /> 000</li>
        <li>&lt;210&gt; 84<br /> &lt;211&gt; 23<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 84<br /> 000</li>
        <li>&lt;210&gt; 85<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 85<br /> 000</li>
        <li>&lt;210&gt; 86<br /> &lt;211&gt; 23<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 86<br /> 000</li>
        <li>&lt;210&gt; 87<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 87<br /> 000</li>
        <li>&lt;210&gt; 88<br /> &lt;211&gt; 23<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 88<br /> 000</li>
        <li>&lt;210&gt; 89<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 89<br /> 000</li>
        <li>&lt;210&gt; 90<br /> &lt;211&gt; 22<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 90<br /> 000</li>
        <li>&lt;210&gt; 91<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 91<br /> 000</li>
        <li>&lt;210&gt; 92<br /> &lt;211&gt; 22<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 92<br /> 000</li>
        <li>&lt;210&gt; 93<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 93<br /> 000</li>
        <li>&lt;210&gt; 94<br /> &lt;211&gt; 20<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 94<br /> 000</li>
        <li>&lt;210&gt; 95<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 95<br /> 000</li>
        <li>&lt;210&gt; 96<br /> &lt;211&gt; 20<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 96<br /> 000</li>
        <li>&lt;210&gt; 97<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 97<br /> 000</li>
        <li>&lt;210&gt; 98<br /> &lt;211&gt; 20</li>
        <li>&lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 98<br /> 000</li>
        <li>&lt;210&gt; 99<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 99<br /> 000</li>
        <li>&lt;210&gt; 100<br /> &lt;211&gt; 20<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 100<br /> 000</li>
        <li>&lt;210&gt; 101<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 101<br /> 000</li>
        <li>&lt;210&gt; 102<br /> &lt;211&gt; 20<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 102<br /> 000</li>
        <li>&lt;210&gt; 103<br /> &lt;211&gt; 29<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 103<br /> 000</li>
        <li>&lt;210&gt; 104<br /> &lt;211&gt; 21<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 104<br /> 000</li>
        <li>&lt;210&gt; 105<br /> &lt;211&gt; 29<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 105<br /> 000</li>
        <li>&lt;210&gt; 106<br /> &lt;211&gt; 21<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 106<br /> 000</li>
        <li>&lt;210&gt; 107<br /> &lt;211&gt; 29<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 107<br /> 000</li>
        <li>&lt;210&gt; 108<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 108<br /> 000</li>
        <li>&lt;210&gt; 109<br /> &lt;211&gt; 29<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 109<br /> 000</li>
        <li>&lt;210&gt; 110<br /> &lt;211&gt; 27<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 110<br /> 000</li>
        <li>&lt;210&gt; 111<br /> &lt;211&gt; 29<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 111<br /> 000</li>
        <li>&lt;210&gt; 112<br /> &lt;211&gt; 24<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 112<br /> 000</li>
        <li>&lt;210&gt; 113<br /> &lt;211&gt; 257<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 113</li>
        <li>&lt;210&gt; 114<br /> &lt;211&gt; 259<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 114</li>
        <li>&lt;210&gt; 115<br /> &lt;211&gt; 259<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 115</li>
        <li>&lt;210&gt; 116<br /> &lt;211&gt; 12<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 116</li>
        <li>&lt;210&gt; 117<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc<br /> &lt;222&gt; (5)..(5)<br /> &lt;223&gt; X is Val or Cys</li>
        <li>&lt;400&gt; 117</li>
        <li>&lt;210&gt; 118<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 118</li>
        <li>&lt;210&gt; 119<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (5)..(5)<br /> &lt;223&gt; Xaa is Pro or Ala</li>
        <li>&lt;400&gt; 119</li>
        <li>&lt;210&gt; 120<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 120</li>
        <li>&lt;210&gt; 121<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 121</li>
        <li>&lt;210&gt; 122<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 122</li>
        <li>&lt;210&gt; 123<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (5)..(5)<br /> &lt;223&gt; Xaa is Ala or Asn</li>
        <li>&lt;400&gt; 123</li>
        <li>&lt;210&gt; 124<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (5)..(5)<br /> &lt;223&gt; Xaa is Gly or Thr</li>
        <li>&lt;400&gt; 124</li>
        <li>&lt;210&gt; 125<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (5)..(5)<br /> &lt;223&gt; Xaa is Val or Ser</li>
        <li>&lt;400&gt; 125</li>
        <li>&lt;210&gt; 126<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 126</li>
        <li>&lt;210&gt; 127<br /> &lt;211&gt; 10<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (4)..(4)<br /> &lt;223&gt; Xaa is Pro or Ala</li>
        <li>&lt;400&gt; 127</li>
        <li>&lt;210&gt; 128<br /> &lt;211&gt; 10<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;</li>
        <li>&lt;221&gt; misc_feature<br /> &lt;222&gt; (4)..(4)<br /> &lt;223&gt; Xaa is Pro or Ala</li>
        <li>&lt;400&gt; 128</li>
        <li>&lt;210&gt; 129<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 129</li>
        <li>&lt;210&gt; 130<br /> &lt;211&gt; 9</li>
        <li>&lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 130</li>
        <li>&lt;210&gt; 131<br /> &lt;211&gt; 10<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (6)..(6)<br /> &lt;223&gt; Xaa is Tyr or Lys</li>
        <li>&lt;400&gt; 131</li>
        <li>&lt;210&gt; 132<br /> &lt;211&gt; 8<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;220&gt;<br /> &lt;221&gt; misc_feature<br /> &lt;222&gt; (5) .. (5)<br /> &lt;223&gt; Xaa is Pro or Ala</li>
        <li>&lt;400&gt; 132</li>
        <li>&lt;210&gt; 133<br /> &lt;211&gt; 12<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 133</li>
        <li>&lt;210&gt; 134<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 134</li>
        <li>&lt;210&gt; 135<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 135</li>
        <li>&lt;210&gt; 136<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 136</li>
        <li>&lt;210&gt; 137<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 137</li>
        <li>&lt;210&gt; 138<br /> &lt;211&gt; 6<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 138</li>
        <li>&lt;210&gt; 139<br /> &lt;211&gt; 6<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 139</li>
        <li>&lt;210&gt; 140<br /> &lt;211&gt; 12<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 140</li>
        <li>&lt;210&gt; 141<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 141</li>
        <li>&lt;210&gt; 142<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 142</li>
        <li>&lt;210&gt; 143<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 143</li>
        <li>&lt;210&gt; 144<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 144</li>
        <li>&lt;210&gt; 145<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 145</li>
        <li>&lt;210&gt; 146<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 146</li>
        <li>&lt;210&gt; 147<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 147</li>
        <li>&lt;210&gt; 148<br /> &lt;211&gt; 9<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 148</li>
        <li>&lt;210&gt; 149<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 149</li>
        <li>&lt;210&gt; 150<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 150</li>
        <li>&lt;210&gt; 151<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 151</li>
        <li>&lt;210&gt; 152<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 152</li>
        <li>&lt;210&gt; 153<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 153</li>
        <li>&lt;210&gt; 154<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 154</li>
        <li>&lt;210&gt; 155<br /> &lt;211&gt; 11<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence</li>
        <li>&lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 155</li>
        <li>&lt;210&gt; 156<br /> &lt;211&gt; 10<br /> &lt;212&gt; PRT<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 156</li>
        <li>&lt;210&gt; 157<br /> &lt;211&gt; 42<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 157</li>
        <li>&lt;210&gt; 158<br /> &lt;211&gt; 37<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 158</li>
        <li>&lt;210&gt; 159<br /> &lt;211&gt; 45<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 159</li>
        <li>&lt;210&gt; 160<br /> &lt;211&gt; 37<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 160</li>
        <li>&lt;210&gt; 161<br /> &lt;211&gt; 1136<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 161</li>
        <li>&lt;210&gt; 162<br /> &lt;211&gt; 827<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 162</li>
        <li>&lt;210&gt; 163<br /> &lt;211&gt; 1046<br /> &lt;212&gt; DNA<br /> &lt;213&gt; Artificial Sequence<br /> &lt;220&gt;<br /> &lt;223&gt; Description of Artificial Sequence: synthetic, no natural origin</li>
        <li>&lt;400&gt; 163</li>
      </ol>
    </p>
  </description>
  <claims id="claims_eng" lang="eng" format="original" date-changed="20070504">
    <claim num="1" id="clm-00001-en" independent="true">
      <claim-text>A fusion protein comprising<claim-text>(a) at least one binding domain comprising an antibody or binding site thereof specifically recognizing an epitope of a plant pathogen; and</claim-text><claim-text>(b) a membrane localisation sequence and/or motif that leads to membrane anchoring and, optionally, a cellular targeting sequence.</claim-text></claim-text>
    </claim>
    <claim num="2" id="clm-00002-en">
      <claim-text>The fusion protein of claim 1 comprising at least one further domain comprising a protein or peptide sequence which is toxic to the pathogen or detrimental to its replication, transmission or life cycle.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-en">
      <claim-text>The fusion protein of claim 1 or 2 wherein the membrane localisation sequence is proteolytically sensitive.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-en">
      <claim-text>The fusion protein of any one of claims 1 to 3 wherein said membrane localisation sequence is human T cell receptor transmembrane domains or any other member of the immunoglobulin superfamily, glyco-phosphatidyl inositol (GPI) anchors, KAR1, middle-T antigen, cytochrome b5 or syn1.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-en">
      <claim-text>The fusion protein of any one of claims 1 to 4 wherein said domains are linked by covalent or non-covalent bonds.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-en">
      <claim-text>The fusion protein of any one of claims 2 to 5 wherein the toxic activity of the protein or peptide sequence is activated by the presence of the pathogen, a component thereof or a component of a host cell.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-en">
      <claim-text>The fusion protein of claim 6 wherein the toxic activity of the protein or peptide sequence is activated by a pathogen specific or host cell protease.</claim-text>
    </claim>
    <claim num="8" id="clm-00008-en">
      <claim-text>The fusion protein of any one of claims 1 to 7 wherein said antibody or binding site thereof is a recombinant full-size antibody, dimeric secretory IgA antibody, multimeric IgM antibody, F(ab')<sub>2</sub>-fragment, Fab-fragment, Fv-fragment, single chain Fv antibody (scFv), bispecific scFv, diabody, single domain antibody (dAb), minibody or molecular recognition unit (MRU), derived from hybridoma cells, synthetic, semi-synthetic, naÃ¯ve and immunocompetent phage display or ribosome display libraries, or by the generation of fully synthetic designer antibodies.</claim-text>
    </claim>
    <claim num="9" id="clm-00009-en">
      <claim-text>The fusion protein of any one of claims 1 to 8 comprising at least two binding domains for the same or different epitope(s).</claim-text>
    </claim>
    <claim num="10" id="clm-00010-en">
      <claim-text>The fusion protein of claim 9 wherein said epitopes are from the same or different pathogen(s).</claim-text>
    </claim>
    <claim num="11" id="clm-00011-en">
      <claim-text>The fusion protein of any one of claims 2 to 10 wherein the toxin is an enzyme or a viral structural or non-structural protein or a binding domain as defined in any one of claims 1 to 10.</claim-text>
    </claim>
    <claim num="12" id="clm-00012-en">
      <claim-text>The fusion protein of claim 11 wherein said enzyme is chitinase or glucanase, glucose oxidase, superoxide dismutase, DNAse or RNAse or RIP or lipase or active fragments thereof either singly or in any combination(s).</claim-text>
    </claim>
    <claim num="13" id="clm-00013-en">
      <claim-text>The fusion protein of any one of claims 1 to 12 wherein the pathogen is a virus, bacterium, mycoplasma, fungus, nematode or insect.</claim-text>
    </claim>
    <claim num="14" id="clm-00014-en">
      <claim-text>The fusion protein of any one of claims 1 to 13 wherein at least one of said domains is fused to a C- or N-terminal carrier protein.</claim-text>
    </claim>
    <claim num="15" id="clm-00015-en">
      <claim-text>The fusion protein of any one of claims 1 to 14 wherein at least one of said domains comprises a fluorophore.</claim-text>
    </claim>
    <claim num="16" id="clm-00016-en">
      <claim-text>A pathogenicide comprising the fusion protein of any one of claims 1 to 15.</claim-text>
    </claim>
    <claim num="17" id="clm-00017-en">
      <claim-text>The fusion protein of any one of claims 1 to 15 or the pathogenicide of claim 16 wherein said binding domain(s) and said further domain(s) are capable of self assembly in vivo.</claim-text>
    </claim>
    <claim num="18" id="clm-00018-en">
      <claim-text>The pathogenicide of claims 16 or 17 wherein at least one of said binding domains of the fusion protein of any one of claims 1 to 15 specifically recognizes a viral movement and/or replicase protein.</claim-text>
    </claim>
    <claim num="19" id="clm-00019-en">
      <claim-text>A polynucleotide encoding the fusion protein of any one of claims 1 to 15 or 17 or the pathogenicide of any one of claims 16 to 18.</claim-text>
    </claim>
    <claim num="20" id="clm-00020-en">
      <claim-text>A vector comprising the polynucleotide of claim 19.</claim-text>
    </claim>
    <claim num="21" id="clm-00021-en">
      <claim-text>A vector comprising separate polynucleotides encoding at least one of said binding domain(s) and/or said further domain(s) of the fusion protein of any one of claims 1 to 15 or 17 or the pathogenicide of any one of claims 16 to 18.</claim-text>
    </claim>
    <claim num="22" id="clm-00022-en">
      <claim-text>A composition comprising vectors wherein each vector contains at least one polynucleotide encoding at least one binding domain and/or at least one further domain of the fusion protein of any one of claims 1 to 15 or 17 or the pathogenicide of any one of claims 16 to 18; and wherein the expression of at least two of said polynucleotides results in the production of said fusion protein or said pathogenicide or assembly of the same in vivo.</claim-text>
    </claim>
    <claim num="23" id="clm-00023-en">
      <claim-text>The vector of claim 20 or 21 or the composition of claim 22 wherein the polynucleotide is operatively linked to regulatory sequences allowing the expression of the fusion protein, pathogenicide or the domains thereof in a host cell.</claim-text>
    </claim>
    <claim num="24" id="clm-00024-en">
      <claim-text>The vector or composition of claim 23 wherein said regulatory sequence is a constitutive, chimeric, ubiquitous, tissue specific, organ specific or inducible promoter.</claim-text>
    </claim>
    <claim num="25" id="clm-00025-en">
      <claim-text>A host cell comprising the polynucleotide of claim 19, the vector of any one of claims 20, 21, 23 or 24, or the composition of any one of claims 22 to 24.</claim-text>
    </claim>
    <claim num="26" id="clm-00026-en">
      <claim-text>A method for the production of a molecular pathogenicide comprising:<claim-text>(a) culturing the host cell of claim 25 under conditions suitable for the expression of the polynucleotide; and</claim-text><claim-text>(b) recovering the fusion protein, pathogenicide or the domains thereof from the culture.</claim-text></claim-text>
    </claim>
    <claim num="27" id="clm-00027-en">
      <claim-text>A molecular pathogenicide obtainable by the method of claim 26 or encodable by the polynucleotide of claim 19.</claim-text>
    </claim>
    <claim num="28" id="clm-00028-en">
      <claim-text>A method for the production of pathogen resistant transgenic plants, plant cells or plant tissue comprising the introduction of a polynucleotide of claim 19, the vector of claim 20, 21, 23 or 24 or the vectors of the composition of any one of claims 22 to 24 into the genome of a plant, plant cell or plant tissue.</claim-text>
    </claim>
    <claim num="29" id="clm-00029-en">
      <claim-text>A transgenic plant cell which contains stably integrated into the genome a polynucleotide of claim 19, a vector of claim 20, 21, 23 or 24 or the vectors of the composition of any one of claims 22 to 24 or obtainable according to the method of claim 28.</claim-text>
    </claim>
    <claim num="30" id="clm-00030-en">
      <claim-text>A transgenic plant or plant tissue comprising plant cells of claim 29 or obtainable by the method of claim 28.</claim-text>
    </claim>
    <claim num="31" id="clm-00031-en">
      <claim-text>The transgenic plant of claim 30 wherein the fusion protein or pathogenicide are made functional against pathogens by in vivo assembly after cotransformation of at least two independent plant expression constructs or after sexual crossing to form hybrid offspring from two parental plants expressing one or more of the domains of the fusion protein or the pathogenicide, or any other form of genetic recombination.</claim-text>
    </claim>
    <claim num="32" id="clm-00032-en">
      <claim-text>The transgenic plant of claim 30 or 31 which displays improved resistance against a pathogen that the wild type plant was susceptible to.</claim-text>
    </claim>
    <claim num="33" id="clm-00033-en">
      <claim-text>Harvestable parts or propagation material of a plant of any one of claims 30 to 32, said harvestable parts or propagation material comprising plant cells of claim 29.</claim-text>
    </claim>
    <claim num="34" id="clm-00034-en">
      <claim-text>A kit comprising the fusion protein of any one of claims 1 to 15 or 17, the pathogenicide of any one of claims 16 to 18, the polynucleotide of claim 19, the vector of claim 20, 21, 23 or 24, the composition of any one of claims 22 to 24 or the molecular pathogenicide of claim 27.</claim-text>
    </claim>
    <claim num="35" id="clm-00035-en">
      <claim-text>Use of the fusion protein of any one of claims 1 to 15 or the pathogenicide of any one of claims 16 to 18, the polynucleotide of claim 19, the vector of claim 20, 21, 23 or 24, the composition of any one of claims 22 to 24 or the molecular pathogenicide of claim 27 for the protection of a plant against the action of a pathogen.</claim-text>
    </claim>
  </claims>
  <claims id="claims_fre" lang="fre" format="original" date-changed="20070504">
    <claim num="1" id="clm-00001-fr" independent="true">
      <claim-text>ProtÃ©ine de fusion comprenant :<claim-text>a) au moins un domaine de liaison comprenant un anticorps ou un site de liaison de celui-ci qui reconnaÃ®t de faÃ§on spÃ©cifique un Ã©pitope d'une plante pathogÃ¨ne ; et</claim-text><claim-text>b) une sÃ©quence pour localisation dans une sÃ©quence et/ou un motif qui conduit Ã  la fixation sur la membrane et, Ã©ventuellement, une sÃ©quence de ciblage cellulaire.</claim-text></claim-text>
    </claim>
    <claim num="2" id="clm-00002-fr">
      <claim-text>ProtÃ©ine de fusion de la revendication 1, comprenant au moins un autre domaine comprenant une sÃ©quence de protÃ©ine ou de peptide qui est toxique pour le pathogÃ¨ne ou nuisible pour sa rÃ©plication, sa transmission et son cycle de vie.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-fr">
      <claim-text>ProtÃ©ine de fusion de la revendication 1 ou 2,<br />caractÃ©risÃ©e en ce que<br /> la sÃ©quence de localisation dans la membrane est sensible de faÃ§on protÃ©olytique.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  3,<br />caractÃ©risÃ©e en ce que<br /> la sÃ©quence de localisation dans la membrane est un domaine trans-membranaire du rÃ©cepteur de cellule T humaine ou n'importe quel autre membre de la super-famille des immunoglobulines, des fixations de glyco-phosphatidyl inositol (GPI), KAR1, antigÃ¨ne middle-T, cytochrome b5 ou syn1.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  4,<br />caractÃ©risÃ©e en ce que<br /> les domaines sont liÃ©s par des liaisons covalentes ou non covalentes.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-fr">
      <claim-text>ProtÃ©ine fusion de l'une quelconque des revendications 2 Ã  5,<br />caractÃ©risÃ©e en ce que<br /> l'activitÃ© de la sÃ©quence de protÃ©ine et de peptide est activÃ©e par la prÃ©sence du pathogÃ¨ne, un de ses composants ou un composant d'une cellule hÃ´te.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-fr">
      <claim-text>ProtÃ©ine de fusion de la revendication 6,<br />caractÃ©risÃ©e en ce que<br /> l'activitÃ© de la sÃ©quence de protÃ©ine et de peptide est activÃ©e par un pathogÃ¨ne spÃ©cifique ou une protÃ©ase de cellule hÃ´te</claim-text>
    </claim>
    <claim num="8" id="clm-00008-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  7,<br />caractÃ©risÃ©e en ce que<br /> l'anticorps ou son site de liaison est un anticorps Ã  taille complÃ¨te recombinÃ©, un anticorps IgA sÃ©crÃ©teur dimÃ¨re, un anticorps IgM multi-mÃ¨re, un fragment F(ab')2, un fragment Fab, un fragments Fv, un anticorps Fv Ã  chaÃ®ne unique (scFv), un scFv bispÃ©cifique, un diacorps, un anticorps Ã  domaine unique (dAb), un minicorps ou une unitÃ© de reconnaissance molÃ©culaire (MRU), dÃ©rivÃ© de cellules d'hybridomes, de bibliothÃ¨ques d'affichage de phage ou de ribosome synthÃ©tiques, semi-synthÃ©tiques, naÃ¯fs ou par la gÃ©nÃ©ration d'anticorps sur mesure, complÃ¨tement synthÃ©tiques.</claim-text>
    </claim>
    <claim num="9" id="clm-00009-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  8, comprenant au moins deux domaines de liaison pour le mÃªme Ã©pitope ou un ou plusieurs Ã©pitopes diffÃ©rents.</claim-text>
    </claim>
    <claim num="10" id="clm-00010-fr">
      <claim-text>ProtÃ©ine de fusion de la revendication 9,<br />caractÃ©risÃ©e en ce que<br /> les Ã©pitopes sont du mÃªme pathogÃ¨ne ou d'un ou plusieurs pathogÃ¨ne diffÃ©rents.</claim-text>
    </claim>
    <claim num="11" id="clm-00011-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 2 Ã  10,<br />caractÃ©risÃ©e en ce que<br /> la toxine est un enzyme ou une protÃ©ine virale structurale ou non structurale ou un domaine de liaison tels que dÃ©finis dans n'importe laquelle des revendications 1 Ã  10.</claim-text>
    </claim>
    <claim num="12" id="clm-00012-fr">
      <claim-text>ProtÃ©ine de fusion de la revendication 9,<br />caractÃ©risÃ©e en ce que<br /> l'enzyme est la chitinase ou la glucanase, la glucose oxydase, la superoxyde dismutase, l'ADNase ou l'ARNase ou la RIP ou la lipase ou leurs fragments actifs soit seuls ou dans n'importe quelle(s) combinaison(s).</claim-text>
    </claim>
    <claim num="13" id="clm-00013-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  12,<br />caractÃ©risÃ©e en ce que<br /> le pathogÃ¨ne est un virus, une bactÃ©rie, un mycoplasme, une moisissure, un nÃ©matode ou un insecte.</claim-text>
    </claim>
    <claim num="14" id="clm-00014-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  13,<br />caractÃ©risÃ©e en ce qu'<br /> au moins un des domaines est condensÃ© avec une protÃ©ine porteur Ã  terminaison C ou terminaison N.</claim-text>
    </claim>
    <claim num="15" id="clm-00015-fr">
      <claim-text>ProtÃ©ine fusion de l'une quelconque des revendications 1 Ã  14,<br />caractÃ©risÃ©e en ce qu'<br /> au moins un des domaines comprend un fluorophore.</claim-text>
    </claim>
    <claim num="16" id="clm-00016-fr">
      <claim-text>PathogÃ©nicide comprenant la protÃ©ine de fusion de n'importe laquelle des revendications 1 Ã  15.</claim-text>
    </claim>
    <claim num="17" id="clm-00017-fr">
      <claim-text>ProtÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15, ou pathogÃ©nicide de la revendication 16,<br />caractÃ©risÃ©s en ce que<br /> le ou les domaines de liaison et le ou les autres domaines sont capables de s'auto-assembler in vivo.</claim-text>
    </claim>
    <claim num="18" id="clm-00018-fr">
      <claim-text>PathogÃ©nicide des revendications 16 ou 17,<br />caractÃ©risÃ© en ce qu'<br /> au moins l'un des domaines de liaison de la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15, reconnaÃ®t de faÃ§on spÃ©cifique un mouvement viral et/ou une protÃ©ine de rÃ©plicase.</claim-text>
    </claim>
    <claim num="19" id="clm-00019-fr">
      <claim-text>PolynuclÃ©otide qui code la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15 ou 17 ou le pathogÃ©nicide de l'une quelconque des revendications 16 Ã  18.</claim-text>
    </claim>
    <claim num="20" id="clm-00020-fr">
      <claim-text>Vecteur comprenant le polynuclÃ©otide de la revendication 19.</claim-text>
    </claim>
    <claim num="21" id="clm-00021-fr">
      <claim-text>Â°) Vecteur comprenant des polynuclÃ©otides sÃ©parÃ©s qui codent un ou plusieurs des domaines de liaison et/ou un ou plusieurs des autres domaines de la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15 ou 17 ou le pathogÃ©nicide de l'une quelconque des revendications 16 Ã  18.</claim-text>
    </claim>
    <claim num="22" id="clm-00022-fr">
      <claim-text>Composition comprenant des vecteurs,<br />caractÃ©risÃ©e en ce que<br /> chaque vecteur contient au moins un polynuclÃ©otide qui code au moins un domaine de liaison et/ou au moins un autre domaine de la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15 ou 17 ou le pathogÃ©nicide de l'une quelconque des revendications 16 Ã  18 ; et au moins deux des polynuclÃ©otides ont pour rÃ©sultat la production de la protÃ©ine de fusion ou du pathogÃ©nicide ou un assemblage des mÃªmes in vivo.</claim-text>
    </claim>
    <claim num="23" id="clm-00023-fr">
      <claim-text>Vecteur de la revendication 20 ou 21 ou composition de la revendication 22,<br />caractÃ©risÃ© en ce que<br /> le polynuclÃ©otide est liÃ© de faÃ§on opÃ©rationnelle aux sÃ©quences rÃ©gulatrices permettant l'expression de la protÃ©ine de fusion, du pathogÃ©nicide ou leurs domaines dans une cellule hÃ´te.</claim-text>
    </claim>
    <claim num="24" id="clm-00024-fr">
      <claim-text>Vecteur ou composition de la revendication 23,<br />caractÃ©risÃ© en ce que<br /> la sÃ©quence rÃ©gulatrice est un promoteur constitutif, chimÃ©rique, trÃ¨s rÃ©pandu, spÃ©cifique d'un tissu, spÃ©cifique d'un organe ou inductible.</claim-text>
    </claim>
    <claim num="25" id="clm-00025-fr">
      <claim-text>Cellule hÃ´te comprenant le polynuclÃ©otide de la revendication 19, le vecteur de l'une quelconque des revendications 20, 21, 23 ou 24 ou la composition de l'une quelconque des revendications 22 Ã  24.</claim-text>
    </claim>
    <claim num="26" id="clm-00026-fr">
      <claim-text>ProcÃ©dÃ© pour la production d'un pathogÃ©nicide molÃ©culaire comprenant :<claim-text>a) la culture d'une cellule hÃ´te de la revendication 25 dans des conditions appropriÃ©es pour l'expression du polynuclÃ©otide ; et</claim-text><claim-text>b) rÃ©cupÃ©ration de la protÃ©ine de fusion, du pathogÃ©nicide ou de leurs domaines Ã  partir de la culture.</claim-text></claim-text>
    </claim>
    <claim num="27" id="clm-00027-fr">
      <claim-text>PathogÃ©nicide molÃ©culaire pouvant Ãªtre obtenu par le procÃ©dÃ© de la revendication 26 ou qui peut Ãªtre codÃ© par le polynuclÃ©otide de la revendication 19.</claim-text>
    </claim>
    <claim num="28" id="clm-00028-fr">
      <claim-text>ProcÃ©dÃ© de production de plantes transgÃ©niques rÃ©sistant Ã  un pathogÃ¨ne, de cellules de plante ou de tissus de plante comprenant l'introduction d'un polynuclÃ©otide de la revendication 19, d'un vecteur des revendications 20, 21, 23 ou 24 ou les vecteurs de la composition de l'une quelconque des revendications 22 Ã  24, dans le gÃ©nome d'une plante, la cellule d'une plante ou le tissu d'une plante.</claim-text>
    </claim>
    <claim num="29" id="clm-00029-fr">
      <claim-text>Cellule de plante transgÃ©nique qui contient, intÃ©grÃ© de faÃ§on stable dans le gÃ©nome, un polynuclÃ©otide de la revendication 19, un vecteur des revendications 20, 21, 23 ou 24 ou les vecteurs de la composition de l'une quelconque des revendications 22 Ã  24 ou pouvant Ãªtre obtenue selon le procÃ©dÃ© de la revendication 28.</claim-text>
    </claim>
    <claim num="30" id="clm-00030-fr">
      <claim-text>Plante transgÃ©nique ou tissus de plante comprenant des cellules de plante de la revendication 29 ou pouvant Ãªtre obtenue par le procÃ©dÃ© de la revendication 28.</claim-text>
    </claim>
    <claim num="31" id="clm-00031-fr">
      <claim-text>Plante transgÃ©nique de la revendication 30,<br />caractÃ©risÃ©e en ce que la protÃ©ine de fusion ou le pathogÃ©nicide sont rendus fonctionnels contre les pathogÃ¨nes par un assemblage in vivo aprÃ¨s cotransformation d'au moins deux groupes de recombinaison d'expression de plante indÃ©pendants, ou aprÃ¨s un croisement sexuel pour former un descendant hybride Ã  partir de plantes parentales exprimant un ou plusieurs des domaines de la protÃ©ine de fusion ou le pathogÃ©nicide, ou n'importe quelle autre forme de recombinaison gÃ©nÃ©tique.</claim-text>
    </claim>
    <claim num="32" id="clm-00032-fr">
      <claim-text>Plante transgÃ©nique de la revendication 30 ou 31 qui dispose d'une rÃ©sistance amÃ©liorÃ©e contre un pathogÃ¨ne que n'est pas susceptible d'avoir une plante sauvage.</claim-text>
    </claim>
    <claim num="33" id="clm-00033-fr">
      <claim-text>Parties rÃ©coltables ou matÃ©riau de propagation d'une plante de l'une quelconque des revendications 30 Ã  32, les parties rÃ©coltables ou le matÃ©riau de propagation comprenant les cellules de plante de la revendication 29.</claim-text>
    </claim>
    <claim num="34" id="clm-00034-fr">
      <claim-text>Kit comprenant la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15 ou 17, le pathogÃ©nicide de l'une quelconque des revendications 16 Ã  18, le polynuclÃ©otide de la revendication 19, le vecteur des revendications 20, 21, 23 ou 24, la composition de l'une quelconque des revendications 22 Ã  24 ou le pathogÃ©nicide de la revendication 27.</claim-text>
    </claim>
    <claim num="35" id="clm-00035-fr">
      <claim-text>Utilisation de la protÃ©ine de fusion de l'une quelconque des revendications 1 Ã  15 ou du pathogÃ©nicide de l'une quelconque des revendications 16 Ã  18, du polynuclÃ©otide de la revendication 19, le vecteur des revendications 20, 21, 23 ou 24, la composition de l'une quelconque des revendications 22 Ã  24 ou le pathogÃ©nicide de la revendication 27, pour la protection d'une plante contre l'action d'un pathogÃ¨ne.</claim-text>
    </claim>
  </claims>
  <claims id="claims_ger" lang="ger" format="original" date-changed="20070504">
    <claim num="1" id="clm-00001-de" independent="true">
      <claim-text>Fusionsprotein umfassend<claim-text>(a) zumindest eine BindungsdomÃ¤ne umfassend einen AntikÃ¶rper oder eine Bindungsstelle davon, der/die ein Epitop eines Pflanzenpathogens spezifisch erkennt; und</claim-text><claim-text>(b) eine Membranlokalisationssequenz und/oder ein Membranlokalisationsmotiv, das zur Verankerung in einer Membran fÃ¼hrt, und gegebenenfalls eine zellulÃ¤re Targeting-Sequenz.</claim-text></claim-text>
    </claim>
    <claim num="2" id="clm-00002-de">
      <claim-text>Fusionsprotein gemÃ¤Ã Anspruch 1, umfassend zumindest eine weitere DomÃ¤ne, die eine Protein- oder Peptidsequenz umfasst, die fÃ¼r das Pathogen toxisch ist oder seine Replikation, seine Transmission oder seinen Lebenszyklus beeintrÃ¤chtigt.</claim-text>
    </claim>
    <claim num="3" id="clm-00003-de">
      <claim-text>Fusionsprotein gemÃ¤Ã Anspruch 1 oder 2, wobei die Membranlokalisationssequenz proteolytisch sensitiv ist.</claim-text>
    </claim>
    <claim num="4" id="clm-00004-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 3, wobei die Membranlokalisationssequenz transmembrane DomÃ¤nen eines menschlichen T-Zell-Rezeptors oder eines anderen Mitglieds der Immunoglobulinsuperfamilie, Glykophosphatidylinosit (GPI)-Anker, KAR1, mittleres T-Antigen, Cytochrom b5 oder syn 1 ist.</claim-text>
    </claim>
    <claim num="5" id="clm-00005-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 4, wobei die DomÃ¤nen durch kovalente oder nicht-kovalente Bindungen verknÃ¼pft sind.</claim-text>
    </claim>
    <claim num="6" id="clm-00006-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 2 bis 5, wobei die toxische AktivitÃ¤t der Protein- oder Peptidsequenz durch die Anwesenheit des Pathogens, einer Komponente davon oder einer Komponente einer Wirtszelle aktiviert wird.</claim-text>
    </claim>
    <claim num="7" id="clm-00007-de">
      <claim-text>Fusionsprotein gemÃ¤Ã Anspruch 6, wobei die toxische AktivitÃ¤t der Protein- oder Peptidsequenz durch eine pathogenspezifische Protease oder eine Wirtszellprotease aktiviert wird.</claim-text>
    </claim>
    <claim num="8" id="clm-00008-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 7, wobei der AntikÃ¶rper oder die Bindungsstelle davon ein rekombinanter vollstÃ¤ndiger AntikÃ¶rper, dimerer sekretorischer IgA-AntikÃ¶rper, multimerer IgM-AntikÃ¶rper, F(ab')<sub>2</sub>-Fragment, Fab-Fragment, Fv-Fragment, Einzelketten-Fv-AntikÃ¶rper (scFv), bispezifischer scFv, Diabody, EinzeldomÃ¤nenantikÃ¶rper (dAb), Minibody oder eine molekulare Erkennungseinheit (MRU) ist, der/die von Hybridomzellen, synthetischen, semi-synthetischen, nativen oder immunkompetenten Phagen-Display- oder Ribosomen-Display-Bibliotheken, oder durch die Herstellung von vollstÃ¤ndig synthetischen Designer-AntikÃ¶rpern gewonnen wird.</claim-text>
    </claim>
    <claim num="9" id="clm-00009-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 8, umfassend zumindest zwei BindungsdomÃ¤nen fÃ¼r das gleiche oder verschiedene Epitop(e).</claim-text>
    </claim>
    <claim num="10" id="clm-00010-de">
      <claim-text>Fusionsprotein gemÃ¤Ã Anspruch 9, wobei die Epitope von dem gleichen oder von verschiedenen Pathogen(en) stammen.</claim-text>
    </claim>
    <claim num="11" id="clm-00011-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 2 bis 10, wobei das Toxin ein Enzym oder ein virales Struktur- oder Nicht-Strukturprotein oder eine wie in einem der AnsprÃ¼che 1 bis 10 definierte BindungsdomÃ¤ne ist.</claim-text>
    </claim>
    <claim num="12" id="clm-00012-de">
      <claim-text>Fusionsprotein gemÃ¤Ã Anspruch 11, wobei das Enzym Chitinase oder Glucanase, Glucoseoxidase, Superoxid-Dismutase, DNAse oder RNAse oder RIP oder Lipase ist oder aktive Fragmente davon, entweder einzeln oder in einer oder mehreren beliebigen Kombination(en).</claim-text>
    </claim>
    <claim num="13" id="clm-00013-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 12, wobei das Pathogen ein Virus, Bakterium, Mycoplasma, Pilz, Nematode oder Insekt ist.</claim-text>
    </claim>
    <claim num="14" id="clm-00014-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 13, wobei zumindest eine der DomÃ¤nen an ein C- oder N-terminales TrÃ¤gerprotein fusioniert ist.</claim-text>
    </claim>
    <claim num="15" id="clm-00015-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 14, wobei zumindest eine der DomÃ¤nen ein Fluorophor umfasst.</claim-text>
    </claim>
    <claim num="16" id="clm-00016-de">
      <claim-text>Pathogenizid, umfassend das Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15.</claim-text>
    </claim>
    <claim num="17" id="clm-00017-de">
      <claim-text>Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder Pathogenizid gemÃ¤Ã Anspruch 16, wobei die BindungsdomÃ¤ne(n) und die weitere DomÃ¤ne(n) zur Selbstzusammenlagerung in vivo in der Lage sind.</claim-text>
    </claim>
    <claim num="18" id="clm-00018-de">
      <claim-text>Pathogenizid gemÃ¤Ã Anspruch 16 oder 17, wobei zumindest eine der BindungsdomÃ¤nen des Fusionsproteins gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 ein virales Movement- und/oder Replikaseprotein spezifisch erkennt.</claim-text>
    </claim>
    <claim num="19" id="clm-00019-de">
      <claim-text>Polynucleotid, das das Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder 17 oder das Pathogenizid gemÃ¤Ã einem der AnsprÃ¼che 16 bis 18 codiert.</claim-text>
    </claim>
    <claim num="20" id="clm-00020-de">
      <claim-text>Vektor, umfassend das Polynucleotid gemÃ¤Ã Anspruch 19.</claim-text>
    </claim>
    <claim num="21" id="clm-00021-de">
      <claim-text>Vektor, umfassend separate Polynucleotide, die zumindest eine der BindungsdomÃ¤ne(n) und/oder weitere(n) DomÃ¤ne(n) des Fusionsproteins gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder 17 oder des Pathogenizids gemÃ¤Ã einem der AnsprÃ¼che 16 bis 18 codieren.</claim-text>
    </claim>
    <claim num="22" id="clm-00022-de">
      <claim-text>Zusammensetzung, umfassend Vektoren, wobei jeder Vektor zumindest ein Polynucleotid enthÃ¤lt, das zumindest eine BindungsdomÃ¤ne und/oder zumindest eine weitere DomÃ¤ne des Fusionsproteins gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder 17 oder des Pathogenizids gemÃ¤Ã einem der AnsprÃ¼che 16 bis 18 codiert; und wobei die Expression von zumindest zwei der Polynucleotide zur Produktion des Fusionsproteins oder des Pathogenizids oder zur in vivo-Zusammenlagerung desselben fÃ¼hrt.</claim-text>
    </claim>
    <claim num="23" id="clm-00023-de">
      <claim-text>Vektor gemÃ¤Ã Anspruch 20 oder 21 oder Zusammensetzung gemÃ¤Ã Anspruch 22, wobei das Polynucleotid funktionell mit regulatorischen Sequenzen verknÃ¼pft ist, die die Expression des Fusionsproteins, Pathogenizids oder der DomÃ¤nen davon in einer Wirtszelle erlauben.</claim-text>
    </claim>
    <claim num="24" id="clm-00024-de">
      <claim-text>Vektor oder Zusammensetzung gemÃ¤Ã Anspruch 23, wobei die regulatorische Sequenz ein konstitutiver, chimÃ¤rer, ubiquitÃ¤rer, gewebsspezifischer, organspezifischer oder induzierbarer Promotor ist.</claim-text>
    </claim>
    <claim num="25" id="clm-00025-de">
      <claim-text>Wirtszelle, umfassend das Polynucleotid gemÃ¤Ã Anspruch 19, den Vektor gemÃ¤Ã einem der AnsprÃ¼che 20, 21, 23 oder 24 oder die Zusammensetzung gemÃ¤Ã einem der AnsprÃ¼che 22 bis 24.</claim-text>
    </claim>
    <claim num="26" id="clm-00026-de">
      <claim-text>Verfahren zur Produktion eines molekularen Pathogenizids umfassend:<claim-text>(a) ZÃ¼chten der Wirtszelle gemÃ¤Ã Anspruch 25 unter Bedingungen, die zur Expression des Polynucleotids geeignet sind; und</claim-text><claim-text>(b) Gewinnen des Fusionsproteins, Pathogenizids oder der DomÃ¤nen davon aus der Kultur.</claim-text></claim-text>
    </claim>
    <claim num="27" id="clm-00027-de">
      <claim-text>Molekulares Pathogenizid, erhÃ¤ltlich durch das Verfahren gemÃ¤Ã Anspruch 26 oder codierbar durch das Polynucleotid gemÃ¤Ã Anspruch 19.</claim-text>
    </claim>
    <claim num="28" id="clm-00028-de">
      <claim-text>Verfahren zur Herstellung von pathogenresistenten transgenen Pflanzen, Pflanzenzellen oder Pflanzengewebe, umfassend das EinfÃ¼hren eines Polynucleotids gemÃ¤Ã Anspruch 19, des Vektors gemÃ¤Ã Anspruch 20, 21, 23 oder 24 oder der- Vektoren der Zusammensetzung gemÃ¤Ã einem der AnsprÃ¼che 22 bis 24 in das Genom einer Pflanze, Pflanzenzelle oder eines Pflanzengewebes.</claim-text>
    </claim>
    <claim num="29" id="clm-00029-de">
      <claim-text>Transgene Pflanzenzelle, die stabil in das Genom integriert ein Polynucleotid gemÃ¤Ã Anspruch 19, einen Vektor gemÃ¤Ã Anspruch 20, 21, 23 oder 24 oder die Vektoren der Zusammensetzung gemÃ¤Ã einem der AnsprÃ¼che 22 bis 24 enthÃ¤lt oder erhÃ¤ltlich durch das Verfahren gemÃ¤Ã Anspruch 28.</claim-text>
    </claim>
    <claim num="30" id="clm-00030-de">
      <claim-text>Transgene Pflanze oder transgenes Pflanzengewebe, umfassend Pflanzenzellen gemÃ¤Ã Anspruch 29 oder erhÃ¤ltlich durch das Verfahren gemÃ¤Ã Anspruch 28.</claim-text>
    </claim>
    <claim num="31" id="clm-00031-de">
      <claim-text>Transgene Pflanze gemÃ¤Ã Anspruch 30, wobei das Fusionsprotein oder das Pathogenizid durch in vivo-Zusammenlagerung nach Cotransformation von mindestens zwei unabhÃ¤ngigen Pflanzenexpressionskonstrukten oder nach sexueller Kreuzung, um hybride Nachkommen aus zwei parentalen Pflanzen herzustellen, die eine oder mehrere der DomÃ¤nen des Fusionsproteins oder des Pathogenizids exprimieren, oder durch eine beliebige andere Form genetischer Rekombination funktionsfÃ¤hig gegenÃ¼ber Pathogenen gemacht ist.</claim-text>
    </claim>
    <claim num="32" id="clm-00032-de">
      <claim-text>Transgene Pflanze gemÃ¤Ã Anspruch 30 oder 31, die eine verbesserte Resistenz gegen ein Pathogen aufweist, gegen das die Wildtyppflanze anfÃ¤llig ist.</claim-text>
    </claim>
    <claim num="33" id="clm-00033-de">
      <claim-text>Erntebare Teile oder Vermehrungsmaterial einer Pflanze gemÃ¤Ã einem der AnsprÃ¼che 30 bis 32, wobei die erntebaren Teile oder das Vermehrungsmaterial Pflanzenzellen gemÃ¤Ã Anspruch 29 umfassen.</claim-text>
    </claim>
    <claim num="34" id="clm-00034-de">
      <claim-text>Kit umfassend das Fusionsprotein gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder 17, das Pathogenizid gemÃ¤Ã einem der AnsprÃ¼che 16 bis 18, das Polynucleotid gemÃ¤Ã Anspruch 19, den Vektor gemÃ¤Ã Anspruch 20, 21, 23 oder 24, die Zusammensetzung gemÃ¤Ã einem der AnsprÃ¼che 22 bis 24 oder das molekulare Pathogenizid gemÃ¤Ã Anspruch 27.</claim-text>
    </claim>
    <claim num="35" id="clm-00035-de">
      <claim-text>Verwendung des Fusionsproteins gemÃ¤Ã einem der AnsprÃ¼che 1 bis 15 oder des Pathogenizids gemÃ¤Ã einem der AnsprÃ¼che 16 bis 18, des Polynucleotids gemÃ¤Ã Anspruch 19, des Vektors gemÃ¤Ã Anspruch 20, 21, 23 oder 24, der Zusammensetzung gemÃ¤Ã einem der AnsprÃ¼che 22 bis 24 oder des molekularen Pathogenizids gemÃ¤Ã Anspruch 27 zum Schutz einer Pflanze gegen die Wirkung eines Pathogens.</claim-text>
    </claim>
  </claims>
  <drawings>
    <figure num="1">
      <img he="N/A" wi="N/A" file="EP1123398B1_00001.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="2">
      <img he="N/A" wi="N/A" file="EP1123398B1_00002.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="3">
      <img he="N/A" wi="N/A" file="EP1123398B1_00003.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="4">
      <img he="N/A" wi="N/A" file="EP1123398B1_00004.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="5">
      <img he="N/A" wi="N/A" file="EP1123398B1_00005.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="6">
      <img he="N/A" wi="N/A" file="EP1123398B1_00006.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="7">
      <img he="N/A" wi="N/A" file="EP1123398B1_00007.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="8">
      <img he="N/A" wi="N/A" file="EP1123398B1_00008.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="9">
      <img he="N/A" wi="N/A" file="EP1123398B1_00009.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="10">
      <img he="N/A" wi="N/A" file="EP1123398B1_00010.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="11">
      <img he="N/A" wi="N/A" file="EP1123398B1_00011.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="12">
      <img he="N/A" wi="N/A" file="EP1123398B1_00012.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="13">
      <img he="N/A" wi="N/A" file="EP1123398B1_00013.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="14">
      <img he="N/A" wi="N/A" file="EP1123398B1_00014.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="15">
      <img he="N/A" wi="N/A" file="EP1123398B1_00015.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="16">
      <img he="N/A" wi="N/A" file="EP1123398B1_00016.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="17">
      <img he="N/A" wi="N/A" file="EP1123398B1_00017.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="18">
      <img he="N/A" wi="N/A" file="EP1123398B1_00018.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="19">
      <img he="N/A" wi="N/A" file="EP1123398B1_00019.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="20">
      <img he="N/A" wi="N/A" file="EP1123398B1_00020.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="21">
      <img he="N/A" wi="N/A" file="EP1123398B1_00021.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="22">
      <img he="N/A" wi="N/A" file="EP1123398B1_00022.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="23">
      <img he="N/A" wi="N/A" file="EP1123398B1_00023.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="24">
      <img he="N/A" wi="N/A" file="EP1123398B1_00024.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="25">
      <img he="N/A" wi="N/A" file="EP1123398B1_00025.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="26">
      <img he="N/A" wi="N/A" file="EP1123398B1_00026.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="27">
      <img he="N/A" wi="N/A" file="EP1123398B1_00027.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="28">
      <img he="N/A" wi="N/A" file="EP1123398B1_00028.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="29">
      <img he="N/A" wi="N/A" file="EP1123398B1_00029.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="30">
      <img he="N/A" wi="N/A" file="EP1123398B1_00030.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="31">
      <img he="N/A" wi="N/A" file="EP1123398B1_00031.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="32">
      <img he="N/A" wi="N/A" file="EP1123398B1_00032.PNG" alt="drawing sheet" img-content="drawing" img-format="png" />
    </figure>
    <figure num="33">
      <img he="N/A" wi="N/A" file="EP1123398B1_00033.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="34">
      <img he="N/A" wi="N/A" file="EP1123398B1_00034.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="35">
      <img he="N/A" wi="N/A" file="EP1123398B1_00035.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="36">
      <img he="N/A" wi="N/A" file="EP1123398B1_00036.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="37">
      <img he="N/A" wi="N/A" file="EP1123398B1_00037.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="38">
      <img he="N/A" wi="N/A" file="EP1123398B1_00038.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="39">
      <img he="N/A" wi="N/A" file="EP1123398B1_00039.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="40">
      <img he="N/A" wi="N/A" file="EP1123398B1_00040.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="41">
      <img he="N/A" wi="N/A" file="EP1123398B1_00041.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="42">
      <img he="N/A" wi="N/A" file="EP1123398B1_00042.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="43">
      <img he="N/A" wi="N/A" file="EP1123398B1_00043.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="44">
      <img he="N/A" wi="N/A" file="EP1123398B1_00044.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="45">
      <img he="N/A" wi="N/A" file="EP1123398B1_00045.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="46">
      <img he="N/A" wi="N/A" file="EP1123398B1_00046.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="47">
      <img he="N/A" wi="N/A" file="EP1123398B1_00047.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="48">
      <img he="N/A" wi="N/A" file="EP1123398B1_00048.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="49">
      <img he="N/A" wi="N/A" file="EP1123398B1_00049.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="50">
      <img he="N/A" wi="N/A" file="EP1123398B1_00050.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="51">
      <img he="N/A" wi="N/A" file="EP1123398B1_00051.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="52">
      <img he="N/A" wi="N/A" file="EP1123398B1_00052.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="53">
      <img he="N/A" wi="N/A" file="EP1123398B1_00053.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="54">
      <img he="N/A" wi="N/A" file="EP1123398B1_00054.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="55">
      <img he="N/A" wi="N/A" file="EP1123398B1_00055.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="56">
      <img he="N/A" wi="N/A" file="EP1123398B1_00056.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="57">
      <img he="N/A" wi="N/A" file="EP1123398B1_00057.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="58">
      <img he="N/A" wi="N/A" file="EP1123398B1_00058.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="59">
      <img he="N/A" wi="N/A" file="EP1123398B1_00059.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="60">
      <img he="N/A" wi="N/A" file="EP1123398B1_00060.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="61">
      <img he="N/A" wi="N/A" file="EP1123398B1_00061.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="62">
      <img he="N/A" wi="N/A" file="EP1123398B1_00062.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="63">
      <img he="N/A" wi="N/A" file="EP1123398B1_00063.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="64">
      <img he="N/A" wi="N/A" file="EP1123398B1_00064.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="65">
      <img he="N/A" wi="N/A" file="EP1123398B1_00065.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="66">
      <img he="N/A" wi="N/A" file="EP1123398B1_00066.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="67">
      <img he="N/A" wi="N/A" file="EP1123398B1_00067.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="68">
      <img he="N/A" wi="N/A" file="EP1123398B1_00068.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="69">
      <img he="N/A" wi="N/A" file="EP1123398B1_00069.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="70">
      <img he="N/A" wi="N/A" file="EP1123398B1_00070.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="71">
      <img he="N/A" wi="N/A" file="EP1123398B1_00071.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="72">
      <img he="N/A" wi="N/A" file="EP1123398B1_00072.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="73">
      <img he="N/A" wi="N/A" file="EP1123398B1_00073.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="74">
      <img he="N/A" wi="N/A" file="EP1123398B1_00074.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="75">
      <img he="N/A" wi="N/A" file="EP1123398B1_00075.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="76">
      <img he="N/A" wi="N/A" file="EP1123398B1_00076.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="77">
      <img he="N/A" wi="N/A" file="EP1123398B1_00077.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="78">
      <img he="N/A" wi="N/A" file="EP1123398B1_00078.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="79">
      <img he="N/A" wi="N/A" file="EP1123398B1_00079.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="80">
      <img he="N/A" wi="N/A" file="EP1123398B1_00080.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="81">
      <img he="N/A" wi="N/A" file="EP1123398B1_00081.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="82">
      <img he="N/A" wi="N/A" file="EP1123398B1_00082.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="83">
      <img he="N/A" wi="N/A" file="EP1123398B1_00083.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="84">
      <img he="N/A" wi="N/A" file="EP1123398B1_00084.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="85">
      <img he="N/A" wi="N/A" file="EP1123398B1_00085.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="86">
      <img he="N/A" wi="N/A" file="EP1123398B1_00086.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="87">
      <img he="N/A" wi="N/A" file="EP1123398B1_00087.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="88">
      <img he="N/A" wi="N/A" file="EP1123398B1_00088.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="89">
      <img he="N/A" wi="N/A" file="EP1123398B1_00089.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="90">
      <img he="N/A" wi="N/A" file="EP1123398B1_00090.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="91">
      <img he="N/A" wi="N/A" file="EP1123398B1_00091.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="92">
      <img he="N/A" wi="N/A" file="EP1123398B1_00092.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="93">
      <img he="N/A" wi="N/A" file="EP1123398B1_00093.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="94">
      <img he="N/A" wi="N/A" file="EP1123398B1_00094.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="95">
      <img he="N/A" wi="N/A" file="EP1123398B1_00095.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="96">
      <img he="N/A" wi="N/A" file="EP1123398B1_00096.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="97">
      <img he="N/A" wi="N/A" file="EP1123398B1_00097.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="98">
      <img he="N/A" wi="N/A" file="EP1123398B1_00098.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="99">
      <img he="N/A" wi="N/A" file="EP1123398B1_00099.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="100">
      <img he="N/A" wi="N/A" file="EP1123398B1_00100.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="101">
      <img he="N/A" wi="N/A" file="EP1123398B1_00101.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="102">
      <img he="N/A" wi="N/A" file="EP1123398B1_00102.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="103">
      <img he="N/A" wi="N/A" file="EP1123398B1_00103.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="104">
      <img he="N/A" wi="N/A" file="EP1123398B1_00104.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="105">
      <img he="N/A" wi="N/A" file="EP1123398B1_00105.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="106">
      <img he="N/A" wi="N/A" file="EP1123398B1_00106.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="107">
      <img he="N/A" wi="N/A" file="EP1123398B1_00107.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="108">
      <img he="N/A" wi="N/A" file="EP1123398B1_00108.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="109">
      <img he="N/A" wi="N/A" file="EP1123398B1_00109.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="110">
      <img he="N/A" wi="N/A" file="EP1123398B1_00110.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="111">
      <img he="N/A" wi="N/A" file="EP1123398B1_00111.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="112">
      <img he="N/A" wi="N/A" file="EP1123398B1_00112.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="113">
      <img he="N/A" wi="N/A" file="EP1123398B1_00113.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="114">
      <img he="N/A" wi="N/A" file="EP1123398B1_00114.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="115">
      <img he="N/A" wi="N/A" file="EP1123398B1_00115.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="116">
      <img he="N/A" wi="N/A" file="EP1123398B1_00116.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="117">
      <img he="N/A" wi="N/A" file="EP1123398B1_00117.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="118">
      <img he="N/A" wi="N/A" file="EP1123398B1_00118.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="119">
      <img he="N/A" wi="N/A" file="EP1123398B1_00119.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="120">
      <img he="N/A" wi="N/A" file="EP1123398B1_00120.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="121">
      <img he="N/A" wi="N/A" file="EP1123398B1_00121.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="122">
      <img he="N/A" wi="N/A" file="EP1123398B1_00122.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="123">
      <img he="N/A" wi="N/A" file="EP1123398B1_00123.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="124">
      <img he="N/A" wi="N/A" file="EP1123398B1_00124.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="125">
      <img he="N/A" wi="N/A" file="EP1123398B1_00125.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="126">
      <img he="N/A" wi="N/A" file="EP1123398B1_00126.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="127">
      <img he="N/A" wi="N/A" file="EP1123398B1_00127.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="128">
      <img he="N/A" wi="N/A" file="EP1123398B1_00128.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="129">
      <img he="N/A" wi="N/A" file="EP1123398B1_00129.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="130">
      <img he="N/A" wi="N/A" file="EP1123398B1_00130.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="131">
      <img he="N/A" wi="N/A" file="EP1123398B1_00131.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="132">
      <img he="N/A" wi="N/A" file="EP1123398B1_00132.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="133">
      <img he="N/A" wi="N/A" file="EP1123398B1_00133.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="134">
      <img he="N/A" wi="N/A" file="EP1123398B1_00134.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="135">
      <img he="N/A" wi="N/A" file="EP1123398B1_00135.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="136">
      <img he="N/A" wi="N/A" file="EP1123398B1_00136.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="137">
      <img he="N/A" wi="N/A" file="EP1123398B1_00137.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="138">
      <img he="N/A" wi="N/A" file="EP1123398B1_00138.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="139">
      <img he="N/A" wi="N/A" file="EP1123398B1_00139.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="140">
      <img he="N/A" wi="N/A" file="EP1123398B1_00140.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="141">
      <img he="N/A" wi="N/A" file="EP1123398B1_00141.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="142">
      <img he="N/A" wi="N/A" file="EP1123398B1_00142.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="143">
      <img he="N/A" wi="N/A" file="EP1123398B1_00143.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="144">
      <img he="N/A" wi="N/A" file="EP1123398B1_00144.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="145">
      <img he="N/A" wi="N/A" file="EP1123398B1_00145.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="146">
      <img he="N/A" wi="N/A" file="EP1123398B1_00146.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="147">
      <img he="N/A" wi="N/A" file="EP1123398B1_00147.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="148">
      <img he="N/A" wi="N/A" file="EP1123398B1_00148.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="149">
      <img he="N/A" wi="N/A" file="EP1123398B1_00149.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="150">
      <img he="N/A" wi="N/A" file="EP1123398B1_00150.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="151">
      <img he="N/A" wi="N/A" file="EP1123398B1_00151.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="152">
      <img he="N/A" wi="N/A" file="EP1123398B1_00152.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="153">
      <img he="N/A" wi="N/A" file="EP1123398B1_00153.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="154">
      <img he="N/A" wi="N/A" file="EP1123398B1_00154.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="155">
      <img he="N/A" wi="N/A" file="EP1123398B1_00155.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="156">
      <img he="N/A" wi="N/A" file="EP1123398B1_00156.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="157">
      <img he="N/A" wi="N/A" file="EP1123398B1_00157.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="158">
      <img he="N/A" wi="N/A" file="EP1123398B1_00158.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="159">
      <img he="N/A" wi="N/A" file="EP1123398B1_00159.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="160">
      <img he="N/A" wi="N/A" file="EP1123398B1_00160.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="161">
      <img he="N/A" wi="N/A" file="EP1123398B1_00161.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="162">
      <img he="N/A" wi="N/A" file="EP1123398B1_00162.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="163">
      <img he="N/A" wi="N/A" file="EP1123398B1_00163.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="164">
      <img he="N/A" wi="N/A" file="EP1123398B1_00164.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="165">
      <img he="N/A" wi="N/A" file="EP1123398B1_00165.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="166">
      <img he="N/A" wi="N/A" file="EP1123398B1_00166.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="167">
      <img he="N/A" wi="N/A" file="EP1123398B1_00167.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="168">
      <img he="N/A" wi="N/A" file="EP1123398B1_00168.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="169">
      <img he="N/A" wi="N/A" file="EP1123398B1_00169.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="170">
      <img he="N/A" wi="N/A" file="EP1123398B1_00170.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="171">
      <img he="N/A" wi="N/A" file="EP1123398B1_00171.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
    <figure num="172">
      <img he="N/A" wi="N/A" file="EP1123398B1_00172.PNG" alt="image" img-content="undefined" img-format="png" inline="yes" />
    </figure>
  </drawings>
  <image file="EP1123398B1.PDF" type="pdf" size="2054116" pages="130" />
</lexisnexis-patent-document>